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PROJECT SUMMARY 
 
This study has estimated the value of the pain and suffering associated with 
microbiological foodborne disease for the UK using both Quality Adjusted Life Year 
(QALY) and monetary (Willingness to Pay (WTP)) metrics.  
 
QALYs are derived from the Integrate study (Wellcome Trust and Department of 
Health grant HICF-T5-354), systematic review of the literature and expert opinion. 
The QALY burden of illness was calculated using Markov Transition Models to 
represent the short and lifetime experiences of patients with each foodborne 
pathogen.  
 
The causes of the greatest burden of foodborne illness in terms of QALY are 
Campylobacter spp. and Norovirus, primarily due to the large number of individuals 
who are infected by these pathogens each year. Campylobacter spp. and Norovirus 
are also associated with the greatest burden when assessed in monetary terms. The 
pathogen with the most severe impact, in terms of expected QALY loss per case, 
was Listeria monocytogenes due to the high death rate from this bacterium. 
 
Giardia lamblia accounts for relatively few foodborne cases but is ranked third in 
terms of aggregate QALY burden (6% of the total QALY loss), and fourth in terms of 
WTP due to the relatively high probability of developing Irritable Bowel 
Syndrome (IBS) as a result of infection.  
 
IBS is the primary driver of burden, dominating even losses associated with death.  
This is because of its high incidence, long duration and the high loss of quality of life 
by patients experiencing the condition. The large share of burden associated with 
IBS applies to the analyses using both QALY and monetary metrics.  
 
Although children and elderly are more at risk of severe outcomes, for the main 
contributors of overall burden (Campylobacter spp. and Norovirus);  it is the adult 
group (16-64 year olds) who suffer the majority of the burden. This is because they 
are the largest population group most likely to suffer from IBS as a sequela of 
infection, and have a longer life span over which the impacts can accrue. 
 
Monetary estimates are expressed in terms of respondents’ WTP to avoid pain and 
suffering associated with foodborne disease (FBD) (among both adults and children). 
FBDs were represented using (i) vignettes (descriptions of symptoms) and (ii) the 
EuroQol 5 dimension, 3 level health questionnaire (EQ-5D-3L). A UK sample 
(representative of UK population in terms of gender, age and income) were asked for 
their  WTP to avoid the described symptoms for themselves and for their children. In 
total, 4397 usable surveys were completed. The results indicate an absence of large 
scale protest responses to the valuation scenario. 
 
Asking respondents to trade off illness (defined through the EQ-5D-3L), length of life 
and income allows derivation of the monetary value of a QALY, which is estimated  
to range between £6,100 and £61,500 for those with annual incomes between 
£10,000 and £100,000 respectively. For median income the QALY value is estimated 
to be £19,456. 
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For individual symptoms and duration of these, WTP to avoid pain and suffering are 
presented for adults, and for parents (on behalf of their children). Look up tables 
(Appendix O) are produced to allow the user to create a combination of symptoms to 
estimate the WTP for an individual case. The Markov Transition Models are built in 
Excel with the user able to adjust underlying values and assumptions in order to 
assess changes in aggregate burden, in QALY and monetary terms, by pathogen. 
 
The QALY and monetary metric estimates can be used in impact assessments and 
economic evaluation (post implementation review) for strategic priorities and policy 
options to reduce FBD risks; preparing briefings and food chain analyses, and 
supporting Finance & Strategic Planning in developing appropriate Key Performance 
Indicators. Appendix O is created to help with such uses. Uncertainties are reflected 
in the confidence intervals for both QALY and WTP estimates throughout the report.   
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LIST OF ABBREVIATIONS 
 
CEA Cost Effectiveness Analysis 
CRF Chronic Renal Failure 
CV Contingent Valuation 
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NHS National Health Service 
NICE National Institute for Health and Care Excellence 
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PTO Person Trade Off  
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TTO Time Trade Off 
TTP Thrombotic Thrombocytopenic Purpura 
VAS Visual Analog Scale 
VTEC Vero cytotoxin-producing Escherichia Coli 
WHO World Health Organisation 
WTP Willingness to Pay 
 
GLOSSARY 
 
Censored 
Variables 
“Censored” refers to the fact that the outcome variable (utility score) is 
constrained to lie between 0 and 1. 
Conditional Logit 
Model 
a model designed to explain how respondent make choices in a choice 
experiment. The probability of choosing a given option is selected is 
explained in terms of the characteristics of the alternatives rather than 
attributes of the individuals (as in the multinominal logit model). 
Contingent 
Valuation 
a stated preference approach to valuing non-market goods and services 
where individuals are asked what they are willing to pay (or accept) for 
a change in provision of a non-market good or service. 
Cost Benefit 
Analysis 
a decision-making tool that compares costs and benefits of a proposed 
policy or project in monetary terms. 
Cost 
Effectiveness 
Analysis 
An analysis aimed to find the least cost option for achieving an 
objective, or to generate the highest benefits per unit of money spent 
Cost Utility 
Analysis 
the use of generalised measures of quality and length of life gains in the 
economic evaluation of health care interventions 
Dichotomous 
Choice 
Experiment 
a stated preference method and form of choice modelling in which 
respondents are presented with a series of alternatives and asked to 
choose their most preferred. 
Disease Outcome 
Tree 
an approach to describing an illness by severity, with branches of the 
tree (diagram) describing disease progression resulting in recovery, 
death, or long-term sequelae   
EQ-5D-3L descriptive system of health-related quality of life states consisting of 
five dimensions (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression) each of which can take one of three responses.  
The responses record three levels of severity (no problems/some or 
moderate problems/extreme problems) within a particular EQ5D 
dimension. 
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Foodborne 
Disease 
any illness resulting from the food spoilage of contaminated food, 
pathogenic bacteria, viruses or parasites that contaminate food, as well 
as chemical or natural toxins such as poisonous mushrooms and 
various species of beans that have not been boiled for at least 10 
minutes. Terms like ‘food poisoning’ and ‘food related disease’ are also 
used interchangeably to mean foodborne disease. In this study, the 
focus is on the foodborne diseases caused by microbiological 
pathogens.  
Markov 
Transition Model 
a stochastic model used to model randomly changing systems where it 
is assumed that future states depend only on the current state not on 
the events that occurred before it. Generally, this assumption enables 
reasoning and computation with the model that would otherwise be 
intractable. For this reason, in the fields of predictive modelling and 
probabilistic forecasting, it is desirable for a given model to exhibit the 
Markov property. 
Multinominal 
Logit Model 
a model designed to explain how respondent make choices in a choice 
experiment. In the usual multinomial logit model, the probability of 
choosing an option is explained in terms of the characteristics of the 
individuals. 
Pseudo 
Confidence 
Intervals 
confidence intervals produced from a Monte Carlo simulation of a data 
sample 
 
S-efficient Design A design criterion for constructing DCE experiments that minimises 
sample size needed to identify parameters, given their priors. 
Sequelae a condition which is the consequence of a previous disease or injury 
Tobit Model The model supposes that there is a latent (i.e. unobservable) variable. 
This variable linearly depends on xi via a parameter (vector) ß, which 
determines the relationship between the independent variable (or 
vector) xi and the latent variable (just as in a linear model). In addition, 
there is a normally distributed error term to capture random influences 
on this relationship. The observable variable is defined to be equal to 
the latent variable whenever the latent variable is above zero and zero 
otherwise. 
Willingness To 
Pay 
The monetary measure of the value of obtaining a gain in the provision 
of good or service or avoiding a loss. 
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EXECUTIVE SUMMARY 
 
Food Standards Agency (FSA) uses health and monetary metrics to estimate the 
costs and benefits of policy options for reducing this disease burden. The objective 
of this project is to provide new estimates of pain and suffering imposed by 
foodborne diseases (FBD) for the following 10 pathogens1 deemed to be the most 
material for FSA and FSS in terms of (i) the extent of FBD by the pathogen; (ii) the 
severity of the FBD and (iii) the cost of the FBD to the UK. The pain and suffering 
associated with these pathogens are estimated using two metrics: QALYs and 
money.  
 
 Campylobacter spp.*, 
 Clostridium perfringens,  
 Cryptosporidium parvum,  
 Giardia lamblia,  
 Hepatitis E 
 Listeria monocytogenes,  
 Norovirus*,  
 Salmonella (non-typhoidal)*,  
 Shigella spp.  
 VTEC O157* 
*: Age differentiated models were estimated for these pathogens.  
 
Quality Adjusted Life Years (QALY) – approach and results 
The project conceptualises, using expert opinion, Markov State Transition Models 
(MTMs) for each pathogen. These models are parameterised to estimate the burden 
of disease using QALYs.  MTMs represent the flow of a defined cohort of people 
through the various health states which characterise FDB for each of the 10 selected 
pathogens. For Campylobacter spp., for example, the MTM includes separate states 
for: healthy; uncomplicated diarrhoea/vomiting; hospitalising diarrhoea; febrile 
convulsions; mesenteric adenitis; septicaemia; Guillain-Barre Syndrome (GBS), 
Irritable Bowel Syndrome (IBS); reactive arthritis; and death. The models are 
parameterised with values for the transition probabilities between states and the 
utility losses associated with being in those states relative to being healthy. The 
values for the transition probabilities and utility losses are identified from a 
systematic literature review (see Appendices B and C). The variation in these 
identified values produces substantial uncertainty in the results which is reported. 
Fully executable models are provided for a decision-maker to use their own model 
input parameter values, which allows exploration of the impact of each identified 
input value (see Appendix O).  
 
The parameterised models are used to determine the burden of disease for the UK 
by subtracting the total QALYs accrued by the population from the QALYs that would 
have been accrued by the population if there had been no disease caused by the 
pathogen. The disease burden is estimated for: (i) the short term burden of disease – 
over a single year in which new infections occur, and (ii) the long term burden of 
disease – in which the total burden of illness associated with those new infections is 
estimated over 100 years. QALYs lost in future years are discounted at a rate of 
3.5% in line with the NICE reference case. 
 
Campylobacter spp. and Norovirus dominate the overall QALY burden, accounting 
for 52% and 36% of the overall burden of the 10 pathogens considered (QALY loss 
                                            
1
 Enteroaggregative Escherichia coli was also considered but had to be abandoned due to lack of sufficient data. 
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of 140 000).  Although Giardia lamblia has a relatively lower prevalence, a relatively 
high number of the cases translate into long term sequelae, leading to a relatively 
high burden (6% of total burden) which is greater than that caused by far more 
prevalent Salmonella. Listeria monocytogenes generates by far the greatest QALY 
loss per case: 4.03 compared to 0.67 for Norovirus and 0.26 for Campylobacter spp. 
IBS dominates the QALY loss associated with sequelae because of the long-term 
nature of this sequela. The predicted burden per case for each pathogen, and the 
confidence intervals for these estimates, are shown in Table ES.1. 
 
Table ES.1: Total lifetime QALYs lost due to infections from 10 foodborne 
pathogens falling in a given year in order from largest to smallest burden of 
illness 
Pathogen 
Deterministic 
Burden 
(QALYs) 
Mean 
Probabilistic 
Burden 
(QALYs) 
Lower 
Pseudo 
Confidence 
Interval1 
Upper 
Pseudo 
Confidence 
Interval1 
Campylobacter spp. 72,911 69,108 39,284 108,238 
Norovirus 49,877 48,068 26,738 72,777 
Giardia lamblia 7,916 6,634 3,602 10,641 
Salmonella (non-
typhoidal) 7,023 6,924 4,100 10,652 
Listeria monocytogenes 734 672 628 716 
VTEC O157 588 537 440 651 
Clostridium perfringens  317 305 174 485 
Hepatitis E 76 51 44 60 
Cryptosporidium parvum 63 59 36 89 
Shigella spp. 32 29 19 42 
 
An exploratory analysis of the burden by age stratification indicates that for 
Campylobacter spp., Norovirus and Salmonella, the aggregate burden of disease 
falling mainly on the adult group (aged 16-64), as does the burden per case. This 
pattern is not universal, with the opposite pattern for VTEC O157, with children and 
the elderly bearing the greatest burden. 
 
Willingness to Pay (WTP) – approach and results 
The second approach to estimating the burden of FBD used monetary values. A 
stated preference survey is designed and employed to elicit WTP measures to avoid 
short term and long term symptoms and diseases (or ‘conditions’ for short) caused 
by the 10 pathogens.  
 
The short term and long term conditions are represented in two forms in parallel 
approaches:  
 
Vignette descriptions 
 A nationally representative sample 
of 1040 adults regarding themselves 
being ill 
 592 adults - parents regarding their 
children aged 2-17 being ill 
EuroQol 5 dimension, 3 level health 
questionnaire (EQ5D-3L) 
 A nationally representative sample 
of 2097 adults  
 668 parents of children aged 2-17 
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In total, 4397 usable surveys were completed across the UK. There are no national population 
statistics for parents of children aged 2-17, but age and income descriptors show close to national 
statistics.  
The questionnaires are presented in Appendices I - K. Vignettes are described using 
medical definition of symptoms. EQ-5D-3L are described using the approach’s 
definitions of: five dimensions (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression) and three levels of severity (no problems/some or moderate 
problems/extreme problems). 
 
In both versions, a sub-sample of parents was interviewed specifically relating to 
their children because children cannot identify such values for themselves. The 
questionnaire used two design approaches:  
 
 The Discrete Choice Experiment (DCE) was used for short and long term 
conditions in the EQ-5D-3L WTP study. In the vignette WTP study a DCE was 
used for short term conditions, with the attributes and their levels embedded 
within the descriptions of illness, and  
 The Dichotomous Choice Contingent Valuation (CV) was used for the long term 
conditions such as IBS or GBS.  
 
Extensive testing of the SP questionnaire in six focus groups, a series of cognitive 
interviews, and a pilot survey indicated that respondents understood and were able 
to complete the task of trading off money (WTP) with experiencing a condition. 
Protest behaviour, for example caused by relating this task to the context of NHS 
provision of healthcare free at the point of use, was not a problem. Very few 
respondents objected to paying to avoid the conditions, and they were removed from 
the sample (3.2% vignette sample, 3.7% EQ-5D-3L sample)2.  
 
Another measure of the validity of the responses is the proportion of respondents 
who found the questionnaire too difficult. For this survey, very few reported that the 
short term vignette based questions were “very difficult” to understand (2% of adults 
and 4% of parents), with the equivalent figures for the long term vignette illness. 
 
In the EQ-5D valuation instrument, ill health was represented by 3 levels of 5 
dimensions of health. Very few respondents reported that the short term EQ-5D-3L 
valuation questions were “very difficult” to understand (2% of adults, 5% of parents), 
with equivalent figures for the long term EQ-5D-3L questions (4% and 8% 
respectively). 
 
For short term conditions affecting adults we find models estimated on the DCE 
vignette choice data yield intuitive and plausible results. The attributes are significant 
and of the expected sign: the disutility of illness increases with duration and severity 
of symptoms. Economically intuitive results are found that (i) the WTP increases with 
respondents’ income level, and (ii) the WTP to avoid additional days of illness 
increases with the costs respondents report they incur from being too ill to work. 
However, the proportion of WTP that is due to the cost of work days lost is very small 
                                            
2
 If the “Other” responses are included in the sample (ie not counted as protest), the protest rates go down to 
2.7% and 2.4%, respectively.  
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and possible to isolate from the key results we are interested in, i.e. WTP to avoid 
pain and suffering alone.  
 
This study is one of a small number to integrate EQ-5D representations of health 
within an economic valuation instrument – combining health states with durations 
and cost. For the adult sample, models estimated on the DCE choice data, for both 
short and long term conditions, yield intuitive results with attributes significant and of 
the expected sign. The same holds true to a large extent for the parental sample 
making choices regarding short term episodes of child ill health. This breaks down 
for the models of long term child ill health, with little attention paid to the health 
attributes. Asking respondents to trade off illness (defined through the EQ-5D-3L), 
length of life and income allows derivation of the monetary value of a QALY, which is 
estimated to range between £6,100 and £61,500 for those with annual incomes 
between £10,000 and £100,000 respectively. For median income the QALY value is 
estimated to be £19,456. 
 
As a result of using vignettes that describe symptoms, WTP to avoid varying 
illnesses constructed of composite attributes can be estimated. For example, an 
adult on median household income is predicted to be willing to pay £69 to avoid a 3-
day illness involving ‘a high temperature, with aching muscles and chills, diarrhoea 
and vomiting’. They would be willing to pay £93 to avoid a 5 day illness involving a 
high temperature, with aching muscles and chills, diarrhoea and blood in their stools 
necessitating a visit to the doctor.  
 
The short term models for children’s illness also generate intuitive results, with 
parents’ choices affected by the duration and nature of the child’s illness but also the 
cost, with that cost effect again moderated by their income. WTP to avoid varying 
illnesses constructed from composite attributes can be estimated for children’s 
illness, too. For example, a parent on median household income is predicted to be 
willing to pay £148 to avoid a 5 day illness in which their child experiences a high 
temperature with diarrhoea and vomiting.  
 
Far larger WTP estimates are derived for the 11 long term conditions that adults may 
suffer as a result of FBD. For example, WTP to avoid pain and suffering due to a 
year’s experience of GBS is valued at £7,581, while someone aged 40 is willing to 
pay £13,653 to avoid the pain and suffering due to acquiring lifelong IBS. The 
equivalent values to avoid Septicaemia and Chronic Renal Failure are £19,869 and 
£45,804, respectively. 
 
As one might expect, the values parents are willing to pay for their child to avoid 
serious complications from FBD far exceed what they would pay to avoid the 
conditions themselves. For example, they would pay £22,744 to avoid the pain and 
suffering of their child acquiring lifelong IBS. The equivalent values to avoid 
Septicaemia and Chronic Renal Failure are £98,074 and £146,296 respectively. 
 
Uses of results 
These individual WTP values can be aggregated to national values when combined 
with the MTMs which estimate the numbers experiencing each health state in a 
given year. For Campylobacter spp. the aggregate WTP to avoid the pain and 
suffering from all 280,000 foodborne cases that occur in a year is estimated to be 
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£424m. This value incorporates the discounted, long term burden from sequelae 
associated with Campylobacter spp. and, in this case, is dominated by IBS. Table 
ES.2 shows the aggregated WTP to avoid pain and suffering associated with 
aggregate burden per pathogen.  
 
Table ES.2: Aggregated monetary value of avoiding pain and suffering 
associated with aggregate foodborne disease burden, by pathogen 
 
Burden 
£ million 
95% Confidence 
Intervals 
Campylobacter spp. 424.2 (308.2-540.3) 
Clostridium perfringens 9 (7.6 - 10.4) 
Cryptosporidium parvum 0.8 (0.6 - 1) 
Giardia lamblia 40 (27.8 - 52.2) 
Hepatitis E 12.5 (9.2-15.8) 
Listeria monocytogenes 18.5 (10.8 - 26.2) 
Norovirus 248.5 (164.9 - 332.1) 
Salmonella (Non-Typhoidal) 143.9 (119.1 – 168.7) 
Shigella spp. 7.7 (5.8 - 9.7) 
VTEC O157  38.4 (31.9 – 45.0) 
Total 943.6  
 
These values are based on foodborne cases attributable to the named pathogens. 
The microbial cause of FBD is not always identified and this diagnostic gap means 
that the values reported are likely to underestimate the value of pain and suffering 
caused by each of the 10 pathogens. 
 
This study provides new estimates of the number of FBD cases and the consequent 
burden of disease. For individual symptoms and their duration, WTP to avoid pain 
and suffering are presented for adults and for parents (on behalf of their children) in 
the look up tables (Appendix O). These allow the user to create combinations of 
symptoms to estimate the WTP for an individual case. The Markov Transition Models 
are built in Excel with these look up tables enabling the user to adjust underlying 
values and assumptions in order to assess changes in aggregate burden, in QALY 
and monetary terms, by pathogen. 
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1 INTRODUCTION 
 
1.1 Background / policy context 
 
Actions to reduce the burden are likely to involve costs and hence their evaluation 
should include estimates of both the costs and benefits, the latter being the value of 
averted disease. The FSA analysis uses existing estimates for medical and 
productivity costs. This project is commissioned to estimate the value of the pain and 
suffering caused by microbiological foodborne disease (FBD). This is done using both 
QALY and monetary metrics. 
 
1.2 Project scope 
The geographical scope of the project is the UK. The costs considered are the pain 
and suffering associated with FBD caused by 10 pathogens. These pathogens were 
selected as the most material for FSA and FSS in terms of (i) the extent of FBD by the 
pathogen; (ii) the severity of the FBD and (iii) the cost of the FBD to the UK.  
 
 Campylobacter spp.*, 
 Clostridium perfringens,  
 Cryptosporidium parvum,  
 Giardia lamblia,  
 Hepatitis E 
 Listeria monocytogenes,  
 Norovirus*,  
 Salmonella (non-typhoidal)*,  
 Shigella spp.  
 VTEC O157* 
*: Age differentiated models were estimated for these pathogens. Enteroaggregative Escherichia coli 
was initially considered. An absence of suitable data means that only a partial analysis of this pathogen 
is possible, with no burden estimates generated. 
 
The project considers the burden of all cases arising in a single year. The diseases 
are defined in terms of short and long term symptoms and conditions – the latter 
continue after the initial year as a result of sequelae. 
 
1.3 Objectives of this study 
 
The objectives of the study are to: 
 develop Markov State Transition Models (MTMs) for a set of foodborne pathogens 
and their sequelae 
 revise preliminary QALY values for the disease states within the MTMs using a 
combination of literature, expert opinion and patient values 
 produce QALY estimates for sequelae relevant to the set of foodborne pathogens 
such as Guillain–Barré Syndrome (GBS), Reactive Arthritis (RA), Irritable Bowel 
Syndrome (IBS), Hemolytic Uremic Syndrome (HUS) etc. 
 establish how the age of onset of a patient impacts the QALY loss associated with 
a set of foodborne pathogens 
 conduct primary research using a stated preference design to elicit individual WTP 
values to avoid microbiological FBD pertaining specifically to the selected 
pathogens and their sequelae 
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 use the EuroQol 5 dimension, 3 level health questionnaire (EQ-5D-3L) within a 
stated preference valuation instrument to estimate the monetary value of a QALY 
gain 
 aggregate the QALY and monetary value estimates to the national level for the set 
of pathogens. 
 
1.4 Report structure 
The report contains six Sections:  
 Section 2 provides a brief overview of the project’s approach; 
 Section 3 provides an overview of the use of QALYs; 
 Section 4 reports the use of Markov State Transition Models (MTMs) to derive  
estimates of QALY burden, by pathogen; 
 Section 5 gives details of the stated preference survey component of the project; 
and 
 Section 6 provides monetary values are reported for short and long term effects 
and aggregated to national level using the value of a QALY derived within the 
study, and using the vignettes approach to WTP.  
 
The report also contains 15 Appendixes: 
 
A. Markov transition models 
B. Systematic review of the clinical literature 
C. Systematic review of primary health weights used in burden of illness studies of 
foodborne pathogens 
D. Parameter values and references for the MTMs 
E. Integrate data and validation of MTM utility values 
F. Examples of valuation questions – adult & child disease, short and long term 
G. Long term illness (including sequelae) valuation – design information 
H. Vignette survey (adults) 
I. Vignette survey (parents) 
J. EQ-5D-3L survey (adults) 
K. EQ-5D-3L survey (parents) 
L. Data analysis (Vignette survey) 
M. Data analysis (EQ-5D-3L survey) 
N. Aggregation of willingness to avoid foodborne diseases – Campylobacter spp. 
O. Separate Excel files presenting the ‘look up’ tables allowing the users to update 
QALY and WTP estimates using new data on disease burden.  
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2 OVERVIEW OF THE PROJECT METHOD 
 
The project uses Markov State Transition Models (MTMs) to analyse the flow of 
people through the various health states which characterise FBD for a set of 
pathogens. These models are parameterised and validated using both secondary and 
primary data. These MTMs include short, mild and long term conditions associated 
with all the modelled pathogens. 
 
The MTMs are used to estimate the QALY losses associated with all cases associated 
with each pathogen in a year. The estimates are calculated for that current year, and 
over the duration of patients’ lives, with QALY losses projected to occur in the future 
being discounted to convert into their equivalent ‘present value’. 
 
A stated preference (SP) survey is designed and employed to elicit WTP measures to 
avoid illness caused by the set of foodborne pathogens.  
 
The short term and long term conditions are represented in two forms in parallel 
approaches:  
 
Vignette descriptions 
 
 A nationally representative sample 
of 1040 adults regarding themselves 
being ill 
 592 adults - parents regarding their 
children aged 2-17 being ill 
EuroQol 5 dimension, 3 level health 
questionnaire (EQ5D-3L) 
 A nationally representative sample 
of 2097 adults  
 668 parents of children aged 2-17 
Note: the questionnaires are presented in Appendix H - K. There are no national population statistics for 
parents of children aged 2-17, but age and income descriptors show close to national statistics. 
 
Vignettes are described using medical definition of symptoms. EQ-5D-3L are 
described using the approach’s definitions of: five dimensions (mobility, self-care, 
usual activities, pain/discomfort, anxiety/depression) and three levels of severity (no 
problems/some or moderate problems/extreme problems). Both versions use both 
long and short term illnesses associated with those pathogens.  
 
The questionnaire uses two design approaches:  
 
 the Discrete Choice Experiment (DCE) was used for short and long term conditions 
in the EQ-5D-3L WTP study. In the vignette WTP study a DCE was used for short 
term conditions, with the attributes and their levels embedded within the 
descriptions of illness, and  
 the Dichotomous Choice Contingent Valuation (CV) was used for the long term 
conditions such as IBS or GBS.  
 
The use of the EQ-5D-3L allows estimation of the monetary value of QALY losses and 
gains. These values are aggregated by modifying the MTMs to accumulate monetary 
losses, rather than utility decrements, caused by a pathogen over a year. The project 
generates estimates of QALY and monetary losses for each considered pathogen, 
accounting for sequelae.  
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Figure 1 shows the study methodology, deliverables submitted throughout the project 
and the relevant Sections and Appendixes.  
 
Figure 1:  Project methodology showing deliverables with links to sections 
and appendixes
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3 QUALITY ADJUSTED LIFE YEARS  
 
3.1 What are QALYs? 
The QALY is a composite measure of health status and length of life used to measure 
the impact of healthcare interventions on patients (Drummond, 2005). The focus is on 
the health status, generally measured using a generic measure such as the EQ-5D 
(which has three or five level versions (EuroQol, 2016, Herdman et al., 2011) rather 
than clinical outcomes. This helps decision makers allocate healthcare resources by 
facilitating the comparison of the relative cost-effectiveness of interventions in different 
areas of health. For example, the impact of a cancer treatment can be compared with 
that of an intervention for a person with a mental health related condition. The use of 
such measures of generalised quality and length of life gains in the economic 
evaluation of health care interventions is known as cost-utility analysis. 
 
The use of QALYs is underpinned by the extra-welfarist view and as such is not 
consistent, and moves away from, cost-benefit analysis which has become the 
standard economic evaluation technique used in public sectors other than health (HM 
Treasury, 2011). The welfarist paradigm has been argued to be at odds with the aims 
of the NHS, particularly to provide equitable healthcare. Many of these arguments 
focus on how the relevant impacts are identified (Brouwer et al., 2008, Brouwer et al., 
2000), measured and valued. For example, improved health may enable individuals to 
engage in the workforce, become more productive, earn more money and pay more 
taxes. Whilst these consequences are important, their inclusion in an economic 
evaluation may introduce bias into decision making, penalising treatments for 
conditions which are more likely to affect the economically disadvantaged, women 
(due to the pay gap) or the elderly. Using willingness to pay (WTP), it has been argued 
to depend on individuals’ ability to pay, again favouring treatments for the affluent. The 
very existence of a publicly funded healthcare system indicates a societal preference 
for a more equitable distribution of healthcare. Using cost-benefit evaluation based on 
WTP in a system where patients are not required to pay for healthcare is therefore 
somewhat counterintuitive. Instead, an extra-welfarist paradigm using Cost 
Effectiveness Analysis (CEA) is used in the UK to value new healthcare interventions. 
However, this is not consistent with other public sectors. The use of QALYs is 
consistent with NICE methods for technology appraisal and other NICE programmes 
(NICE, 2013).  
 
Disability Adjusted Life Years (DALYs) are endorsed by the World Health Organisation 
(WHO, 2016a). The WHO global burden of disease (GBD) measures burden of 
disease using DALY. This time-based measure combines years of life lost due to 
premature mortality and years of life lost due to time lived in states of less than full 
health (WHO, 2016b). The DALY metric was developed in the original GBD 1990 
study to assess the burden of disease consistently across diseases, risk factors and 
regions (Murray and Lopez, 1996). The WHO endorses the use of DALYs in 
preference to QALYs to estimate the burden of FBD. For example, the WHO published 
a report estimating the global burden of FBD  (WHO, 2015) which includes estimates 
of the burden of FBD caused by 31 bacteria, viruses, parasites, toxins and chemicals. 
The estimates are based on the best available data at the time of reporting, and 
identified data gaps were filled using imputation, assumptions and other methods. 
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In principle, DALYs are also a measure of health adjusted life years but importantly 
they vary in how they are measured and valued and have been shown to produce 
different values to QALYs (Sassi, 2006). DALYs are framed as years lost from a global 
ideal length and quality of life whereas QALYs lost are framed against the QALYs that 
would have been achieved by the population of interest.  
 
DALYs are weighted in favour of adults in view of the fact that they support children 
and the elderly, whilst QALYs account for age in the average healthy utility value of 
the population (Sassi, 2010). Finally, with regards to the weights applied to the years 
lived differ in DALYs and QALYs: DALYs use disability weights, a measure of the 
severity of disease bounded between 1 for full health and 0 for death. It is not possible 
to exist in a state worse than death. Disability weights do not reflect the wider quality 
of life impacts of disease, such as impact on daily activities and mental health. The 
method of valuing severity also differs for disability weights. Generally, a ‘person trade 
off approach’ is used and this has typically been based on the opinion of experts 
rather than patients and the public (Murray and Lopez, 1996). Such values are 
therefore not compatible with the estimation of QALYs which require a preference 
based valuation of generalised Health-related quality of life (HRQoL). 
 
3.2 How can QALYs be used for FBDs? 
QALYs were the measure of choice in the terms of reference for this project. The 
relevant decision problem posed was: what is the burden of illness of selected 
foodborne pathogens valued using QALYs? The use of QALY adjusted life years 
allows the FSA and FSS to align with NICE and the NHS in their valuation of 
interventions to promote generalised health. The use of QALYs also allows the FSA 
and FSS to compare interventions in diverse areas. The burden of illness estimates 
will allow the FSA and FSS to determine priorities for interventions in FBD by showing 
the total QALY burden caused by each pathogen as well as the burden caused per 
case. 
 
To calculate the total burden of disease caused by a foodborne pathogen it is 
necessary to estimate the number of cases, the progression of symptoms experienced 
by cases, the severity of those symptoms and the number of cases who die as a result 
of their disease. Traditionally, the burden of FBD has been modelled with the use of 
Disease Outcome Trees (DOTs) which illustrate the proportion of cases suffering from 
different symptoms. However, the duration of symptoms were rarely taken into 
account in such models. In reality, patients who suffer symptoms for longer time 
periods experience a greater burden of disease.  
 
Furthermore, DOTs are linear and do not allow the movement of patients back into 
previous health states. For example, it is possible for a case to become healthy and 
then become re-infected, thus becoming an additional new case, within a given time 
period. Failure to account for such cases may lead to burden being underestimated. 
The use of Markov State Transition Models (MTMs) mitigates these problems. This is 
why MTMs have been used to estimate QALY in this study – as reported in the next 
section.  
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4 MARKOV STATE TRANSITION MODELS  
 
This section is supported by Appendix A which sets out the decision-analytic model 
structures derived for this study. 
 
4.1 What are MTMs 
In the UK, the National Institute for Health and Care Excellence (NICE) has defined a 
set of decision-making processes and methods to inform whether, for example, 
technologies (as part of the NICE Technology Appraisal Programme), diagnostics (as 
part of the NICE Diagnostic Assessment Programme) or public health interventions 
(as part of the NICE Public Health Programme) are an effective use of a fixed budget 
for healthcare service provision. Method guides have been produced to inform NICE 
processes and set out how to develop the required evidence base including 
epidemiological, clinical and economic data. The first method guide developed 
informed the NICE Technology Appraisal programme, which has become the core 
guide referred to as the ‘NICE Reference Case’ (NICE, 2013). This suggests the use 
of decision-analytic model based cost-effectiveness analysis as the main mechanism 
to assimilate all available information and produce an estimate of the incremental 
costs (healthcare resource use) and benefits (QALYs) of the technology under 
appraisal compared with current practice. Decision analytic models can take a number 
of forms (Brennan et al., 2006) but the most commonly used type of model in NICE 
appraisals are Markov State Transition Models.  
 
Brennan et al. (2006) produced a useful taxonomy of model types with an extended 
catalogue of 14 techniques including those that are not commonly used in economic 
evaluation of healthcare interventions. The types of models are differentiated in terms 
of the definition for the model population as either cohort or individual and whether 
interaction between individuals is permitted within the model. Cohort models are those 
defined as representing a proportion of patients that share common characteristics, 
whereas individual models can be defined as those accounting for each patient 
separately with different characteristics. Interaction is defined as the assumption of 
independence or not between individuals within a model such as infectious disease 
transmission or service capacity constraints. 
 
MTMs are cohort models. In a Markov model, a population travels through different 
health states in a given time period. A probability is associated with moving from each 
state to a new state. Cases also have a probability of remaining in the same state, 
allowing the duration of symptoms to be taken into account. Each state has a health 
utility value associated with it, indicating the severity of being in that state. Health utility 
is accrued by the population based on the number of cases in each health state in 
each time period. To determine the burden of disease, the total QALYs accrued by the 
population is subtracted from the QALYs that would have been accrued by the 
population if there had been no disease caused by the issue of interest, in this case 
foodborne pathogens.  
 
There are some weaknesses associated with using Markov models to capture the 
health loss from foodborne pathogens. Markov models are “memoryless” as they 
operate at a cohort level. For example, the probability of a case developing severe 
complications could not depend on their previous experience of the disease as it is 
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impossible to identify the pathways followed by individual cases. Similarly, an 
individual cannot have a higher likelihood of developing a FBD if they have previously 
had a disease in the same year.  
 
The parameters included in such cohort models are based on population averages. 
Demographic factors such as age and co-morbidity may impact on different 
individuals’ experience of FBD in terms of their likelihood of developing complications 
or sequelae, their duration of illness, or its severity. A Markov model cannot capture 
these individual level factors and their impact on burden of disease. However, the 
population can be broken down into sub-groups who form a new population with their 
own parameter values. For each of these sub-groups, a new Markov model is 
required. This approach has been used in this study to determine how age of onset 
may impact the burden of disease caused by FBDs. 
 
Another assumption of Markov models is that all health states occur independently of 
another. For example, if a model for FBD included complications for uncomplicated 
diarrhoea and vomiting, a patient could not be in both of these states at once. In order 
to model such a combined health state, an additional state would need to be added to 
the model, adding a significant number of new parameters. This may make the 
identification of relevant data significantly more difficult. For example, with one 
uncomplicated state, the incidence of a FBD could be used as the probability of 
moving from healthy to uncomplicated in a year. With three uncomplicated states 
detailed above, three transition probabilities would be required, breaking down the 
aggregate incidence into different symptoms. As such, in the models used in this 
study, one generic uncomplicated state is used to represent uncomplicated diarrhoea 
with or without vomiting. 
 
The analysis was designed to answer the following three research questions: 
 
 What is annual burden of foodborne illness caused by the selected 10 foodborne 
pathogens in the UK in terms of the QALYs lost due to infection? 
 What proportion of the burden of foodborne illness is due to long term burden 
associated with the sequelae of infection? 
 Does burden of foodborne disease per case in four key pathogens differ amongst 
age groups? (Campylobacter spp., Norovirus, Salmonella (non-typhoidal) and 
VTEC O157) 
The approach taken in this project was structured around the stated decision problem 
(see Table 1 and further detail in Appendix A).  
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Table 1: Decision problem and approach overview 
Decision 
problem 
What is annual burden of illness caused by 10 foodborne pathogens in 
the UK in terms of the QALYs lost due to infection? 
The 10 foodborne pathogens were: Campylobacter spp., Clostridium 
perfringens, Cryptosporidium parvum, Giardia lamblia, Hepatitis E, 
Listeria monocytogenes, Norovirus, Salmonella (non-typhoidal), 
Shigella spp. and VTEC O157. 
 
Enteroaggregative Escherichia coli was also considered. An absence 
of suitable data means that only a partial analysis of this pathogen is 
possible, with no burden estimates generated. 
Comparators The health of the UK population in the absence of any of the 10 
foodborne pathogens. A utility for full health of 0.856 was used 
(Janssen and Szende, 2013), representing the average utility of an 
individual in full health across all age groups. 
Model type Pathogen specific Markov state transition models 
Population The 2014 UK population (n=64,596,800).  
The median age is assumed to be 40 years old. 
Perspective Costs: health service perspective 
Consequences (QALYs):  
(i) adults - the impact on the person with the FBD  
(ii) children- parent of the person with the FBD 
Time Horizon Each model is separated into two phases i) short term and ii) long 
term. The short term phase takes place over a period of one year and 
incorporates the short term symptoms and complications of infection 
with a foodborne pathogen. The long term phase has a time horizon of 
100 years and only incorporates the long term sequelae of infection 
alongside sequelae specific and all-cause mortality. 
Burden of 
Illness  
QALYs lost due to short term symptoms and complications and the 
long term sequelae resulting from infection in a specific year. 
Discounting No discounting is applied in the short term phase as this takes place 
over a period of one year. 
A discount rate of 3.5% is applied to QALYs lost due to sequelae 
occurring in the long term model. 
 
4.2 Results 
The final model structures are shown in Appendix A. The model input values are 
available in the submitted adaptable Excel spreadsheets (and available from the 
authors on request). The estimated number of annual cases of symptoms relating from 
the 10 exemplar foodborne pathogens are presented in Table 2. 
 
Burden of illness estimates could not be calculated for Enteroaggregative Escheriicha 
coli due to a lack of data in the literature. Outbreaks of this bacteria in the developed 
world have been rare. Furthermore, the one major outbreak which occurred in 
Germany in 2011 was atypical as the pathogen had developed a shiga toxin resulting 
in high rates of haemolytic uremic syndrome and deaths (Buchholz et al., 2011). As 
such it was deemed that accurate and representative burden of illness estimates could 
not be estimated. 
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Table 2: Predicted number of symptom cases for 10 foodborne pathogens per 
year 
  
Mild 
symptoms1 
Hospitalising 
complications2 
Long term 
sequelae3 
Deaths 
Campylobacter spp. 279,899 3505 26,051 34 
Clostridium perfringens 79,219 184 0 2 
Cryptosporidium parvum 2,759 120 14 0 
Giardia lamblia 7,838 93 2,479 0 
Hepatitis E 282 63 0 4 
Listeria monocytogenes 182 126 0 40 
Norovirus 73,763 373 15,545 14 
Salmonella (Non-Typhoidal) 32,973 3,796 2,288 17 
Shigella spp. 1,198 140 7 0 
VTEC O157  9,838 2,261 62 8 
1 
Uncomplicated diarrhoea and/or vomiting, flu-like illness or uncomplicated jaundice 
2
 Hospitalising diarrhoea, febrile convulsions, mesenteric adenitis, septicaemia, osteomyelitis, haemolytic uremic 
syndrome, thrombotic thrombocytopenic purpura or complicated jaundice 
3 
Guillain-Barre Syndrome, Irritable Bowel Syndrome, Reactive Arthritis, renal failure or neurological damage 
 
4.2.1 Base case analysis: number of cases 
The annual number of cases varied significantly by pathogen. Campylobacter spp. 
was widespread estimated to affect a large number of individuals (n=279,899) when 
compared with the rarer Listeria monocytogenes (n=182). The number of 
hospitalisations due to complications was generally low, with the exception of: 
Campylobacter spp. (n=3,505); Salmonella (n=3,796): and VTEC O157 (n=2,261). 
Despite having the lowest number of annual cases, Listeria monocytogenes caused 
the most deaths (n=40). For three pathogens (Cryptosporidium parvum, Giardia 
lambia and Shigella spp.), no deaths were expected in a given year. 
 
4.2.2 Base case analysis: Burden of Illness 
Table 3 presents the estimated total number of QALYs lost, when compared with a 
healthy population (QALY burden) due to the selected foodborne pathogens in a given 
year. The pathogens are reported in order of total QALY burden from largest to 
smallest. The largest burden of illness was attributable to Campylobacter spp. (72,911 
QALYs) and Norovirus (49,877 QALYs) whilst Shigella spp. had the lowest burden (32 
QALYs).  
 
The expected QALY loss for a single case of FBD, by pathogen, is shown in Table 4. 
Listeria monocytogenes had the largest burden per case with an expected loss of 4.03 
QALYs per case. This was four times the size of the expected burden of Giardia 
lamblia which has the second highest burden per case (1.01 QALYs). Clostridium 
perfringens was the least severe pathogen, with an expected QALY loss of 0.004 per 
case, while Cryptosporidium parvum (0.023 QALYs lost per case) and Shigella spp. 
(0.027 QALYs lost per case) also had low burden of illness per case. 
 
4.2.3 Probabilistic sensitivity analysis 
The probabilistic sensitivity analysis allowed uncertainty in the model parameters to be 
incorporated into the results, providing 95% pseudo confidence intervals around the 
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QALY burden estimates. Table 3 shows the average total burden predicted for each 
pathogen along with the confidence intervals around this estimate. The predicted 
burden per case for each pathogen, and the confidence intervals for these estimates, 
are shown in Table 4. 
 
Table 3: Total lifetime QALYs lost due to infections from 10 foodborne 
pathogens falling in a given year in order from largest to smallest burden of 
illness 
Pathogen 
Deterministic 
Burden 
(QALYs) 
Mean 
Probabilistic 
Burden 
(QALYs)1 
Lower 
Pseudo 
Confidence 
Interval1 
Upper 
Pseudo 
Confidence 
Interval1 
Campylobacter spp. 72,911 69,108 39,284 108,238 
Norovirus 49,877 48,068 26,738 72,777 
Giardia lamblia 7,916 6,634 3,602 10,641 
Salmonella (non-
typhoidal) 7,023 6,924 4,100 10,652 
Listeria monocytogenes 734 672 628 716 
VTEC O157 588 537 440 651 
Clostridium perfringens  317 305 174 485 
Hepatitis E 76 51 44 60 
Cryptosporidium parvum 63 59 36 89 
Shigella spp. 32 29 19 42 
1
 Probabilistic burden is the result of the probabilistic sensitivity analysis and allows for uncertainty in the 
parameters of the deterministic model to be incorporated in the analysis. This provides pseudo confidence intervals 
from a Monte Carlo simulation of a data sample.  
 
Table 4: Expected lifetime burden of illness per case for 10 foodborne 
pathogens in order from largest to smallest 
Pathogen 
Deterministic 
Burden per 
Case (QALYs) 
Mean 
Probabilistic 
Burden per 
Case 
(QALYs) 
Lower 
Pseudo 
Confidence 
Interval 
Upper 
Pseudo 
Confidence 
Interval 
Listeria monocytogenes 4.031 3.690 3.449 3.932 
Giardia lamblia 1.010 0.846 0.460 1.358 
Norovirus 0.673 0.652 0.362 0.987 
Hepatitis E 0.269 0.181 0.156 0.213 
Campylobacter spp. 0.260 0.247 0.140 0.387 
Salmonella (non-
typhoidal) 0.212 0.210 0.124 0.323 
VTEC O157 0.060 0.055 0.045 0.065 
Shigella spp. 0.027 0.024 0.016 0.035 
Cryptosporidium 
parvum 0.023 0.021 0.013 0.032 
Clostridium perfringens  0.004 0.004 0.002 0.006 
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4.2.4 Proportion of Burden of Illness Attributable to Sequelae 
 
Sequelae 
The impact of the long term sequelae of infection is shown by their significant 
contribution to overall burden. Where such sequelae were included, their contribution 
to the overall burden of illness eclipsed that of all over symptoms combined. In 
particular, IBS contributed over 70% of the burden of illness resulting from the six 
models in which it was included. On average the burden of illness from IBS was 
87.8%.  Figure 2 shows the proportion of burden attributable to IBS for each pathogen. 
 
Figure 2: Proportion of Total Burden of Illness Attributable to IBS 
 
 
 
While it may seem surprising that the 96% of the burden of illness from pathogens 
such as Campylobacter spp. derives from IBS, this can be explained by the difference 
between the immediate and short term effects and the experiencing of a long term 
chronic disease. For example, of the predicted 279,899 cases of Campylobacter spp., 
approximately 250,000 will only suffer from mild diarrhoea. With a disutility of 0.092 
per case and a mean duration of 0.78 weeks, the typical Campylobacter spp. sufferer 
will only experience a QALY loss of 0.001 QALYs. However, for the 7.6% of patients 
who experience IBS, their condition has a mean duration of 50 years. Coupled with a 
disutility of 0.18, this means that a patient with IBS will expect to lose approximately 9 
QALYs over their life time. Whilst discounting significantly reduces the present value of 
this value, in the first year of experiencing IBS after the year of infection, a patient 
would expect to lose 9,000 times the number of QALYs as a typical Campylobacter 
spp. sufferer only experiencing mild diarrhoea. Even if the disutility from IBS took the 
lowest identified value in the literature (0.014), patients would still expect to experience 
a loss of 0.7 undiscounted QALYS: 700 times that of a typical suffer. While there is 
variation in the IBS disutility reported in the literature, it will remain the key driver of 
foodborne burden of disease due to its chronic, long lasting nature. 
As the sequelae Guillain-Barré Syndrome (GBS) and Reactive Arthritis (RA) only 
appear in models where IBS is also a sequelae, their relative contribution to burden of 
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illness appears small. This is due to the ability of patients to recover from these 
sequelae in a much shorter timeframe than IBS, which often lasts for the rest of a 
patient’s life. However, as these conditions can still last for many years, their burden 
again dominates that of a typical case with mild diarrhoea and/or vomiting. It is for this 
reason that even though a much smaller number of cases suffer GBS (n=198) and RA 
(4,359) than mild and/or vomiting alone (n~250,000), their burden is still sizeable. In 
fact the burden of illness contributed by RA cases is 5% larger (mean=881 QALYs) 
than that contributed by those with mild diarrhoea (mean= 833 QALYs): a population 
approximately 57 times larger. For VTEC O157, the sequelae of renal failure and 
neurological damage show a similar domination of the burden of illness estimates, 
contributing 91% of QALY loss despite only comprising 0.62% of cases. 
 
4.2.5 Age stratification 
The burden of illness falling across four selected age groups was calculated for 
Campylobacter spp., Norovirus, Salmonella and VTEC O157 (Tables 5 and 6).  
 
Table 5: Total lifetime QALYs lost due to infections from 4 foodborne pathogens 
falling in a given year in the UK, stratified by age group 
  Age Group 
Pathogen 
0 to 4 
(n=4,026,270) 
5 to 15 
(n=8,126,951) 
16 to 64 
(n=41,036,710) 
65+ 
(n=11,406,821) 
Campylobacter 
spp. 785 3433 59200 11109 
Norovirus 396 2147 40469 7422 
Salmonella  
(non-typhoidal) 159 393 5679 1139 
VTEC O157 146 147 84 283 
 
Table 6: Expected lifetime QALYs lost per case for 4 foodborne pathogens, 
stratified by age group 
 
Age Group 
Pathogen 0 to 4 5 to 15 16 to 64 65+ 
Campylobacter spp. 0.026 0.120 0.323 0.288 
Norovirus 0.086 0.231 0.864 0.570 
Salmonella (non-
typhoidal) 0.027 0.084 0.312 0.264 
VTEC O157 0.076 0.074 0.019 0.198 
 
For Campylobacter spp., Norovirus and Salmonella, the distribution of burden of 
disease was similar, with the largest burden falling on the adult group and the second 
highest burden falling on the elderly group (see Figure 3). While the number of 
individuals in these adult groups are larger than the smaller age groups representing 
children, the similar patterns observed in the burden per case estimates over these 
age groups suggests that adults contracting these foodborne pathogens experience 
more severe illness. This is particularly true for adults who contract Norovirus who 
have significantly higher burden of illness per case than any other age group.  
 
The pattern of burden of illness per case is reversed for VTEC O157 where individuals 
over the age of 65 experience the most severe disease followed by children of all 
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ages. This is due to the fact that it was assumed in the model that the sequelae of 
renal failure and neurological damage did not occur in the adult population. For each 
pathogen, the most severe illness was experienced by the age group who were most 
likely to experience the sequelae of infection with the pathogen. 
 
Figure 3: Burden of Illness per Case for Four Key Pathogens Stratified by Age 
 
 
The distribution of burden of illness was reversed for VTEC O157 with children (0 to 4 
years: QALYS lost=146, 5 to 15 years: QALYs lost=147), and particularly the elderly 
(QALYs lost=282), facing a higher burden of illness that adults (QALYs lost=84). This 
was also reflected in the burden per case where the expected QALY loss per case of 
VTEC O157 for an individual over 65 years (QALYs lost=0.198) is ten times greater 
than an individual who is between 16 and 64 years (QALYs lost=0.019). 
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5 WILLINGNESS TO PAY VALUES 
 
5.1 Study Design 
The monetary valuation component of the project estimated the economic value of 
(averted) FBD burden. These values are presented at the individual level and 
aggregated to the national level. The stated preference survey used two approaches 
to defining FBDs from the 10 pathogens  
 
Table 7: Willingness to Pay study design parameters 
Description 
of health 
states due 
to FBD 
EQ5D: The estimates derived provide a monetary value per QALY, which 
means that an aggregate value can be generated by from the aggregate 
QALY burden estimates.  
 
Vignettes: The vignette health states that featured in the WTP study are 
mapped on to the Markov Transition Models (MTMs) health states 
through which people suffering illness from the pathogens of interest 
pass. This enables aggregation to the national level because the MTMs 
include estimates of the numbers of people passing through each 
disease state within a year. 
Severity of 
FBD 
Short term or uncomplicated (e.g. lasting up to 14 days) that may be 
widespread but have a relatively low impact on people. 
Long term or more severe consequences and sequelae. These may 
affect patients for months or years and may cause disability or even 
death. 
Population Adults to avoid experiencing FBD themselves. 
Parents (or guardians) to avoid their children experiencing FBD (children 
aged between 2 – 17 years, focusing on one child if the person has more 
than one) 
Disease burden between adults and children distinguished through the 
MTM and QALY work. 
Willingness 
to Pay 
(WTP) 
elicitation 
format 
Discrete choice experiments (DCEs): respondents were asked to 
choose their most preferred choice. Attributes of the choice were several 
symptoms (described as vignettes or through EQ5D, duration and cost).  
However, the representation was modified to make it feel more intuitive to 
respondents. 
Contingent valuation (CV): respondents were asked for their WTP to 
avoid the long term conditions such as IBS or GBS.  
 
Further details about the survey design can be found in Appendixes F-M. 
5.1.1 Description of FBD and design of the WTP elicitation questions 
In the EQ5D-3L version, respondents choose between spending time in competing 
health states described using the generic EQ-5D-3L. In the vignette version, FBD is 
described using a textual vignette. The EQ-5D-3L approach is entirely generic and 
potentially values all possible EQ-5D states. The disadvantage of the EQ-5D 
representation, evident in the focus groups, is that they are less intuitive than the 
vignettes. This was especially so for short term and mild illnesses.  
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For each disease state within the MTMs, a description of that state (e.g. in terms of 
length and nature of symptoms) was generated in conjunction with the project’s clinical 
lead (Professor O’Brien) and used as the basis for vignettes presented to respondents 
within the valuation process. 
 
The vignette approach allows direct valuation of the outcome of interest. Also such a 
vignette provides an intuitive representation of an illness episode to respondents – this 
means the illness could be described in terms of specific symptoms (diarrhoea, 
vomiting, stomach cramps, blood in stools etc.) unlike the generic EQ-5D-3L 
representations. 
 
The vignette approach could require the valuation exercise to include each ‘state’ 
within the MTMs: a potentially large set (See Appendix A). The number of illness 
episodes requiring valuation is reduced by recognising the patient experiences 
symptoms, not pathogens, and in most cases there will be no clinical identification of 
the pathogen causing the symptoms. In the focus groups, the possibility of naming the 
pathogens in the questionnaire was considered. This might have caused different 
responses and valuations for the same set of symptoms (perhaps because of a ‘dread’ 
factor associated with certain pathogen names). The discussions in the focus groups 
did not suggest that naming the pathogen was important to respondents: they were 
concerned with symptoms and long term complications rather than labels. This 
‘sharing’ of symptoms in the vignette descriptions applies to “uncomplicated diarrhoea 
and/or vomiting” across many pathogens and also to many of the sequelae caused by 
FBD.   
 
Both Vignettes and EQ-5D designs had four different versions, which are described in 
the rest of this section:  
 
 Adults – short term, uncomplicated, foodborne illness 
 Adults – long term, complicated, foodborne illness 
 Parents (for Children) – short term, uncomplicated, foodborne illness 
 Parents (for Children) – long term, complicated, foodborne illness 
A concern with the stated preference approach is that it may lead to overstatement of 
values, because the costs are not consequential.  In the development of the survey 
design we developed materials to remind people of their fixed budgets, of the other 
things their money could be spent on and that illness was part of normal life.  They 
were also reminded to think only about the (value of) averted pain and suffering not 
the costs of childcare, lost wages etc. This reminder featured in all versions of the 
questionnaire. 
Vignette Design – Adults: Short Term 
The vignettes had the following common foundation (to which specific attributes were 
added according to an efficient experimental design) (see Table 8):  
“You develop a high temperature, with aching muscles and chills.  You have little 
energy and no appetite.  You develop diarrhoea…” 
The resulting description of the illness was presented as a paragraph (Figure F.1 in 
Appendix F) rather than the more usual discrete choice experiment form in which the 
attributes are separated. The respondents given the choice to experience the option A 
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(e.g. the lower level of vomiting is added, stomach cramps, two doctor visits in an 
illness lasting seven days) or Option B (to avoid it at a cost). Costs are not tied to a 
particular solution (e.g. a pill) or an institution (e.g. NHS) to avoid influencing the 
responses through uncertainties about the efficacy of a pill or the political discussions 
surrounding the institutions. This neutral presentation of costs (and other options) was 
tested in focus groups (Appendix F).   
Table 8: Attributes and levels used in the dichotomous choice experiment 
(vignettes - short term illness) 
Attribute Levels 
Vomiting 
none 
"…and vomiting" 
"you experience uncontrolled and frequent vomiting for 2 days - you 
aren’t always able to make it to the toilet/sink before being violently 
sick” 
Stomach 
cramps 
none 
“..and strong stomach cramps”  
Blood in 
stools 
none 
"..and have blood in your stools (poo)” 
GP visits 
none 
“you visit your GP once, who tells you to rest, drink plenty of fluids 
and take paracetamol."  
“you visit your GP twice, who tells you to rest, drink plenty of fluids 
and take paracetamol.” 
Duration “the illness lasts for ‘x’ days.” (x=1,2,4,7,10,14 days) 
Cost £5, £20, £50, £100, £150 or £250 
 
Twenty four such choice sets were constructed, with the combination of illness 
symptoms and durations being determined by an efficient experimental design (Rose 
et al 2012; Scarpa and Rose, 2008). Plausibility required some combinations were 
prohibited in the design. For example, two doctors’ visits were only allowed if the 
duration was seven days or more, and at least one doctors visit was required if blood 
in the stools featured in the illness.  
 
DCEs often feature an opt-out option – whether it is a ‘none of these’ or a ‘status 
quo’/‘current’ option.  The design here did not include this option since this would 
dominate (“no illness - no cost” would always be preferable). Whether either Option A 
or Option B represents a status quo is debatable. Option A represents the status quo 
in the sense that if the person does nothing they will become ill. Option B represents 
the status quo in the sense that (if the person pays) they will stay in their current 
health. Strictly neither option represents the current position (health or income is 
different in either option) and hence the DCE design could be regarded as a ‘forced 
choice’ design. A design decision like this is made to make sure the questionnaire fits 
the context of the valuation and is an acceptable good practice.  
Vignette Design – Children: Short Term 
The analysis of short term conditions relating to children was similar in design and 
analysis as for the adult sample. The attributes were the same even though the 
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phrasing around them was modified to reflect that illness concerned a child.  An 
example choice set question is shown in Figure F.2 in Appendix F. 
Vignette Design – Adults: Long Term 
The design of the long term vignettes was different. Rather than using a DCE design 
in which illnesses were constructed from attributes, a series of long term named 
conditions were described. These mapped on to the complicated, long term conditions 
associated with the 10 pathogens which were modelled as discrete disease states in 
the MTMs. The long term condition vignettes were defined in collaboration with the 
project clinical lead, Professor O’Brien:  
 
Guillain-Barre Syndrome  (GBS) 
Irritable Bowel Syndrome (IBS) 
Reactive Arthritis (RA) 
Mesenteric Adenitis (MA) 
Septicaemia 
Jaundice 
Osteomyelitis 
Thrombotic thrombocytopenic purpura (TTP) 
Chronic Renal Failure (CRF) 
Meningitis 
Brain damage 
 
Of these 11 conditions, the duration of the illness was varied for eight. For the other 
three (IBS, MA, Brain damage) variations in duration were not considered clinically 
appropriate, as they were either too short or lifelong conditions. More detail is given in 
Appendix G.  
 
The design included six cost levels with the cost levels seen conditioned on the 
respondent’s reported household income. Full details are given in Appendix G. An 
example of a choice question is given in Figure F.3 in Appendix F. 
 
Vignette Design – Children: Long Term 
The analysis of the WTP to avoid long term illness in children followed the same 
approach as in the Adult study. Descriptions were modified and some illnesses were 
added or removed to include all illnesses relevant to children: HUS and febrile 
convulsions were added, and TTP was removed.  
 
EQ5D Design – Adults: Short Term 
In the short run DCE design the attributes were the EQ-5D-3L levels (specified as 
dummies), cost and duration of illness. Duration entered the utility function 
multiplicatively i.e. the utility function in the design recognised that illness would last 
for the duration specified, as well as a separate variable, so that it would be possible 
to identify a separate duration effect to account for e.g. a marginal cost of time 
irrespective of the severity of the illness. 
 
The cost attribute took six levels: £5, £20, £50, £100, £150, £250.     
The durations of the illness were set at 1, 2, 4, 7, 10 and 14 days. 
 
The S-efficient design was generated using Ngene (Choicemetrics, 2014) specified 48 
choice sets, blocked into six groups of eight: each respondent saw eight choice-sets 
comprising two alternatives. Alternative A involved a specified duration of ill health 
before returning to current health, Alternative B meant remaining in current health but 
at a cost (see Figure F.5 in Appendix F). The respondents’ “current health”, self–
assessed earlier in the survey, was piped into the DCE sets. A Dynamic Design was 
implemented to ensure that the “ill health” represented in Alternative A was never 
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                      Final Report 
 
eftec 24 March 2017 
better than the current health in Alternative B - the levels in Alternative A were set to 
those of the efficient design, or the current state, whichever was worse. The cognitive 
efficiency of the “current health” was deemed to outweigh the small statistical cost 
(assessed via simulation) of deviating from a full health design.  
 
Additional design elements were used to reduce the cognitive burden for respondents 
in all EQ-5D instruments. The hierarchy of levels within each of the five health 
dimensions were represented visually via background shading within the sets (see 
Figures F.5 and F.6 in Appendix F which show the darker shading for the worse health 
levels). This also aided comparison between the two alternatives since if a health 
attribute took the same level in both options, the identical shading could help the 
respondent discard the attribute as irrelevant in that set. 
 
EQ5D Design – Adults: Long Term 
In the long run DCE design the health attributes were EQ-5D-3L levels (specified as 
dummies). Rather than choosing between current health and a temporary period of ill 
health at a cost, the two options comprised alternative life paths, of differing durations 
and differing incomes. In each case, the specified life span (of given health, income 
and duration) was followed by death (see Figure F.7 in Appendix F).  This allowed 
estimation of the value of a QALY. 
 
EQ5D Design – Parents: Short Term 
The child illness design followed the same structure as for adult illness with parents 
making choices between a reduced health state, and their child’s current health at a 
cost, for a nominated child (see Figure F.6 in Appendix F). 
 
EQ5D Design – Parents: Long Term 
The design of the EQ-5D DCE for long term child ill health took the same form as the 
short term DCE. The parents chose between (i) ill health for their child for a fixed 
duration followed by a return to current health and (ii) a current health option with a 
cost. The durations and costs were much greater in the long term DCE. 
The cost attribute took 6 levels in the design: £5k, £20k, £50k, £100k, £150k, £250k. 
The ‘number of years duration of the illness’ were set at 1, 2, 4, 7, 10 and 14 years.  
Because of the seriousness of the illness, and the duration, the costs were set to be 
substantial values. However, in the presentation to respondents these values were 
pivoted off their income level. 
 
5.1.2 The overall questionnaire structure  
The questionnaire and the materials included within it were subject to extensive testing 
and revision before the main samples were recruited. Six focus groups were held in 
Manchester, Cardiff and London, with materials refined after each. In addition, 20 
cognitive interviews were held using the draft questionnaire and feedback from them 
led to the final questionnaire used in the surveys. Focus group and cognitive interview 
summary reports are presented in Appendix F. 
PDFs of the questionnaires used are in Appendix H (adult illness, vignette), Appendix I 
(child illness, vignette), Appendix J (adult illness, EQ-5D-3L) and Appendix K (child 
illness, EQ-5D-3L). A summary structure for the questionnaires is provided in Table 9.  
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Table 9: Questionnaire structure 
Vignette Questionnaire Structure EQ-5D-3L Questionnaire Structure 
i. demographics (gender, age, occupation, 
income) 
i. demographics (gender, age, occupation, 
income) 
ii. history of diarrhoea, stomach upsets, vomiting 
and food poisoning in family in past year  
ii. history of diarrhoea, stomach upsets, 
vomiting and food poisoning in family in 
past year  
iii. review some descriptions of food poisoning  iii. review some descriptions of food poisoning
  
iv. recall & describe a food poisoning episode 
and give WTP to avoid  
iv. recall & describe a food poisoning episode 
and give WTP to avoid  
v. indicate various costs of being off work (1 day, 
5 days)  
v. indicate various costs of being off work due 
to food poisoning (1 day, 5 days) 
vi. rate their (child’s) health using EQ-5D-3L  vi. a practice vignette DCE set 
vii. explain the short term valuation tasks, and a 
practice choice set  
vii. explanation of EQ-5D-3L 
viii. ‘cheap talk’ script* viii. rate own (child’s) health using EQ-5D-3L
  
ix. 8 short term valuation choice sets  ix. given a FBD vignette  - rate their (child’s) 
health using EQ-5D-3L if they had that 
illness 
x. debrief questions on task difficulty & protest 
behaviour (always paid, never paid)  
x. a practice EQ-5D DCE set 
xi. explain the long term food poisoning 
conditions   
xi. cheap talk script* 
xii. explain the long term valuation tasks, and a 
practice choice set  
xii. eight short term EQ-5D DCE sets  
xiii. 10 long term valuation questions  xiii. debrief questions on task difficulty & protest 
behaviour (always paid, never paid)  
xiv. debrief questions on task difficulty & protest 
behaviour (always paid, never paid)  
xiv. explain the long term food poisoning 
conditions   
xv. rate how their (child’s) health would be, using 
EQ-5D-3L, if they had a FBD (drawn from the 
set of vignettes). Repeated.   
xv. explain the long term valuation tasks 
xvi. demographics (region, ethnicity, education, 
medical training, experience of named 
conditions) 
xvi. eight  long term EQ-5D DCE sets  
 xvii. debrief questions on task difficulty & choice 
behaviour (always paid, never paid)
  
 xviii. rate how their (child’s) health would be, 
using EQ-5D-3L, if they had a food 
poisoning illness (drawn from the set of 
vignettes). Repeated.   
 xix. demographics (region, ethnicity, education, 
medical training, experience of named 
conditions) 
Note: * ‘cheap talk’ scripts are designed to reduce hypothetical bias. Respondents are reminded that they had 
limited income and that illness and temporary discomfort are part of normal life. The parent version of the 
questionnaire also included some additional cheap talk script concerning the unusual nature of them (not) paying to 
alleviate their child’s pain and suffering. 
5.1.3 Sample Recruitment & Descriptive Statistics 
The samples for Adult and Child illness valuation were collected via an online market 
research panel (panel by Research Now) between October 2016 and January 2017. 
For the Adult sample, the specification was for a UK representative sample of adults. 
For the parents, the sample size required was demanding and required them to 
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approach all the parents of children aged 2+ whom they held in their panel. A full 
report of descriptive statistics for the samples is available in Appendices L (vignette 
samples) and M (EQ-5D-3L samples). Table 10 summarises the population 
characteristics.  
 
The explanatory information and valuation questions were cognitively demanding, 
especially so for the long term conditions (hence the time and resources assigned to 
their development and testing). The ability of respondents to process and incorporate 
that information in their choices is partially revealed by statistical analysis of the 
valuation choice data. 
 
Additional insights are available from debrief questions. In the Adult-Vignette sample, 
2% and 8% described the short term sets as ‘very difficult’ and ‘difficult’ respectively.  
The rates in long term sets were 4% and 9%, respectively, a higher but still very small 
percentage.  In the Parent-Vignette sample, 4% and 8% described the short term sets 
as ‘very difficult’ and ‘difficult’, respectively.  The rates in long term sets were 6% and 
11%, respectively. The numbers reporting the short term EQ-5D valuation questions 
as being “very difficult” to understand was low (2% adults, 5% parents) with equivalent 
figures for the long term EQ-5D questions of 4% and 8% respectively. These rates are 
very low and hence a factor confirming the validity of the responses.  
 
Sections 5.2 and 5.3 present the results of the Vignette and EQ-5D-3L versions of the 
questionnaire. Since the data analysis for these two designs require different 
approaches, results are grouped into these versions. Within each section, results for 
short and long term conditions and for adults and parents (for their child) are reported 
separately, where possible. Details of the analysis are presented in Appendix L for 
vignette design and Appendix M for EQ-5D-3L design.  
 
The results are presented here in terms of unit estimates with the median household 
income. The look up tables presented in Appendix O aim to help the user to define the 
combination of symptoms and durations associated with a given pathogen to estimate 
the relevant WTP to avoid pain and suffering. The tables also allow the user to 
estimate WTP to avoid pain and suffering at different levels of gross median 
household income.  
 
Table 10: Sample characteristics 
Sample name Size* Female – 
male (%) 
Geographical distribution 
(England, Scotland, Wales, 
NI) 
Median gross 
household 
income 
Adult - Vignette 1189 (1040) 53-47 83.7% - 8.2% - 5% - 3.1% £25-35,000 
Adult – EQ-5D-3L 2211(2097) 52-48 83.2% - 9.3%  - 5.3% - 2.2% £25-35,000 
Parent - Vignette 653 (592) 60-40 84.9% - 7.8% - 3.7% - 3.6% £35-45,000 
Parent – EQ-5D-3L 720 (668) 50-50 84% - 8% - 6% - 2% £35-45,000 
Total sample 4773 (4397) 
*Figure in brackets is the usable sample once those completing the survey excessively quickly were removed. 
Geographical distributions were close to the true population proportions. Median household income for the UK is 
£31,655 is the gross income adjusted from £26,400 disposable income estimate for 2015/16 in
 3
.  
                                            
3
 
https://www.ons.gov.uk/peoplepopulationandcommunity/personalandhouseholdfinances/incomeandwealth/bulletins
/nowcastinghouseholdincomeintheuk/2015to2016 
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5.2 WTP Results – Vignettes  
More details on Vignette results are provided in Appendix L which show statistically 
significant models and individual variables. Here the key points for adult and parent 
samples are presented for short and long term conditions, Sections 5.2.1 and 5.2.2 
separately.   
5.2.1 Short term Conditions 
 
Adults 
WTP measures for each element of illness are reported in Table 11 based on the 
significant attributes. These are displayed based on median household income and 
with zero costs from being too ill to work (since the objective is to estimate WTP for 
pain and suffering). These results are presented for each symptom per unit duration, 
except for doctors’ visit which the analysis showed was insignificantly different 
between one or two visits. There is also a fixed component of the WTP to avoid the 
pain and suffering of FBD regardless of the duration of the symptoms. 
 
Table 11: WTP to avoid the pain and suffering of short term FBD conditions:  
adult 
 WTP (£)* 95% CI 
Fixed diarrhoeal illness effect** 43.19 32.10 54.29 
For each day of diarrhoea  3.98 3.068 4.88 
For each day of vomiting 1.68 0.53 2.83 
2 days of extreme vomiting  26.76 15.66 37.86 
For each day of with blood in stools 2.96 1.30 4.62 
Doctor visited 17.35 9.63 25.07 
*
Evaluated at gross household income level of £31 655 
**This is the value of the illness episode, irrespective of duration and characteristics. 
 
The unit estimates in Table 11 can be used to estimate different symptom 
combinations. For example, the WTP to the pain and suffering from avoid a 3-day 
illness involving a high temperature, with aching muscles and chills, diarrhoea and 
vomiting is: 
 
£60.17= £43.19 + (3 x £3.98) + (3 x £1.68) 
 
If the illness also involved two days of extreme vomiting (as might be associated with 
Norovirus), the WTP would increase by £26.76. 
 
The role of income in moderating the WTP to avoid short term foodborne illness is 
evident in Figure 4 which shows an increase in WTP of 13% between those with gross 
household income of £30,000 and £100,000. 
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Figure 4: Income effect on WTP to avoid a 3 day adult illness with a high 
temperature, aching muscles and chills and diarrhoea and vomiting - adults 
 
 
Parents 
The analysis of short term conditions relating to children followed the approach 
described for adults – starting with estimation of a conditional logit model (reported in 
Appendix L). WTP estimates are reported in Table 12 for the statistically significant 
attributes.  There is a much larger estimate for the ‘fixed’ effect: the amount parents 
are willing to avoid the baseline illness (high temperature, aching muscles and chills, 
little energy and no appetite with diarrhoea), irrespective of additional characteristics 
compared to the value for adults (compared £43.19, Table 11).  This is to be expected. 
The marginal effects are broadly similar. 
 
Table 12:  WTP to avoid the pain and suffering of short term FBD conditions:  
parent 
 WTP (£)* 95% CI 
Fixed effect** £125.73 111.43 140.02 
For each day of diarrhoea / vomiting £4.87 3.80 5.93 
2 days of extreme vomiting £17.41 5.30 29.53 
For each day of with blood in stools £5.04 3.06 7.02 
*: 
Evaluated at household income level of £31,655 
**: This is the value of the illness episode, irrespective of duration and characteristics 
The unit estimates in Table 12 can be used to estimate different symptom 
combinations. For example, WTP to avoid the pain and suffering from a 3 day illness 
for their child involving a high temperature, with aching muscles and chills and 
diarrhoea is: 
£140.34 = £125.73 + 3*£4.87  
 
If the illness also involved blood in the child’s stools the WTP would increase to 
£155.46. 
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5.2.2 Long term Conditions 
 
Adults 
Analysis of the long term conditions requires a logit model which provides results in 
terms of the median WTP: the value at which 50% of the sample will pay to avoid the 
illness.  These values are reported in Table 13, evaluated for someone aged 40 (the 
age of the representative respondent used in the MTMs) and at the median household 
income of £31,655.   
 
As with the short term illness results, there is also a ‘fixed effect’ for the long term 
conditions, which is the sum they are willing to pay irrespective of the duration of the 
illness. There is also a marginal effect, which is the additional contribution to the WTP 
to avoid pain and suffering for each additional year of illness. 
 
The scale of the age-duration interaction effect is evident in Figure 5. Holding income 
at the median level, the plot shows how WTP to avoid pain and suffering due to 
lifelong IBS declines with the age of the respondent. The WTP of £2,666 at age 70 is 
85% lower than the value at age 30 (£17,286). 
 
Table 13:  WTP to avoid the pain and suffering of long term FBD conditions:  
adult (£, evaluated at median income (£31 655), age of 40)  
 Fixed effect 
£ per case 
Marginal effect  
£ per year 
GBS  
ns 7,581        
(4,686-10,476) 
IBS 
13,653        
 (8,186-19,119) 
na 
RA 
ns 1,584       
(1,121-2,046) 
MA 0 na 
Septicaemia  19,869        
(10,062-29,675) 
ns 
Osteomyelitis -4,005       
(-8,784-774) 
8076 
(4,382-11,770) 
TTP 
6,034         
(605-11,462) 
5,264        
(1,635-8894) 
CRF 
45,804       
(21,056-70,552) 
ns 
Meningitis ns 5,108        
(2,615-7,602) 
Jaundice  26,700       
(15,457-37,944) 
5,112        
(-130-10,355) 
Brain damage 223,871      
(155,409-292,333) 
na 
(95% CI in parenthesis) 
na: length of illness not included for the condition 
ns: length of illness was included but not significant & dropped from the model 
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Figure 5: Effect of the age of onset on adults’ WTP to avoid pain and suffering 
due to lifelong IBS 
 
The WTP is moderated by income as well as age as shown in Figure 6 which shows 
(for three age levels: 20, 40, 60) how WTP to avoid pain and suffering due to lifelong 
IBS increases with gross household income levels. 
 
Figure 6: Age and Income effect on adults’ WTP to avoid pain and suffering due 
to lifelong IBS  
 
 
 
Parents 
Table 14 reports the implied median WTP to avoid pain and suffering due to each of 
the long term conditions. Although there is limited sensitivity to duration of illness 
within some conditions, there does seem to be a reasonable sensitivity across 
conditions.  The most extreme illness (brain damage, HUS, CRF and Jaundice, which 
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involves a liver transplant – see Appendix G for illness descriptions) all have values in 
excess of £100,000, while MA and Osteomyelitis are much lower.   
 
Table 14: WTP to avoid the pain and suffering of long term FBD conditions:  
parent (£, evaluated at median income (£31 655))  
 Fixed effect 
£ per case 
Marginal effect 
£ per year 
GBS 63,923          
(28,161-99,686) 
7072          
(-550-14,694) 
IBS 22,744          
(14,185-31,303) 
na 
RA 17,030          
(12,008-22,052) 
2,222         
(628-3,815) 
MA 1,747                  
(909-2,586) 
na 
Septicaemia  98,074      
(63,475-132,674) 
ns 
Osteomyelitis 8,869              
(4,489-13,249) 
5,766         
(-169-11,701) 
HUS 173,263     
(122,056-224,470) 
ns 
CRF 146,296     
(110,152-182,440) 
ns 
Meningitis 57,625          
 (41,846-73,403) 
ns 
Jaundice involving a liver 
transplant  
117,132       
(85,102-149,163) 
na 
Brain damage 352,412     
(257,302-447,520) 
na 
Febrile convulsions 7,979               
(3340-12,618) 
na 
(95% CI in parenthesis) 
na: length of illness not included for the condition 
ns: length of illness was included but not significant & dropped from the model except for Osteomyelitis 
which was only very marginally not significant 
 
5.3 WTP Results – EQ-5D  
More details on EQ-5D results are provided in Appendix M which shows statistically 
significant models and individual variables. Here the key points for adult and parent 
samples are presented for short and long term conditions, Sections 5.3.1 and 5.3.2 
separately.   
5.3.1 Short term Conditions 
 
Adults 
Because the marginal utility of money varies with gross household income levels, in 
Table 15 three values are reported: for median gross household income (£31,655) and 
at a lower (£10,000) and higher (£100,000) value.   
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Table 15:  WTP to avoid pain and suffering associated with 1 day of reduced 
health, relative to full health, £/day 
 Low Income 
£10,000 
Median Income 
£31,655 
High Income 
£100,000 
mobility_D2 -1.36 -1.47 -1.95 
mobility_D3 -3.52 -3.81 -5.17 
selfcare_D2 -2.25 -2.43 -3.30 
selfcare_D3 -6.67 -7.23 -9.80 
usualactivities_D2 -1.45 -1.57 -2.12 
usualactivities_D3 -3.30 -3.58 -4.85 
pain_D2 -1.83 -1.99 -2.69 
pain_D3 -8.00 -8.67 -11.75 
anxiety_D2 -0.40* -0.43* -0.59* 
anxiety_D3 -5.49 -5.95 -8.06 
T -4.85 -5.25 -7.12 
T x LE -0.002 -0.002 -0.002 
Ill -21.91 -23.73 -32.17 
All estimates significantly different from zero at p<0.001, unless indicated. 
*
 not significantly different from zero. 
Negative WTP values correspond to a decline in utility from the base category. Mobility, self care, performing usual 
activities, pain / discomfort, anxiety/depression are the five dimensions of EQ-5D. The three levels apply to each of 
these five dimensions in terms of Level D1: “no problems”, D2: “some problems” and D3: “the worst case” (confined 
to bed, unable to self-care, unable to perform usual activities, extreme pain and extremely anxious or depressed). 
T: the length of the illness, irrespective of health state. LE: self-reported lost earnings per day (LE). 
ILL: an individual specific Alternative Specific Constant (ASC) coded as 1 for the illness option and 0 otherwise.  
 
The ‘fixed effects’ imply that a respondent with median income is willing to pay £23.73 
to avoid pain and suffering due to illness, and an additional £5.25 per day of illness, 
irrespective of the health state. Although significant, the effect of lost earnings is 
negligible: for every £ per day in lost earnings expected, their WTP increases by 0.2 
pence, i.e. someone with expected lost earnings per day of £100 will place a value on 
avoiding day of illness of £5.30, compared to £5.10 for someone with zero lost 
earnings.  
 
The WTP to avoid pain and suffering due to a period of ill health can be aggregated 
from its elements – as shown in Appendix O. For example, an illness that last for 5 
days and reduces mobility to being confined to bed, and involves extreme pain or 
discomfort, would be valued at: 
 
£112.38 = £23.73 + 5 * (5.25 + 8.67 + 3.81) 
 
A more minor illness: 3 days of moderate pain or discomfort would be valued at:  
 
£45.45 = £23.73 + 3 * (5.25 + 1.99)  
 
Those on higher incomes are willing to pay more to avoid the illness but the effect is 
not proportional to income: moving from £32,000 to £100,000 of income leads to a 
36% increase in values.   
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Parents  
Because the marginal utility of money varies with income level, Table 16 reports three 
values: for gross median income (£31,655) and at lower (£10,000) and higher 
(£100,000) income levels. 
 
Table 16:  Parents’ WTP to avoid pain and suffering associated with 1 day of 
child’s ill health, relative to full health, £/day 
 Income 
£10,000 
Median income 
£31,655 
Income 
£100,000 
mobility_D2 -1.76 -1.86 -2.26 
mobility_D3 -2.63 -2.78 -3.39 
selfcare_D2 0.65* 0.69* 0.84* 
selfcare_D3 -2.90 -3.07 -3.73 
usualactivities_D2 -1.53 -1.62 -1.97 
usualactivities_D3 -4.47 -4.72 -5.75 
pain_D2 -3.71 -3.92 -4.77 
pain_D3 -9.16 -9.68 -11.78 
anxiety_D2 0.65* 0.69* 0.84* 
anxiety_D3 -4.63 -4.89 -5.95 
T -3.94 -4.16 -5.07 
All estimates significantly different from zero at p<0.001, unless indicated. 
*
 not significantly different from zero 
 Negative WTP values correspond to a decline in utility from the base category. Mobility, selfcare, performing usual 
activities, pain / discomfort, anxiety/depression are the five dimensions of EQ-5D. The three levels apply to each of 
these five dimensions in terms of Level D1: “no problems”, D2: “some problems” and D3: “the worst case” (confined 
to bed, unable to self-care, unable to perform usual activities, extreme pain and extremely anxious or depressed). 
T: the length of the illness, irrespective of health state,  
 
The results from the Parent EQ-5D study for short term child ill health have largely 
‘worked’, as judged by the sign and significance of terms and the plausibility of the 
WTP values presented in Table 16.  
 
5.3.2 Long term Conditions 
 
Adults 
Table 17 reports estimates of the marginal willingness to pay per year to avoid pain 
and suffering due to each of the 10 health states below full health. 
For the higher level (level 3) illness states, the WTP to avoid a year in that state are 
relatively high proportions of income: up to 94% to avoid being confined to bed for one 
year and 86% to avoid a year of extreme pain. 
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Table 17: WTP to avoid year in a health state, as proportions of current income 
variable WTP SE Z 
mobility_D2 0.49 0.09 5.41 
mobility_D3 0.94 0.04 23.97 
selfcare_D2 0.30 0.095 3.16 
selfcare_D3 0.86 0.06 13.25 
usualactivities_D2 0.32 0.08 4.01 
usualactivities_D3 0.63 0.09 7.02 
pain_D2 0.45 0.09 4.94 
pain_D3 0.86 0.06 14.05 
anxiety_D2 0.48 0.09 5.22 
anxiety_D3 0.84 0.07 11.82 
Mobility, selfcare, performing usual activities, pain / discomfort, anxiety/depression are the five dimensions of EQ-
5D. The three levels apply to each of these five dimensions in terms of Level D1: “no problems”, D2: “some 
problems” and D3: “the worst case” (confined to bed, unable to self-care, unable to perform usual activities,  
 
Parents 
The analysis reported in Appendix M indicates that respondents paid very little 
attention to the EQ-5D-3L health attribute levels when making their choices – most 
parameter estimates are insignificant. However, the respondents did take account of 
the duration of the illness and the cost to avoid illness. Further, there was a significant 
effect of income on what people would pay to avoid their child’s pain and suffering due 
to illness.  Although these results indicate that parents are willing to pay to avoid long 
term illness for their children, they are of little use as the choices. Hence any WTP 
values derived from them are not differentiated by the severity of the illness 
experienced by the child.  
 
5.3.3 Monetary Value of a QALY 
The model estimated for the responses to the EQ-5D version of the questionnaire 
(Appendix M) can be used to estimate the value of obtaining an additional year of full 
health i.e. the WTP to acquire a QALY. Conceptually this identifies the reduction in 
income that would exactly offset the increase in utility associated with the length of life 
being extended by one year at full health. 
 
Analysis of the choice data indicated that respondents were not discounting. An 
assumption has to be made as to whether additional income is earned when the 
additional year of life is gained. Both no additional income and additional median 
income assumptions are tested (Appendix M).  
 
To illustrate the effect of household income and the number of life years remaining (T), 
Table 18 reports the values for a QALY for three different income levels, and for an 
initial T of 1 and 10. 
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Table 18: WTP for a QALY, by income level, and number of years of life 
remaining (£) 
 Gross Median Household Income 
 £10,000 £31,655 £100,000 
T=1 6,100 
(3,400-8,90) 
19,456 
(10,700-28,200) 
61,500 
(33,900-89,100) 
T=10 12,300 
(3,600-20,900) 
38,900 
(11,600-66,200) 
122,900 
(36,500-209,200) 
T: expected life span. (95% confidence intervals in the brackets). 
 
As expected, the WTP increases in proportion to income. If one takes the median 
income of £31,655 then the WTP for a QALY would be £19,456 for a year gained 
immediately.  
 
These results assume that there is no rate of time preference. As the additional year of 
life occurs at the end of the period, then discounting with a positive discount rate will 
reduce the WTP. 
 
These results are based on the assumption that the additional year of life does not 
affect wealth, i.e. that consumption in that year has to be met by reallocating 
consumption from other years. An alternative assumption is that the earning capacity 
of the individual was the same in that additional year. This changes the fundamental 
object being valued: it is now an additional year of life, plus an addition to wealth of Y. 
WTP for a QALY increases simply by the amount of annual income. Thus, WTP for a 
QALY for an individual at median income, under these assumptions, would be 
£31,655 + £19,456 = £51,111 per year. Similarly, all other estimates simply need to be 
updated by the value of annual income.  
 
5.4 Aggregation of WTP to avoid foodborne illness 
The WTP estimates reported in Section 5.3 are at the level of the individual (adult, 
child, short term, long term). In this Section, aggregated results are presented for 
vignette and EQ-5D versions of the questionnaire.  
 
Going forward the WTP results could be updated with respect to  
 
 Any changes in the sensitivity to FBD and hence WTP to avoid it (this would 
require new update surveys which would not be necessary on an annual basis 
unless there is significant change in the health evidence) 
 Inflation – best through changes in real income to address the income effect on 
WTP. HM Green Book advice should be followed for this.  
 Population changes (perhaps not annually but to reflect any significant changes 
in the number and composition of the population). ONS population statistics can 
be used for this.  
 
5.4.1 Aggregation - Vignettes 
The MTMs provide the foundation for the monetary aggregation based on vignette 
WTPs. They define the health states people move through, the numbers doing so and 
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the utility decrement associated with that state. Aggregate WTP estimates of burden 
involve replacement of the QALY disutility of the states with the estimated WTP to 
avoid the pain and suffering associated with those states. There are however 
complications in doing so regarding: 
 
Duration & WTP 
For some conditions (such as septicaemia) respondents were not sensitive to long 
term duration meaning only a “fixed effect” WTP is available. Such duration-invariant 
WTPs are accommodated within the WTP aggregation by multiplying the estimated 
monetary fixed effect by the number of UK cases simulated by the model.   
 
For conditions for which there is both a fixed and marginal effect, both a WTP value 
associated with the number of cases, and a value associated with the duration of 
those cases are included.  
 
Death 
The vignette WTP study does not provide a value for death. We designed the 
valuation question in terms of certain outcomes instead of risks of any given ill health 
state occurring. Therefore, the survey would not ask respondents about their WTP to 
avoid their certain death. To address this gap we use the value of a QALY reported in 
Section 5.3.3 of £19,456.   
 
We report this process of aggregation in detail for Campylobacter spp., before 
presenting results for the full set of 10 pathogens. 
 
Table 19 reports WTP values estimated for the marginal value for a year in each state, 
and any fixed effects. Note that these values are weighted averages of the adult and 
child illness values, to reflect that the aggregate number of cases include both adults 
and children. For Campylobacter spp., Salmonella, Norovirus and VTEC O157, the 
age weightings were taken from the age stratified MTMs developed in the study. For 
Hepatitis E all cases were assumed to occur in adults and for the remaining five 
pathogens the proportional split between adults and child cases was taken from data 
provided by Public Health England (private correspondence). The weightings are in 
each of the MTM Excel look up tables in Appendix O. 
 
Table 19: Values used in estimating aggregate WTP to avoid disease – 
Conditions relevant to Campylobacter spp. only 
 
Fixed effect 
(£’000 per case) 
Marginal effect 
(£’000 per year) 
Uncomplicated Diarrhoea /vomiting 0.060 2.006 
Hospitalizing Diarrhoea /vomiting 0.084 3.313 
Febrile Convulsions 7.978 0 
Mesenteric Adenitis 1.747 0 
Septicaemia 35.98 0 
GBS 6.83 7.581 
IBS 14.05 0 
RA 6.51 1.584 
Dead -- 19.5 
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The values in Table 19 are multiplied by the number of person episodes spent in each 
state from Section 4. Table 20 reports these values generated using the two 
monetisation approaches. 
 
For Campylobacter spp. the magnitude of the monetary values is quite different 
between the vignette WTP study (£429m) and that from monetising the QALY burden 
using a value of £19,456 per QALY (£1,419m).  A large part of the difference in total 
burden is due to the difference in the monetary value assigned to IBS: vignette WTP to 
avoid pain and suffering due to IBS is 14,050 per case, while the monetary value of a 
QALY is £60,093.  The large number of cases of IBS (21,500) associated with 
Campylobacter spp., and their long duration, means this difference in £/case leads to 
substantial differences in the aggregate monetary burden. 
 
Table 20:  Estimates of monetary burden from pain and suffering arising from an 
annual caseload of Campylobacter spp. 
 WTP (£’000) 
Total 424,244 (308,244 - 540,264) 
Uncomplicated Diarrhoea 34,939 (30,900 - 38,900) 
Hospitalizing Diarrhoea 472 (427 - 518) 
Febrile Convulsions 339 (138 - 540) 
Mesenteric Adenitis 426 (218 - 635) 
Septicaemia 22,515 (15,700 – 29,300) 
GBS 6,855 (4,800 - 8,900) 
IBS 302,071 (187,160 - 417,00) 
RA 41,972 (29,800 – 54,100) 
Dead (from all of at the above) 14,654 (7,900 - 21,400) 
 
The aggregation process reported for Campylobacter spp. is repeated for the other 
nine pathogens, generating the values reported in Table 21. 
 
Table 21: Aggregated monetary value of avoiding pain and suffering associated 
with aggregate foodborne disease burden, by pathogen  
 
Burden 
£ million 95% Conf Intervals 
Campylobacter spp. 424.2 (308.2-540.3) 
Clostridium perfringens 9 (7.6 - 10.4) 
Cryptosporidium parvum 0.8 (0.6 - 1) 
Giardia lamblia 40 (27.8 - 52.2) 
Hepatitis E 12.5 (9.2-15.8) 
Listeria monocytogenes 18.5 (10.8 - 26.2) 
Norovirus 248.5 (164.9 - 332.1) 
Salmonella (Non-Typhoidal) 143.9 (119.1 – 168.7) 
Shigella spp. 7.7 (5.8 - 9.7) 
VTEC O157  38.4 (31.9 – 45.0) 
Total 943.6  
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The monetary value of the FBD burden is considerably lower from the aggregation of 
vignette based WTP values than from the monetisation of the QALY losses:  £921.7m 
based on vignette WTP values against £2715m from monetising the QALY burden at a 
value of £19 456 per QALY.  As discussed with respect to Campylobacter spp., a large 
part of this difference is due to the monetary value assigned to IBS between the two 
approaches. 
 
5.4.2 Aggregation - EQ5D 
Assuming the loss of the QALY occurs at T=1, the value of £19,456 (from Section 5.3) 
is applied to the estimated QALY losses reported in Table 3, giving values reported in 
Table 22. 
 
Table 22: Aggregated monetary value of disease burden QALY losses, by 
pathogen 
 
QALY 
loss £ / QALY Burden, £m 
95% 
Confidence 
Interval 
Campylobacter spp. 72,911 19,456 1418.6 (730.6-2106.6) 
Norovirus 49,877 19,456 970.4 (492.1-1448.6 
Giardia lamblia 7,916 19,456 154.0 (85.8-222.2 
Salmonella (non-typhoidal) 7,023 19,456 136.6 (69.1-204.1 
Listeria monocytogenes 734 19,456 14.3 (8.3-20.30 
VTEC O157 588 19,456 11.4 (6.5-16.3) 
Clostridium perfringens  317 19,456 6.2 (3.3-9.1) 
Hepatitis E 76 19,456 1.5 (1.0-1.9) 
Cryptosporidium parvum 63 19,456 1.2 (0.6-1.8) 
Shigella spp. 32 19,456 0.6 (0.3-0.9) 
TOTAL 
  
2714.8 (2159.3-3270.3) 
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6 SUMMARY AND RECOMMENDATIONS 
 
This study has produced 10 Markov State Transition Models that are used to estimate 
the QALY burden of selected foodborne pathogens over two time frames, one-year 
and a life-time. The life-time horizon incorporates the burden of illness as a result of 
sequelae from the foodborne pathogen.  
 
Published data were used to populate these decision-analytic models but the 
spreadsheet lookup templates developed (Appendix O) allow users to use their own 
data sources to adjust the model input parameters and derive new estimates of 
burden.  
 
The utility values identified in the published literature for selected health states were 
cross checked against current UK values derived from the in-progress Integrate study. 
Utility values for uncomplicated and complicated (hospitalising) illness estimated on a 
sample of c.300 patients from Integrate were found to be similar to the utility values in 
the literature and used in the MTMs. 
 
Using the MTMs, the estimated annual number of cases varies significantly by 
pathogen. Campylobacter spp. has the biggest impact in terms of the number of cases 
compared with the rarer Listeria monocytogenes.  The estimated number of annual 
deaths from Campylobacter spp. (34) is fewer than commonly reported4. 
 
The number of hospitalisations due to complications is generally low, with the 
exception of: Campylobacter spp., Salmonella and VTEC O157. Despite having the 
lowest number of annual cases, Listeria monocytogenes causes the most deaths.  
 
The largest QALY burden of illness is attributable to Campylobacter spp. whilst 
Shigella spp. has the lowest burden. Listeria monocytogenes has the largest burden 
per case. This is four times the size of the expected burden of the next most severe 
pathogen Giardia lamblia.  
 
Probabilistic sensitivity analysis allowed uncertainty in the model parameters to be 
incorporated into the results and showed substantial variation around the mean QALY 
burden estimates as reported in Section 4.  
 
Results from an age-disaggregated analysis indicate that for Campylobacter spp., 
Norovirus and Salmonella, the age profile of the burden of illness was similar across 
four age groups (0-4, 5-15, 16-64 and 65+). For those pathogens the largest burden 
fell on the adult group (16-64) with the second highest burden falling on the elderly 
group (65+). In contrast, for VTEC O157 the highest burden was associated with the 
elderly, followed by children (5-15). 
 
Giardia lamblia accounts for relatively few cases but is ranked the third in terms of 
overall QALY burden per pathogen (6% total QALY loss). This is largely a result of the 
relatively high probability of developing Irritable Bowel Syndrome (IBS).  IBS accounts 
                                            
4
 See https://www.food.gov.uk/sites/default/files/multimedia/pdfs/campylobacterstrategy.pdf  
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for a very large proportion of the aggregate burden from microbiological FBD. It 
dominates QALY losses associated with death. This is because of its relatively high 
incidence, long duration and the high disutility placed upon the condition. The large 
share of burden associated with IBS applies to both QALY and monetary analyses but 
to a lesser extent.  
 
Turning to the monetary analysis, the study has involved the development and testing 
of stated preference valuation instruments concerning the value of pain and suffering 
associated with FBD. These instruments have used vignette and EQ-5D-3L 
representations of illness. The EQ-5D component is one of very few studies which 
have sought to include a payment vehicle alongside EQ-5D attributes and a duration 
term. Thus, this project was a test case for this approach. An attraction of such an 
approach is the possibility of estimating the monetary value of a QALY.  
 
The results indicate that it is possible to successfully implement Stated Preference 
surveys concerning the value of pain and suffering associated with FBD. Rates of 
protest behaviour, such as rejection of the scenario in which one is asked to pay to 
avoid illness, were low. The magnitude of estimated WTP values was plausible with 
little evidence of extreme ‘yea saying’, or overstatement of values.  
 
There were differences between the experience of using vignette and EQ-5D-3L 
approaches. The former approach ‘worked’ when implemented with respect to both 
adult and child illness, for short and long term conditions. The EQ-5D-3L valuation 
approach resulted in significant parameter estimates, of the anticipated sign, and WTP 
results in plausible ranges for adult illness. For the parent sample concerned with child 
illness this was true only for short term ill health, but not long term conditions. In these 
latter results many EQ-5D-3L health parameter estimates were insignificant. The 
results suggest that the duration of the long term conditions was, to a large degree, 
driving choices rather than the specific health states. The ‘success’ of the Vignette – 
WTP study for long term conditions in children implies that this is not caused by a 
wholesale rejection of the valuation scenario by parents. Rather it was the specifics of 
the EQ5D-3L approach that caused the disregarding of health attribute levels. 
 
We note that because the long term child EQ-5D did not include choices between lives 
of differing length for the child, measures of the WTP for a QALY could never be 
derived from such choice data. The WTP for a QALY is derived from the Adult version 
in which people chose between two lives of differing incomes, health states and 
durations.  
 
The WTP estimates for a QALY for someone on median gross household income of 
£31,655 ranged between £19,456 and £38,900 depending on the number of years of 
life remaining prior to the additional year being obtained (1 and 10 years respectively 
for the values reported). 
 
The WTP values estimated at the individual level are aggregated to national values by 
combining the stated preference estimates with the predicted numbers experiencing 
each health state in a given year derived from the MTMs. 
 
For Campylobacter spp. the aggregate WTP to avoid the pain and suffering from all 
280,000 cases that occur in a year is estimated to be £424m. Norovirus is estimated to 
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generate the next greatest burden (£249m) followed by Salmonella (£144m). The 
burden from IBS contributes a very high proportion of these values.  
 
The total monetary value of the burden of pain and suffering from the 10 pathogens is 
predicted to be £943.6m. This is markedly lower than the value (£2,715m) derived 
from monetising the estimated QALY loss, with the difference resulting in large part 
from the valuation of IBS between the two methods. Aggregate value to avoid pain 
and suffering associated with the aggregate burden for each pathogen is reported in 
Table 21 (Section 5).   
 
The key recommendations based on this research include the following:  
 
 the results can be used for impact assessments and evaluations by the FSA 
and FSS 
 FSA and FSS could consider commissioning work on the utility decrements 
associated with IBS given the high disease burden it poses 
 FSA and FSS could consider revisiting its priorities in light of the finding that 
Norovirus and Giardia have relatively high disease burdens.  
 
In terms of which results to use for impact assessments and evaluations, both QALY 
and WTP results are available as the project intended to produce. One option could be 
to work entirely in terms of QALYs and then use the single £ per QALY value to 
monetise that. However, it is clear that respondents do not value (in monetary terms) 
illness in the same relative manner as the QALY values suggest. If one places any 
credence in the patient derived WTP for different illnesses, then using the uniform 
£/QALY estimate will misrepresent the relative burden across pathogens, as well as 
the aggregate value of the burden for the population. In addition, £ per QALY does not 
feature children at all – the estimate comes from the adult respondents choosing two 
alternative life paths for themselves (like the time trade off studies which the QALY 
literature works with). Therefore the best practice would be to use both QALY and 
WTP results, and being transparent about assumptions and coverage of each.   
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APPENDIX A – MARKOV TRANSITION MODELS  
 
This appendix sets out each of the MTMs derived for this study. They are presented in 
the following sub-sections. 
 
A.1 Overview of the models 
Table below reproduces Table 1 from the main report. The rest of this section provides 
further information on each element of the approach.  
 
Table A.1: Decision problem and approach overview 
Decision 
problem 
What is annual burden of illness caused by 10 foodborne pathogens in 
the UK in terms of the QALYs lost due to infection? 
The 10 foodborne pathogens were: Campylobacter spp., Clostridium 
perfringens, Cryptosporidium parvum, Giardia lamblia, Hepatitis E, 
Listeria monocytogenes, Norovirus, Salmonella (non-typhoidal), 
Shigella spp. and VTEC O157. 
Enteroaggregative Escherichia coli was also considered. An absence 
of suitable data means that only a partial analysis of this pathogen is 
possible, with no burden estimates generated. 
Comparators The health of the UK population in the absence of any of the 10 
foodborne pathogens. A utility for full health of 0.856 was used 
(Janssen and Szende, 2013), representing the average utility of an 
individual in full health across all age groups. 
Model type Pathogen specific Markov state transition models 
Population The 2014 UK population (n=64,596,800).  
The median age is assumed to be 40 years old. 
Perspective Costs: health service perspective 
Consequences (QALYs): 
(i) adults - the impact on the person with the FBD  
(ii) children- parent of the person with the FBD 
Time Horizon Each model is separated into two phases i) short term and ii) long 
term. 
The short term phase takes place over a period of one year and 
incorporates the short term symptoms and complications of infection 
with a foodborne pathogen. 
The long term phase has a time horizon of 100 years and only 
incorporates the long term sequelae of infection alongside sequelae 
specific and all-cause mortality. 
Burden of 
Illness  
QALYs lost due to short term symptoms and complications and the 
long term sequelae resulting from infection in a specific year. 
Discounting No discounting is applied in the short term phase as this takes place 
over a period of one year. 
A discount rate of 3.5% is applied to QALYs lost due to sequelae 
occurring in the long term model. 
 
Decision-analytic Model Conceptualisation 
The first stage in creating a decision-analytic model, suitable to inform resource 
allocation decisions, is to define the scope of the decision problem. This is a formal 
stage included in NICE methods guide (NICE, 2013). The process of defining the 
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decision problem includes defining clearly the: relevant study perspective (e.g. health 
system; public-sector; or societal); population (e.g. patients with a specific condition; 
general public); time horizon for the analysis (e.g. one-year; life-time). The process of 
model conceptualisation is an integral part of making sure the decision problem can be 
addressed using the decision-analytic model. A number of best practice guidelines are 
now established within health economics that describe the importance of model 
conceptualisation (Roberts et al., 2012). When conceptualising a decision-analytic 
model it is important to have input from all relevant experts and stakeholders. In the 
case of foodborne pathogens we used a clinical expert (Professor O’Brien) to ratify the 
model conceptualisation process and agree on the final model structures. 
 
Building the decision-analytic model  
A separate decision-analytic model, each with two time frames, was built for each of 
the 10 pathogens. The models were built in Excel. Each Excel file includes instructions 
for using the model alongside details of its structure and tables for storing (adaptable) 
parameter input values (available from the authors on request). These files also 
summarise the data sources for each parameter input value.  
 
Populating the model 
Three types of input parameter were needed to populate each model: state transition 
probabilities, durations of symptoms and utility values for each health state. The point 
estimates of the parameters and full list of sources for transition probabilities, 
durations and utility values are available in Appendix D.  
  
State transition probabilities 
To identify the transition probabilities and durations for the model, a systematic review 
of the clinical literature was conducted. The review aimed to identify epidemiological 
studies describing the experiences of patients with each type of foodborne pathogen 
and the number of cases experiencing different symptoms. This review followed 
published guidelines (Moher et al., 2015) and was conducted in February 2016.  
 
Five electronic databases (PubMed, MEDLINE, Science Direct, EMBASE, Biosis 
Previews) were searched in April 2016 using a structured search strategy (Appendix 
B) by one reviewer (Jo Hardstaff). As the required parameter evidence was broad and 
given that the PICO approach did not apply well to the study question, broad terms 
were used in the search strategy with no specific study types targeted. To be 
considered for inclusion studies had to focus on a diagnosed, confirmed pathogen and 
could not include cases infected with multiple pathogens. Studies conducted in 
developing countries were excluded as the experience of patients was believed to be 
different in these countries. To be included in this study, papers had to be available in 
English language.  
 
Where estimates could not be found using this general search strategy, specific 
targeted searches were made for each pathogen by combining symptom and 
pathogen specific terms, for example “Salmonella AND hospital*” to find specific 
evidence of patients’ experience of hospitalising Salmonella. Data from the studies 
was extracted into a data extraction form in Microsoft Excel. Key data items included: 
pathogen identified, type of study, year of study, country of study, number of 
individuals with pathogen, number of individuals with each symptom and duration of 
symptoms. Due to the limited nature of the evidence, no critical appraisal of the 
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included studies was attempted. The published extension to the IID2 study (Tam et al., 
2014) was identified as the best source of incidence estimates for the UK and 
therefore the probability that a healthy individual would become a case was taken 
exclusively from this source where available. Incidence estimates for Hepatitis E were 
identified in the literature.  
 
The probability that a case would develop a complication or sequelae was calculated 
using case estimates identified in the systematic review. For the purpose of 
calculation, it is assumed that individuals described in the literature followed the same 
clinical experience as described by the model structure. As such, the occurrence of 
specific complications and sequelae are assumed to be mutually exclusive from the 
occurrence of all other complications and sequelae. While this is not strictly true in 
practice, it would be impossible to add health states for all possible interactions of 
symptoms and to identify the data to populate these states. For example, cases of 
septicaemia are assumed to have arisen directly from uncomplicated cases. Cases 
were aggregated as though they were from one study before each probability was 
estimated. This gives an advantage over averaging the implied probabilities from 
individual studies in that larger studies are given a larger weight in the calculation of 
the transition probability.  
 
Duration of symptoms 
To generate a QALY it is necessary to understand how long each symptom will last. 
Median durations of illness for each symptom were also identified in the systematic 
review. Estimates of the medians were averaged across sources and then these 
means were used to calculate the probability of an individual remaining in the same 
state for the next stage of the model. This calculation relied on the fact that at the 
median duration, half of the individuals suffering from a symptom would have 
recovered, died or experienced a different symptom whilst half would continue to 
suffer. Equation 1 was used to calculate the transition probability required for a one 
week period such that half of the individuals with a symptom will have recovered by 
the median duration. 
 
P(𝑆𝑖,𝑡+1|𝑆𝑖,𝑡) = √0.5
𝑥?̃?
        (1) 
 
Where 𝑆𝑖,𝑡 is a case in a state in a given time period, 𝑆𝑖,𝑡+1 is the same case in the 
same state in the next time period and 𝑥𝑖 is the median duration a case stays in the 
health state 𝑆. 
 
Utilities: published values 
Utility values are then combined with the duration of symptoms to generate a burden 
of illness using a QALY. The primary analysis used a rapid review to identify studies 
which had valued the health impact of symptoms relating to foodborne infection. In 
total, 19 studies which presented primary estimates of health utility were identified 
(Appendix C). In all but one of these studies, the health outcome used was the 
disability adjusted life year (DALY). As such, these studies included disability weights 
for symptoms rather than utilities or disutilities. Such weights are inappropriate in the 
context of the UK health service and would not integrate with the current paradigm as: 
states cannot be worse than death; they are generally determined by experts rather 
than patient or health system user preferences and; severity in terms of the extent of 
disability is not the same as lost quality of life.  
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As such, a new, pragmatic search was conducted to identify generic utilities for each 
of the symptoms. This search began by utilising the Tufts database of economic 
evaluations which can be searched for utility estimates for specific conditions and 
symptoms (Tufts Medical Center, 2016). Each symptom was searched for using the 
utility values search in the database. Where available, disutilities for each symptom 
were recorded along with study details. Disutilities were calculated by subtracting the 
utility of a symptom related health state from the utility of full health used in each 
study. In some cases, where limited data was available for a specific symptom, a 
proxy was used instead. For example, only one study was identified for febrile 
convulsions and none for mesenteric adenitis so epileptic seizures and appendicitis 
were used as proxy conditions. For haemolytic uremic syndrome and thrombotic 
thrombocytopenic purpura where no values were found, specific searches were made 
in the EMBASE database for studies which had valued the relevant health states. This 
was accomplished by combining the clinical term (and different spellings of these), 
with terms for health state utility including: “health state”, “utility”, “quality of life”, “time 
trade off” and “standard gamble”.  
 
The studies and values identified within them are reported in Appendix D. The results 
of this search are shown in Table A.2. As it is possible that studies used different 
values for full health, the implied disutilities of health states were recorded. This 
allowed the estimates to be subtracted from the utility for normal health used in this 
study. This value, 0.856, was taken from published population norms for the UK using 
time trade off methods to value EQ-5D states (Janssen and Szende, 2013). This value 
represents the average utility of normal health in the absence of foodborne disease 
across the age spectrum of the study population.  
 
Table A.2: Symptom related disutilities 
Symptom Disutility 
Flu-like Illness -0.026 
Uncomplicated Diarrhoea and/or Vomiting -0.092 
Mild Jaundice -0.109 
Febrile Convulsions -0.140 
Hospitalising Diarrhoea -0.167 
Irritable Bowel Syndrome  -0.181 
Severe Jaundice -0.246 
Mesenteric Adenitis -0.385 
Reactive Arthritis -0.388 
Thrombotic Thrombocytopenic Purpura -0.403 
Neurological Damage -0.436 
Osteomyelitis -0.448 
Guillain-Barré Syndrome  -0.497 
Renal Failure -0.587 
Septicaemia -0.606 
Meningitis -0.827 
Haemolytic Uremic Syndrome -0.840 
Utilities: from Integrate study 
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Utility data were also potentially available from the Integrate study, which collected 
individual patient-level data (http://www.integrateproject.org.uk/).  A sample of patients 
were recruited into the Integrate study when they presented at their GPs with 
diarrhoea and vomiting and asked to complete EQ-5D-3L surveys and record 
symptoms and answer questions on basic demographic details. In some cases, 
patients also provided stool samples to allow for the pathogen causing the illness to 
be identified. Patients then completed a second questionnaire around two to three 
weeks later. Questions concern symptoms, contact with medical services and whether 
they are still ill or the duration of the illness and the EQ-5D-3L. These data provided 
the basis for an analysis of the impact of their illness on self-reported EQ-5D-3L health 
state. These data can be transformed into utility values using the published population 
EQ-5D 3 level tariff (Dolan et al., 1995). More detail on how these data compared with 
the published utility values is shown in Appendix E.  
 
Taking account of sequelae 
Two timeframes were used to generate estimates of the burden of foodborne illness 
using QALYs. The short term time horizon reflects the burden over one year and 
incorporates the short term symptoms and complications of infection with a foodborne 
pathogen. A cohort of the UK population entered the Markov model in week 0. They 
then proceeded through the model, with cases suffering infection, over an initial period 
of 52 weeks. 
 
The long term time horizon reflects the lifetime horizon, and lasts a maximum of 100 
years and only incorporates the long term sequelae of infection alongside sequelae 
specific and all-cause mortality (based on a population with an average age of 40). 
The long term health impact was modelled over 100 years to account for the impact of 
sequelae. For every week and year in which a member of the cohort remained in a 
non-healthy state, they suffered a reduction in utility.   
 
The sequelae of foodborne infections have been identified as a significant cause of 
long term burden (Batz et al., 2014). A structured search of published literature was 
undertaken to characterise the clinical effect of each pathogen.  
 
Table A.3: Sequelae of Foodborne Pathogens Included in this Study 
Pathogen Sequelae 
Campylobacter spp. Guillain-Barré syndrome 
Irritable Bowel Syndrome 
Reactive Arthritis 
Cryptosporidium parvum Irritable Bowel Syndrome 
Giardia lamblia Irritable Bowel Syndrome 
Norovirus Irritable Bowel Syndrome 
Salmonella (Non-typhoidal) Irritable Bowel Syndrome 
Reactive Arthritis 
Shigella spp. Irritable Bowel Syndrome 
VTEC O157 Acute Renal Failure 
Neurological Damage 
 
Little long term information was found regarding IBS. However, Agréus et al. (2001) 
found that in their study, 86.4% of individuals still exhibited symptoms 10 years after 
diagnosis. This value was used to inform the duration of illness estimates for IBS in 
the long term model. When applying this value to the short term model, the probability 
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that a case would return to the healthy state was minimal and as such it was assumed 
to be 0. It is assumed that individuals with IBS are no more likely to die than healthy 
individuals. In the sensitivity analysis, this value was varied by adding a distribution to 
the number of individuals still experiencing symptoms after 10 years and then 
converting each sampled value into a duration. 
 
Reactive arthritis (RA) is a condition in which a proportion of individuals go on to 
develop chronic disease. It is also possible for cases which have apparently resolved 
to relapse. To incorporate these effects a pool of chronic RA cases and a pool of 
“relapsable”, previous, RA cases were created. The total number of cases in each 
year was then calculated as the number of chronic cases added to the number of 
“relapsable” cases multiplied by the relapse rate. Nordstrom et al. (1996) place the 
probability of developing chronic RA as 5-30% and the probability of relapsing at 15-
50%. The analysis in this paper uses the midpoint values of these intervals. Cases of 
relapsed RA were assumed to return to resolve again within a year, re-entering the 
“relapsable” RA pool. It is assumed that individuals with RA are no more likely to die 
than healthy individuals. 
 
Guillain–Barré Syndrome (GBS) is highly heterogeneous with varying levels of severity 
and duration. In the short term, the condition can be extremely severe, with the 
individual’s breathing inhibited. This can be fatal and as such, a GBS specific death 
rate is included in the Markov transition models. The duration of symptoms can also 
vary to a great extent. As such, while a point estimate is used in the models, 
synthesising information from four studies, the probabilistic sensitivity analysis 
provides a better representation of variability in the sequelae. 
 
With regards to the sequelae of VTEC O157, more specifically the experience of 
haemolytic uremic syndrome following infection with VTEC O157, neurological 
damage was assumed to be permanent, meaning that patients could not return to the 
healthy state. Renal failure is associated with a range of potential outcomes assuming 
dialysis, renal transplant and death. As data on this sequelae were limited, a fixed 
duration of 0.76 years was used. This was derived from research which showed that 4 
of 10 individuals with renal failure still suffered from impaired renal functioning one 
year post infection (Pennington, 2014). 
 
Data Analysis 
In the first stage of data analysis, point values were estimated for the burden of 
disease caused by each pathogen measured in QALYs (base case analysis). Single, 
aggregated values were used for the transition probabilities, durations and utilities.  
 
The total utility experienced by the cohort in the initial year and following 100 years 
was calculated. An identical cohort was then entered into a model with only healthy 
and dead states, linked by all-cause mortality. This allowed the calculation of the 
baseline number of QALYs which would have been experienced by the cohort in the 
absence of disease. The total number of QALYs experienced by the cohort in the 
presence of disease was subtracted from the number of QALYs experienced in the 
absence of disease to determine a point estimate for the QALY burden of disease 
caused by each pathogen. 
Probabilistic sensitivity analysis (PSA) 
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Uncertainty in the parameter estimates was incorporated into the analysis using 
probabilistic sensitivity analysis. Each parameter estimate was assigned a distribution 
in the model, taking a new value for each week within the short term model or year in 
the long term model. For each pathogen, 1000 Monte Carlo simulations were 
conducted, with new parameter estimates being drawn in each. The total QALY 
burden was calculated for each iteration and used to create a mean value with 
confidence intervals representing the uncertainty in the estimates.  
 
Two types of distribution were used in the PSA: beta distributions and gamma 
distributions. Beta distributions were used for transition probabilities between states 
and were created by aggregating estimates of the number of cases of each symptom. 
Gamma distributions were used for duration related transition probabilities and 
disutilities. The distributions for symptom durations were created by taking the average 
and variance of the reported median durations in the literature. Whilst this averaging of 
averages potentially overestimates the uncertainty in the duration estimates, no 
individual level duration estimates were available. Similarly, for the disutilities, the 
mean and variance of the reported mean disutilities were used (See Appendix D for 
details).  
 
Stratification by age 
The severity of a FBD and distribution of disease burden may depend on the age of a 
cohort. For example, children and the elderly have weaker immune systems which 
means such individuals may be more susceptible to being infected. Furthermore, such 
individuals may have a higher probability of suffering from more severe complications. 
Finally, the age of onset of sequelae will impact on the burden that can accrue to 
individuals. Children will suffer from sequelae for a large number of years but the 
burden experienced in future years will become heavily discounted. The elderly may 
be more likely to die from other causes, reducing the burden that can accrue due to 
sequelae. Understanding how different age groups experience FBD may aid in the 
prioritisation of interventions to prevent the spread of such pathogens. 
 
However, stratifying the model based on estimates of FBD is data intensive. A 
completely new set of parameter inputs are required for each age band for each 
pathogen. Furthermore, evidence identifying the demographic characteristics of cases 
is limited in the literature. Within this project the age stratified models were developed 
for four key pathogens: Campylobacter spp., Norovirus, Salmonella (non-typhoidal) 
and VTEC O157.  
 
Four key age bands of interest were identified by the researchers; 0-4 (babies and 
toddlers), 5-15 (children), 16-64 (adults) and 65+ (the elderly). Information regarding 
the stratification of burden by age was identified in the systematic review which was 
used to identify the original probability and duration estimates. This information 
generally took the form of a breakdown of case numbers by age for a specific 
symptom of a pathogen. These numbers were converted into proportions and then 
these were applied to the estimates of the number of cases of each symptom 
produced from the aggregated models.  
 
Age band specific transition probabilities were then calculated from these case 
numbers. It was assumed that the duration of illness for each symptom was constant 
across age bands and that the disutility of the symptoms was the same. However, the 
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utility of the healthy population was varied according to population estimates and as 
such the absolute utility levels of each health state varied. Furthermore, age specific 
all-cause mortality was applied to each sample and this increased as the cohort aged. 
 
A.1 Campylobacter spp. 
Figure A.1 presents the Markov Transition Model (MTM) for Campylobacter spp. The 
starting point is the healthy state, whereby upon suffering from the FBD, the patient 
can move within and between states (with a step period of one week).  In the case of 
Campylobacter spp., a patient can, for example, stay within their health state, or go 
from a healthy state to either uncomplicated diarrhoea and/or vomiting or death.  In the 
case of uncomplicated diarrhoea, a patient could continue to have uncomplicated 
diarrhoea and/or vomiting for more than 1 week, return to a healthy state or move to 
diarrhoea with complications (see Figure A.2) or result in Sequelae (see Figure A.3).  
With the exception of death, it would be anticipated that a patient would eventually 
return to a healthy state, although with Sequelae (see Figure A.3), the length of time 
before that occurs could be substantial depending on the transition probabilities.  
 
 
Figure A.1: Campylobacter spp. 
Healthy
Uncomplicated 
Diarrhoea
Dead: All Causes 
+ Pathogen 
Related
Diarrhoea with 
Complications: 
See Figure B
Sequelae: See 
Figure C
 
Figure A.2 shows the four types of complications possible with Campylobacter spp. 
such as febrile convulsions or septicaemia. As illustrated it is possible for a patient to 
remain with this complication for more than one week, eventually return to a healthy 
state, result in sequelae (see Figure A.3), or death. 
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Figure A.2: Campylobacter spp. Complications (figure B) 
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Figure A.3 illustrates the three possible types of sequelae possible with 
Campylobacter spp.; Guillain-Barre Syndrome (GBS), Irritable Bowel Syndrome (IBS) 
and Reactive Arthritis (RA). As illustrated it is possible for a patient to remain with the 
sequelae for more than one week, eventually return to a healthy state, or result in 
death. 
 
Figure A.3: Campylobacter spp. sequelae (figure C) 
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A.2 Clostridium perfringens 
 
Figure A.4 presents the Markov Transition Model (MTM) for Clostridium perfringens. 
The starting point is the healthy state, whereby upon suffering from the FBD, the 
patient can move within and between states (with a step period of one week). In the 
case of Clostridium perfringens, a patient can, for example, stay within their health 
state, or go from a healthy state to either uncomplicated diarrhoea and/or vomiting or 
death. In the case of uncomplicated diarrhoea and/or vomiting, a patient could 
continue to have uncomplicated diarrhoea and/or vomiting for more than one week, 
return to a health state, or diarrhoea with complications (see Figure A.5). With 
Clostridium perfringens a patient is not expected to suffer from long term sequelae. 
 
Figure A.5 shows the two types of complications possible with Clostridium perfringens; 
such as hospitalising diarrhoea or febrile convulsions. As illustrated it is possible for a 
patient to remain with this complication for more than one week, eventually return to a 
healthy state, or result in death. 
  
Figure A.4: Clostridium perfringens (figure B) 
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Figure A.5: Clostridium perfringens complications (figure C) 
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A.3 Cryptosporidium parvum 
Figure A.6 presents the Markov Transition Model (MTM) for Cryptosporidium parvum. 
With Cryptosporidium parvum it is possible for a patient to suffer from diarrhoea with 
complications (See Figure A.7) and/or Sequelae (see Figure A.8). 
 
Figure A.6: Cryptosporidium parvum 
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Figure A.7: Cryptosporidium parvum complications (figure B)
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Figure A.8: Cryptosporidium parvum sequelae (figure C) 
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A.4 Enteroaggregative Escherichia coli 
 
 
Figure A.9 presents the Markov Transition Model (MTM) for Enteroaggregative 
Escherichia coli. With Enteroaggregative Escherichia coli it is possible for a patient to 
suffer from diarrhoea with complications (See Figure A.10) and/or Sequelae (see 
Figure A.11). 
 
Figure A.9: Enteroaggregative Escherichia coli 
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Figure A.10: Enteroaggregative Escherichia coli complications (figure B) 
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Figure A.11: Enteroaggregative Escherichia coli sequelae (figure C) 
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A.5 Giardia lamblia 
Figure A.12 presents the Markov Transition Model (MTM) for Giardia lamblia.  With 
Giardia lamblia it is possible for a patient to suffer from diarrhoea with complications 
(See Figure A.13) and/or Sequelae (see Figure A.14).   
 
Figure A.12: Giardia lamblia 
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Figure A.13: Giardia lamblia complications (figure B) 
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Figure A.14: Giardia lamblia sequelae (figure C) 
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A.6 Hepatitis E 
Figure A.15 presents the Markov Transition Model (MTM) for Hepatitis E. With 
Hepatitis E it is possible for a patient to suffer from complicated jaundice (See Figure 
A.16) but it is not expected to result in any long term sequelae.   
 
Figure A.15: Hepatitis E 
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Figure A.16: Hepatitis E complications (figure B) 
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A.7 Listeria monocytogenes 
Figure A.17 presents the Markov Transition Model (MTM) for Listeria Monocytogenes.  
With Listeria monocytogenes it is possible for a patient to suffer from complications 
(See Figure A18) but not expected to result in any long term sequelae.   
 
Figure A.17: Listeria monocytogenes 
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Figure A.18: Listeria monocytogenes complications (figure B) 
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A.8 Norovirus 
). It is important to note here, as discussed in report that “uncomplicated diarrhoea” 
refers to “uncomplicated diarrhoea and/or vomiting”   
 
Figure A.19 presents the Markov Transition Model (MTM) for Norovirus. With 
Norovirus it is possible for a patient to suffer from complications (See Figure A.20) 
and/or Sequelae (see Figure A.21). It is important to note here, as discussed in report 
that “uncomplicated diarrhoea” refers to “uncomplicated diarrhoea and/or vomiting”   
 
Figure A.19: Norovirus 
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Figure A.20: Norovirus complications (figure B) 
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Figure A.21: Norovirus sequelae (figure C) 
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A.9 Salmonella (Non-Typhoidal) 
Figure A.22 presents the Markov Transition Model (MTM) for Salmonella (Non-
Typhoidal). With Salmonella (Non-Typhoidal) it is possible for a patient to suffer from 
diarrhoea with complications (See Figure A.23) and/or Sequelae (see Figure A.24). 
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Figure A.23: Salmonella (Non-Typhoidal) complications (figure B) 
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Figure A.24: Salmonella (Non-Typhoidal) sequelae (figure C) 
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A.10 Shigella spp. 
Figure A.25 presents the Markov Transition Model (MTM) for Shigella spp. With 
Shigella spp. it is possible for a patient to suffer from diarrhoea with complications 
(See Figure A.26) and/or Sequelae (see Figure A.27). 
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Figure A.25: Shigella spp. 
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Figure A.26: Shigella spp. complications (figure B) 
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Figure A.27: Shigella spp. sequelae (figure C) 
Irritable Bowel 
Syndrome
Complicated Uncomplicated
Dead Healthy
 
 
A.11 VTEC O157 
Figure A.28 presents the Markov Transition Model (MTM) for VTEC O157. With VTEC 
O157 it is possible for a patient to suffer from diarrhoea with complications (See Figure 
A.29) and/or Sequelae (see Figure A.30). 
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Figure A.29: VTEC O157 complications (figure B) 
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Figure A.30: VTEC O157 sequelae (figure C) 
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APPENDIX B: SYSTEMATIC REVIEW OF THE CLINICAL 
LITERATURE 
 
This supporting appendix shows the search terms used in the systematic review of the clinical 
literature which informed the transition probabilities and durations included in the Markov 
Transition Models. 
 
“sequelae and pathogen”, “sequelae and illness”, “side effects or complications or long-term 
and pathogen or illness”, “sequelae from gastrointestinal infections” 
OR  
 “Campylobacter OR Campylobacteriosis AND sequelae OR side effects OR complications 
OR long-term” 
OR 
 “Norovirus AND sequelae OR side effects OR complications OR long-term” 
OR 
 “Hepatitis E AND sequelae OR side effects OR complications OR long-term”  
OR   
 “Listeria OR Listeriosis AND sequelae OR side effects OR complications OR long-term” 
OR 
 “Salmonella OR Salmonellosis AND sequelae OR side effects OR complications OR long-
term” 
OR 
 “Shigella OR Shigellosis AND sequelae OR side effects OR complications OR long-term” 
OR 
 “Cryptosporidium OR Cryptosporidiosis AND sequelae OR side effects OR complications OR 
long-term” 
OR 
 “Giardia OR Giardiasis AND sequelae OR side effects OR complications OR long-term” 
OR 
 “Clostridium perfringens AND sequelae OR side effects OR complications OR long-term” 
OR 
 “Enteroaggregative E. coli AND sequelae OR side effects OR complications OR long-term” 
OR 
 “E.coli O157 AND sequelae OR side effects OR complications OR long-term” 
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APPENDIX C: SYSTEMATIC REVIEW OF PRIMARY HEALTH WEIGHTS USED IN BURDEN OF 
ILLNESS STUDIES OF FOODBORNE PATHOGENS 
Author (Year) Country Type of Utility Elicited Valuation Method Pathogen Specific Symptom 
Utilities Elicited 
Generic Symptom 
Utilities Elicited 
Batz et al., (2014) USA Health-related quality 
of life (HRQoL) for use 
in Quality Adjusted Life 
Years (QALYS) 
The authors created 
EQ-5D-3L profiles 
describing the health 
states resulting from 
infection resulting from 
14 different pathogens. 
These were validated 
by experts and then 
converted to utilities 
using a US preference 
tariff (Shaw et al., 
2015) 
Campylobacter spp. 
Acute illness: 
 
No doctor visit – 0.8270 (EQ-5D: 
11121) 
Visit doctor – 0.7080 (EQ-5D: 
21222) 
Hospitalised, severe – 0.4370 
(EQ-5D: 22322) 
Recovery after hospitalisation – 
0.8600 (EQ-5D: 11211) 
 
Chronic: Guillain-Barré Syndrome 
 
Hospitalised, no ventilator, 
intensive care - -0.1090 (EQ-5D: 
33333) 
Hospitalised, ventilator, intensive 
care - -0.1090 (EQ-5d: 33333) 
Hospitalised, no ventilator, post 
intensive care – 0.4370 (EQ-5D: 
22322) 
Hospitalised, ventilator, post 
intensive care – 0.2160 (EQ-5D: 
32322)  
Recovery, no ventilator, in hospital 
– 0.7080 (EQ-5D: 21222) 
Recovery, ventilator, in hospital – 
0.7080 (EQ-5D: 21222) 
Chronic, do not resume work – 
0.5080 (EQ-5D: 22321) 
 
- 
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Clostridium perfringens 
 
No doctor visit – 0.8160 (EQ-5D: 
11221) 
Visit doctor – 0.7780 (EQ-5D: 
21221) 
Hospitalised, severe – 0.4370 
(EQ-5D: 22322) 
Recovery after hospitalisation – 1 
(EQ-5D: 11111) 
 
Cryptosporidium parvum 
 
No doctor visit – 0.8270 (EQ-5D: 
11121) 
Visit doctor – 0.8160 (EQ-5D: 
11221) 
Hospitalised, severe – 0.4370 
(EQ-5D: 22322) 
Recovery after hospitalisation – 
0.8600 (EQ-5D: 11211) 
Diarrhoea relapse – 0.8270 (EQ-
5D: 11121) 
 
STEC non-0157 (analogous to 
VTEC) 
 
Acute Illness: 
 
No doctor visit – 0.8160 (EQ-5D: 
11221) 
Visit doctor (not lab confirmed) – 
0.7080 (EQ-5D: 21222) 
Visit doctor (lab confirmed) – 
0.7080 (EQ-5D: 21222) 
Hospitalised, non-haemolytic 
uremic syndrome – 0.4370 (EQ-
5D: 22322) 
Recovery, after non- haemolytic 
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uremic syndrome – 0.8160 (EQ-
5D: 11221) 
Hospitalised, haemolytic uremic 
syndrome – -0.1090 (EQ-5D: 
33333) 
Recovery, after  haemolytic 
uremic syndrome – 0.7780 (EQ-
5D: 21221) 
 
End Stage Renal Disease: 
Hemodialysis – 0.5920 (EQ-5D: 
21312) 
Peritoneal dialysis – 0.8270 (EQ-
5D: 21112) 
Transplant surgery – 0.0300 (EQ-
5D: 33323) 
Post-transplant therapy – 0.8440 
(EQ-5D: 1112) 
 
Listeria monocytogenes 
 
Acute illness: 
No doctor visit – 0.8160 (EQ-5D: 
11221) 
Visit doctor – 0.7080 (EQ-5D: 
21222) 
Hospitalised, pregnant - 0.3330 
(EQ-5D: 22323) 
Recovery after hospitalisation, 
pregnant – 0.8600 (EQ-5D: 
11211) 
Hospitalised, moderate - 0.4370 
(EQ-5D: 22322) 
Recovery after hospitalisation, 
moderate – 0.8600 (EQ-5D: 
11211) 
Hospitalised, severe, intensive 
care - -0.1090 (EQ-5D: 33333) 
Hospitalised, severe, post 
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intensive care – 0.2160 (EQ-5D: 
32322) 
Recovery after hospitalisation, 
severe – 0.8330 (EQ-5D: 11212) 
 
Norovirus 
 
No doctor visit – 0.8160 (EQ-5D: 
11221) 
Visit doctor – 0.7780 (EQ-5D: 
21221) 
Hospitalised, severe – 0.4370 
(EQ-5D: 22322) 
Recovery after hospitalisation – 
1(EQ-5D: 11111) 
 
Salmonella (non-typhoidal) 
 
No doctor visit – 0.8270 (EQ-5D: 
11121) 
Visit doctor – 0.7780 (EQ-5D: 
21221) 
Hospitalised, severe – 0.4370 
(EQ-5D: 22322) 
Recovery after hospitalisation – 
0.8600 (EQ-5D: 11211) 
 
Shigella spp. 
 
No doctor visit – 0.8160 (EQ-5D: 
11221) 
Visit doctor – 0.7080 (EQ-5D: 
21222) 
Hospitalised, severe – 0.3330 
(EQ-5D: 22323) 
Recovery after hospitalisation – 
0.8600 (EQ-5D: 11211) 
 
Yersinia enterocolitica 
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No doctor visit – 0.8270 (EQ-5D: 
11121) 
Visit doctor – 0.7780 (EQ-5D: 
21221) 
Hospitalised, sepsis – 0.1670 
(EQ-5D: 22333) 
Recovery after hospitalisation, 
sepsis – 0.8160 (EQ-5D: 11221) 
Hospitalised, non-septic – 0.3330 
(EQ-5D: 22323) 
Recovery after hospitalisation, 
non-septic – 0.8600 (EQ-5D: 
11211) 
Hospitalised, appendectomy – 
0.3330 (EQ-5D: 22323) 
Recovery after appendectomy – 
0.7780 (EQ-5D: 21221) 
Devleeschauwer et al., 
(2015) 
Worldwide Disability weights (DW) 
for use in Disability 
Adjusted Life Year 
(DALY) calculation 
Expert adjustment of 
Global Burden of 
Disease estimates to 
account for varying 
severity of symptoms 
by pathogen 
Norovirus 
Diarrheal disease - 0.074 
 
Campylobacter spp  
Diarrheal disease - 0.101 
Guillain-Barré syndrome – 0.445 
 
Shiga toxin-producing E.coli 
(analogous to VTEC) 
 
Diarrheal disease - 0.091 
Hemoyltic uremic syndrome – 
0.210 
End-stage renal disease – 0.573 
 
Salmonella (non-typhoidal) 
 
Diarrheal disease - 0.101 
Invasive salmonellosis – 0.210 
 
Shigella spp. 
Hepatitis (for Hepatitis 
A) – 0.108 
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Diarrheal disease - 0.101 
 
Cryptosporidium spp 
 
Diarrheal disease - 0.074 
 
Giardia spp 
 
Diarrheal disease - 0.074 
 
Listeria monocytogenes 
 
Sepsis – 0.210 
Central nervous system infection – 
0.426 
Neurological sequelae – 0.292 
 
Haagsma et al., (2008) The 
Netherlands 
DWs for DALYs The authors created 20 
health states 
representing the 
symptoms of 5 
pathogens. These were 
presented in vignettes 
containing a disease 
label, clinical 
description and a 
representation of the 
health state as an EQ-
5D profile. A sample of 
the public (n=107) 
valued the health states 
using visual analogue 
scales (VAS) and the 
time trade off (TTO) 
approach. 
- Gastroenteritis, mild, 1 
day – 0.036 (VAS), 
0.002 (TTO) 
Gastroenteritis, mild, 5 
days – 0.102 (VAS), 
0.010 (TTO) 
Gastroenteritis, 
moderate, 10 days – 
0.130 (VAS), 0.015 
(TTO) 
Gastroenteritis, severe, 
7 days – 0.231 (VAS), 
0.025 (TTO) 
Gastroenteritis, severe, 
14 days – 0.295 (VAS), 
0.041 (TTO) 
Gastroenteritis, chronic, 
6 months – 0.368 
(VAS), 0.099 (TTO) 
 
See Havelaar et al., 
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(2000a) for details of 
GBS severity levels) 
GBS, F1, whole year – 
0.185 (VAS), 0.044 
(TTO) 
GBS, F2, whole year – 
0.420 (VAS), 0.137 
(TTO) 
GBS, F3, whole year – 
0.545 (VAS), 0.215 
(TTO) 
GBS, F4, whole year – 
0.700 (VAS), 0.367 
(TTO) 
GBS, F5, whole year – 
0.722 (VAS), 0.460 
(TTO) 
 
Reactive arthritis, mild, 
1 week – 0.107 (VAS), 
0.004 (TTO) 
Reactive arthritis, mild, 
6 weeks – 0.197 (VAS), 
0.023 (TTO) 
Reactive arthritis, 
moderate, 6 months – 
0.447 (VAS), 0.115 
(TTO) 
Reactive arthritis, 
severe, 6 months – 
0.503 (VAS), 0.186 
(TTO) 
 
Hemolytic uremic 
syndrome (HUS), 
moderate, 1 month – 
0.279 (VAS), 0.056 
(TTO) 
HUS, severe, 1 month 
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– 0.481 (VAS), 0.110 
(TTO) 
Renal failure, whole 
year – 0.628 (VAS), 
0.328 (TTO) 
 
Crohn’s disease, 6 
months – 0.347 (VAS), 
0.105 (TTO) 
Haagsma et al., (2015) Hungary, 
Italy, The 
Netherlands, 
Sweden 
DWs for DALYs Description for health 
symptoms created for 
lay audience using less 
than 70 words. Health 
professionals were 
involved in design of 
these descriptions. 255 
health states were 
evaluated. A discrete 
choice experiment 
(DCE) was used to 
value the health states. 
30,660 respondents 
completed the DCE, 
each answering 15 
questions. The results 
were analysed using a 
probit regression.  
 The weights presented 
below are mean values 
across all four 
countries. 
 
Infectious disease, 
acute episode, mild – 
0.007 
Infectious disease, 
acute episode, 
moderate – 0.051 
Infectious disease, 
acute episode, severe – 
0.125 
Infectious disease, 
post-acute 
consequences – 0.217 
 
Diarrhoea, mild – 0.073 
Diarrhoea, moderate – 
0.149 
Diarrhoea, severe – 
0.239 
 
Thrombocytopenic 
purpura – 0.167 
 
Chronic kidney illness 
(stage IV) – 0.108 
End-stage renal 
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                      Final Report 
 
eftec 92 March 2017 
disease, on dialysis – 
0.487 
End-stage renal 
disease, with kidney 
transplant – 0.030 
 
Irritable bowel 
syndrome – 0.062 
 
Intellectual disability, 
borderline – 0.014 
Intellectual disability, 
mild – 0.053 
Intellectual disability, 
moderate – 0.123 
Intellectual disability, 
severe – 0.213 
Intellectual disability, 
profound – 0.213 
 
Osteomyelitis – 0.053 
Havelaar et al 2000a The 
Netherlands 
DWs for DALYs The authors created 
short clinical 
descriptions for health 
states not available in 
the Global Burden of 
Disease study. These 
were also described 
with EQ-5D profiles. 
These health states 
were then valued by 
asking a panel of 
experts (24 physicians 
and 11 environment 
epidemiologists) to rank 
their severity relative to 
health states with 
existing values. 
Campylobacter spp. 
 
Severe gastroenteritis (requiring 
general practitioner visit) – 0.368 
 
GBS F1 – Completely recovered 
from an episode of GBS but 
having problems with insomnia, 
fatigue and related emotional 
constraints – 0.10 
GBS F2 – Muscle weakness in 
legs and arms. Able to walk at 
least 10m without walking aid but 
cannot run – 0.30 
GBS F3 – Muscle weakness in 
legs and arms and only able to 
walk at least 10m with a walking 
aid – 0.44 
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GBS F4 – Severe muscle 
weakness in legs and arms, not 
able to walk, bedridden or in a 
wheelchair – 0.80 
GBS F5 – Severe muscle 
weakness in legs and arms, not 
able to walk, bedridden and need 
artificial ventilation for at least part 
of the day – 0.94 
Havelaar et al., (2000b) The 
Netherlands 
DWs for DALYs No previous estimates 
available for the 
authors so they use 
assumption that 
reactive arthritis has 
the same disutility as 
mild rheumatoid 
arthritis. They took this 
disutility from a 
previous Dutch study 
which is not available in 
English.  
Campylobacter spp 
 
Reactive arthritis – 0.21 
- 
Havelaar et al., (2004) The 
Netherlands 
DWs for DALYs Experts used the EQ-
5D questionnaire to 
describe the health 
status of patients with 
HUS. This was 
converted to a utility 
score using the values 
in Dolan et al., (2004). 
To determine values for 
end stage renal 
disease (ESRD) the 
authors identified EQ-
5D profiles 
representing various 
levels of severity from 
existing literature (De 
Wit et al., 1998) and 
converted these to 
Shiga toxin-producing Escherichia 
Coli 0157 (analogous to VTEC) 
 
HUS -0.93 
 
Dialysis for ESRD – 0.18 
Transplantation for ESRD – 0.18 
Functioning graft for ESRD – 0.12  
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utility score using the 
above method. 
Janssen et al., (2008) The 
Netherlands 
HRQoL for QALYs A population panel, 
general practitioners 
(n=9), medical advisers 
(n=22), lay people 
(n=105) and a panel of 
the Dutch Consumers 
Association (n=622) 
valued vignettes for 46 
disease stages using 
the visual analog scale 
(VAS) and time tradeoff 
(TTO) methods. 
Vignettes contained 
disease-specific 
information, a generic 
description (EQ-6D5L), 
a description of the 
disease course over 
time, and a visual 
representation of the 
disease. 
 Results from Dutch 
Consumers Association 
panel 
 
Irritable bowel 
syndrome – 0.906 
(TTO) 
Irritable bowel 
syndrome, yearly 
recurrent – 0.913 (TTO) 
Kemmerman  et al., 
(2006) 
 
The 
Netherlands 
DW for DALYs The values presented 
in this paper are not 
original values. 
However, the source 
paper from which the 
values are taken is only 
available in Dutch 
(Melse et al., 1998).  
Listeria monocytogenes 
 
Listeriosis, mild symptoms – 0.01 
Listeriosis, severe symptoms – 
0.11 
Meningitis – 0.32 
 
Neurological disorders 
– 0.25 
 
Reactive arthritis, not 
visiting gp – 0.127 
Reactive arthritis, 
visiting gp – 0.21 
Reactive arthritis, 
hospitalised – 0.37 
 
Sepsis – 0.93 
Lai et al., (2009) Estonia DWs for DALYs A panel of 25 experts 
with a medical 
background valued 26 
 Diarrhoeal infectious 
diseases – 0.011 
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indicator states using a 
person trade off (PTO) 
approach. 257 
additional states were 
then plotted to a VAS, 
using the initial 
indicator states as a 
reference. 
Other intestinal 
infections – 0.119 
 
Viral Hepatitis – 0.282 
 
Childhood infections – 
0.119 
 
Mental retardation – 
0.242 
 
Meningitis – 0.597 
 
Inflammatory disease of 
stomach – 0.177 
 
Osteomyelitis – 0.416 
 
Acute conditions in 
kidney – 0.340 
 
Severe chronic kidney 
disease – 0.300 
Mangen et al., (2004) The 
Netherlands 
DWs for DALYs For reactive arthritis the 
authors assumed an 
EQ-5d state for very 
mild arthritis based on 
the belief that previous 
estimates (Stouthard et 
al., 1997) were too 
high. For inflammatory 
bowel disease, the 
authors required a 
singular DW so 
averaged the weights 
for different severities, 
weighting for the 
duration that patients 
spend in those 
Campylobacter spp 
 
Reactive arthritis, no visiting GP – 
0.127 
 
Inflammatory bowel disease – 
0.26 
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severities. 
Michaud et al., (2006) Atlanta, USA DWs for DALYs Person trade off based 
on Global Burden of 
Disease methodology 
(see Murray et al., 
1996) 
 Watery diarrhoea – 
0.06 
Murray and Lopez 
(1996) 
Global DWs for DALYs A panel of world health 
organisation (WHO) 
experts were asked to 
value 22 indicator 
conditions using a PTO 
approach. These were 
validated against the 
results of nine 
additional experiments 
(number of participants 
unclear).  
 Watery diarrhoea - 
0.066 
 
Age specific values are 
available for the 
symptoms below (15-44 
presented) 
 
Diarrhoeal disease, 
episodes – 0.086 
 
Bacterial meningitis, 
episodes – 0.613 
 
Mental retardation – 
0.483 
 
Hepatitis B/C, episodes 
(analogous to Hepatitis 
E) – 0.209 
Pare et al., (2006) Canada HRQoL Baseline EQ-5D based 
utility scores for IBS 
patients (n=1555) in a 
clinical trial. Valuation 
based Dolan et al., 
(1997) regression 
model. 
 IBS – 0.641 
Salomon et al., (2012) Bangladesh, 
Indonesia, 
Peru, 
Tanzania, 
USA 
DW for DALYs DCE where participants 
(n=30,230) compare 
patients in different 
described health states 
and choose which they 
 Infectious disease, 
acute episode, mild – 
0.005 
Infectious disease, 
acute episode, 
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think if the healthiest. 
Results analysed using 
probit regression. 
moderate – 0.053 
Infectious disease, 
acute episode, severe – 
0.210 
Infectious disease, 
post-acute 
consequences – 0.254 
 
Diarrhoea, mild – 0.061 
Diarrhoea, moderate – 
0.202 
Diarrhoea, severe – 
0.281 
 
ESRD with kidney 
transplant – 0.027 
ESRD on dialysis – 
0.573 
 
Intellectual disability, 
mild – 0.031 
Intellectual disability, 
moderate – 0.080 
Intellectual disability, 
severe – 0.126 
Intellectual disability, 
profound – 0.157 
 
Abdominopelvic 
problem, mild – 0.012 
Abdominopelvic 
problem, moderate – 
0.123 
Abdominopelvic 
problem, severe – 
0.326 
Salomon et al., (2015) Hungray, 
Italy, 
Netherlands, 
DW for DALYs This study presents 
aggregated estimates 
based on Salomon et 
 Infectious disease, 
acute episode, mild – 
0.006 
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Sweden, 
Bangladesh, 
Indonesia, 
Peru, 
Tanzania, 
USA 
al., (2012) and 
Haagsma et al., (2015) 
Infectious disease, 
acute episode, 
moderate – 0.051 
Infectious disease, 
acute episode, severe – 
0.133 
Infectious disease, 
post-acute 
consequences – 0.219 
 
Diarrhoea, mild – 0.074 
Diarrhoea, moderate – 
0.188 
Diarrhoea, severe – 
0.247 
 
Chronic kidney disease 
(Stage 4) – 0.104 
ESRD with kidney 
transplant – 0.024 
ESRD on dialysis – 
0.571 
 
Intellectual disability, 
mild – 0.043 
Intellectual disability, 
moderate – 0.100 
Intellectual disability, 
severe – 0.160 
Intellectual disability, 
profound – 0.200 
 
Abdominopelvic 
problem, mild – 0.011 
Abdominopelvic 
problem, moderate – 
0.114 
Abdominopelvic 
problem, severe – 
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0.324 
 
Thrombocytopenic 
purpura – 0.159 
Stouthard et al., (1997) The 
Netherlands 
DW for DALYs (note, 
the values are 
presented in a fashion 
more akin to HRQoL 
values, i.e. 1 is perfect 
health and 0 is dead. 
A set of indicator 
values were valued by 
a panel of health 
experts using a PTO 
approach. Health states 
were described and 
accompanied by a 
representative EQ-5D 
state. 175 alternative 
health states were then 
position on a VAS 
containing utility values 
representing those 
elicited for the indicator 
states. 
 Digestive tract infection, 
uncomplicated course 
(duration 2 weeks) – 
0.99  
Digestive tract infection, 
complicated course 
(duration 2-4 weeks) – 
0.97  
 
Permanent locomotor 
impairment after 
bacterial meningitis – 
0.83 
Permanent cognitive 
impairment after 
bacterial meningitis – 
0.75 
Permanent locomotor 
and cognitive 
impairment after 
bacterial meningitis – 
0.24 
 
Mild mental handicap – 
0.71 
Moderate mental 
handicap – 0.57 
Severe mental 
handicap – 0.18 
Extreme mental 
handicap – 0.24 
Mental retardation – 
0.91 
 
Inflammatory bowel 
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disease, active 
exacerbation – 0.60 
Inflammatory bowel 
disease, in remission – 
0.82 
Maertens de Noordhout 
et al.,., (2014) 
Belgium DW for DALYs Expert elicitation with 
eight members of the 
Belgian Association of 
Neurology. A Las 
Vegas method was 
used whereby the 
experts distributed 100 
points over the different 
outcomes to determine 
the DWs 
Listeria monocytogenes 
 
Central nervous system infection – 
0.426 
Neurological sequelae – 0.292 
 
Van Lier et al., (2007) The 
Netherlands 
DWs for DALYs Creation of mean 
severity weights by 
weighting severity 
specific weights by 
proportion of patients 
experiencing those 
states. 
Campylobacter spp 
 
Reactive arthritis – 0.14 
 
GBS, first year – 0.25 
 
GBS, long term – 0.16 
 
Salmonella 
 
Reactive arthritis – 0.15 
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APPENDIX D: PARAMETER VALUES AND REFERENCES FOR THE MARKOV TRANSITION 
MODELS 
 
Campylobacter spp. 
Transition Probability 
Point Estimate 
Value Sources and assumptions 
Healthy to uncomplicated diarrhoea  0.004328 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated 
diarrhoea 0.409421 Helms (2002) (2006), Ruzante (2011), Edwards (2014) 
Uncomplicated diarrhoea to hospitalising 
diarrhoea 0.009429 
Oleson, Ruzante (2011), Toljander (2012), Edwards (2014), Nielsen 
(2012), IID2, HES 
Uncomplicated diarrhoea to febrile convulsions 0.000155 Jones (1981) 
Uncomplicated diarrhoea to mesenteric adenitis 0.000889 Based on generic GI complications, Helms (2002) 
Uncomplicated diarrhoea to septicaemia 0.002279 Based on generic extraintestinal infection, Helms (2002) 
Uncomplicated diarrhoea to GBS 0.000711 Helms (2002), Mangen (2015), Toljander (2012), McCarthy (2001) 
Uncomplicated diarrhoea to IBS 0.07615 Mangen (2015), Helms (2002), Nielsen (2012) 
Uncomplicated diarrhoea  to RA 0.015637 Mangen (2015), Helms (2002), Toljander (2012), Hannu, Bremell (1991) 
Hospitalising diarrhoea to hospitalising diarrhoea 0.361350 Helms (2002), Ruzante (2011), HSCIC (2015) 
Hospitalising diarrhoea to GBS 0.000711 Helms (2002), Mangen (2015), Toljander (2012), McCarthy (2001) 
Hospitalising diarrhoea to IBS 0.076150 Mangen (2015), Helms (2002), Nielsen (2012) 
Hospitalising diarrhoea to RA 0.015637 
Mangen (2015), Helms (2002), Toljander (2012), Hannu (2002), Bremell 
(1991) 
Febrile convulsions to febrile convulsions 2.673E-51 Assumption, see Norovirus 
Febrile convulsions to GBS 0.000711 Helms (2002), Mangen (2015), Toljander (2012), McCarthy (2001) 
Febrile convulsions to IBS 0.076150 Mangen (2015), Helms (2002), Nielsen (2012) 
Febrile convulsions to RA 0.015637 
Mangen (2015), Helms (2002), Toljander (2012), Hannu (2002), Bremell 
(1991) 
Mesenteric adenitis to mesenteric adenitis 0.500000 
Based on generic GI complication length, Helms (2002), Hospital 
episode statistics 
Mesenteric adenitis to GBS 0.000711 Helms (2002), Mangen (2015), Toljander (2012), McCarthy 
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Mesenteric adenitis to IBS 0.076150 Mangen (2015), Helms (2002), Nielsen (2012) 
Mesenteric adenitis to RA 0.015637 Mangen (2015), Helms (2002), Toljander (2012), Hannu, Bremell (1991) 
Septicaemia to septicaemia 0.574349 Helms (2002), Dawan (1986) 
Septicaemia to GBS 0.000711 Helms (2002), Mangen (2015), Toljander (2012), McCarthy 
Septicaemia to IBS 0.076150 Mangen (2015), Helms (2002), Nielsen (2012) 
Septicaemia to RA 0.015637 Mangen (2015), Helms (2002), Toljander (2012), Hannu, Bremell (1991) 
GBS to GBS 0.945451 Helms (2002), Rees (1995) 
IBS to IBS 0.999976 Agreus et al (2001) 
RA to RA 0.912168 Hannu (2002), Bremell (1991) 
Death rate, uncomplicated diarrhoea 9.92E-05 
Werber, Ruzante (2011), Mangen (2015), Toljander (2012), Scallan 
(2011) 
Death rate, hospitalising diarrhoea 9.92E-05 
Werber, Ruzante (2011), Mangen (2015), Toljander (2012), Scallan 
(2011) 
Death rate febrile convulsions 9.92E-05 
Werber, Ruzante (2011), Mangen (2015), Toljander (2012), Scallan 
(2011) 
Death rate mesenteric adenitis 9.92E-05 
Werber, Ruzante (2011), Mangen (2015), Toljander (2012), Scallan 
(2011) 
Death rate septicaemia 9.92E-05 
Werber, Ruzante (2011), Mangen (2015), Toljander (2012), Scallan 
(2011) 
Death rate GBS 0.031930 Mangen (2015), Toljander (2012), Rees (1995) 
UK All Cause Mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
 
  
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                      Final Report 
 
eftec 103 March 2017 
Clostridium perfringens 
Transition Probability 
Point Estimate 
Value Sources and Assumptions 
Healthy to uncomplicated diarrhoea 0.001233058 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated diarrhoea 0.508099691 Williams (1985), Mpamugo (1995), Larson (1988) 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.002343041 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to febrile convulsions 0.017512726 Lack of data, see Norovirus 
Hospitalising diarrhoea to hospitalising diarrhoea 0.143587294 Batz (2014), Kitterer (2014) 
Febrile convulsions to febrile convulsions 2.67276E-51 Assumption, 1 hour 
Uncomplicated death rate 2.72657E-05 Mangen (2015), Scallan (2011) 
Hospitalising diarrhoea death rate 2.72657E-05 Mangen (2015), Scallan (2011) 
Febrile convulsions death Rate 2.72657E-05 Mangen (2015), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
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Cryptosporidium parvum 
Transition Probabilities Point Estimate Value Sources and Assumptions 
Healthy to uncomplicated diarrhoea 4.29699E-05 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated diarrhoea 0.62528276 Jokipii (1983), PHLS (1990), Phillips (1992) 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.043299739 IID2, HES (2015) 
Uncomplicated diarrhoea to febrile convulsions 0.017512726 See Norovirus 
Uncomplicated diarrhoea to IBS 0.005102041 Insulander 
Hospitalising diarrhoea to hospitalising diarrhoea 0.259814807 Chmelik (1998), HSCIC (2015) 
Hospitalising diarrhoea to IBS 0.005102041 Insulander (2013) 
Febrile convulsions to febrile convulsions 2.67276E-51 See Norovirus 
Febrile convulsions to IBS 0.005102041 Insulander (2013) 
IBS to IBS 0.986758694 Agreus (2001) 
Uncomplicated diarrhoea death rate 7.00804E-05 Mangen (2015), Scallan (2011) 
Hospitalising diarrhoea death rate 7.00804E-05 Mangen (2015), Scallan (2011) 
Febrile convulsions death rate 7.00804E-05 Mangen (2015), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
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Giardia lamblia 
Transition probability 
Point Estimate 
Value Sources and Assumptions 
Healthy to uncomplicated diarrhoea 0.000122062 IID2 (Tam et al 2014) 
Uncomplicated  diarrhoea to uncomplicated diarrhoea 0.873909358 Jokipii, Ravel 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.001754317 IID2 (Tam et al 2014), HES (2015) 
Uncomplicated diarrhoea to febrile convulsions 0.002565252 Lack of data, see Norovirus 
Uncomplicated diarrhoea to IBS 0.046512024 Hannevik (2009), Hannevik (2014), Rodriguez (1999) 
Hospitalising diarrhoea to hospitalising diarrhoea 0.378929142 Cantey (2011), HES (2015) 
Hospitalising diarrhoea to IBS 0.186309597 Hannevik (2009), Hannevik (2014), Rodriguez (1999) 
Febrile convulsions to febrile convulsions 2.67276E-51 Lack of data, see Norovirus 
Febrile convulsions to IBS 0.279359431 Hannevik (2009), Hannevik (2014), Rrodriguez (1999) 
IBS to IBS 0.999804414 Agreus (2001) 
Uncomplicated diarrhoea death rate 2.8401E-05 Mangen (2015), Scallan (2011) 
Hospitalising diarrhoea death rate 2.8401E-05 Mangen (2015), Scallan (2011) 
Febrile convulsions death rate 2.8401E-05 Mangen (2015), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
 
Hepatitis E 
Transition Probability 
Point Estimate 
Value Sources and Assumptions 
Healthy to uncomplicated jaundice 4.37036E-06 Ljaz (2014), Mangen (2015) (World Bank used for population) 
Uncomplicated jaundice to uncomplicated jaundice 0.629960525 
Colson (2008), Bruffaerts (2015), Dalton (2007, 2008), Deroux 
(2014), Cronin (2011), Sharn 
Uncomplicated jaundice to complicated jaundice 0.210674157 Dalton (2007, 2008), Guillois (2016), HSCIC (2015) 
Complicated jaundice to complicated jaundice 0.85415108 
Aherfi (2014), Bruffaerts (2015), Cheung (2012), Colson (2008), 
Deroux (2014), Despierre (2011), Cronin (2011), Sharn (2014) 
Death rate for uncomplicated jaundice 0.011764706 Mangen (2015), Dalton (2007, 2008) 
Death rate for complicated jaundice 0.011764706 Mangen (2015), Dalton (2007, 2008) 
All cause mortality 0.001229 Office of National Statistics Life Tables, 40 year olds (2014) 
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Listeria monocytogenes 
Transition Probabilities 
Point Estimate 
Value Sources and Assumptions 
From healthy to flu-like illness 2.83573E-06 IID2 (Tam et al 2014) 
From flu-like illness to flu-like illness 0.361992425 Arslan (2015), Berthelot (2012), Dalton (1997), Miettenen (1999) 
From flu-like illness to septicaemia 0.302215123 
Mangen (2015), Goulet (2008), Koch (2006), Paul (1994), HSCIC 
(2015) 
From septicaemia to septicaemia 0.629069827 
Arslan (2015), Berthelot (2012), Aureli (2000), Pelegrin (2014), HSCIC 
(2015) 
From septicaemia to meningitis 0.192752166 Mangen (2015), Goulet (2008), Paul (1994), HSCIC (2015) 
From meningitis to meningitis 0.629069827 Lack of data, assumed same as Septicaemia 
From flu-like illness to death 0.129390018 
Mangen (2015), Werber (2013), Arslan (2015), Lyytikäinen (2006), 
Paul (1994), Pelegrin (2014), Scallan (2011) 
From septicaemia to death 0.129390018 
Mangen (2015), Werber (2013), Arslan (2015), Lyytikäinen (2006), 
Paul (1994), Pelegrin (2014), Scallan (2011) 
From meningitis to death  0.129390018 
Mangen (2015), Werber (2013), Arslan (2015), Lyytikäinen (2006), 
Paul (1994), Pelegrin (2014), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
 
  
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                      Final Report 
 
eftec 107 March 2017 
Norovirus 
Transition Probability 
Point Estimate 
Value Sources and assumptions 
Healthy to uncomplicated diarrhoea 0.00114829 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated 
diarrhoea 0.165787465 Shimizu (2012), MMWR Morb Mortal Wkly Rep 
Uncomplicated diarrhoea to febrile convulsions 0.014686392 
Chen (2009), Chan (2011), NB adjusetd to account for UK population 
aged 0-9 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.004259443 Zanini (2012), CDC (2008), Olesen (2005), IID2 (Tam et al 2014) 
Uncomplicated to IBS 0.178979444 Zanini (2012), Nelson (2012) 
Hospitalising diarrhoea to hospitalising diarrhoea 0.595704605 Shimizu (2012), Chen (2009), Chan (2011) 
Hospitalising diarrhoea to IBS 0.093398318 Zanini (2012), Nelson (2012) 
Febrile convulsions to febrile convulsions 2.67276E-51 Assumption, 1 day 
Febrile convulsions to IBS 0.209821429 Zanini (2012), Nelson (2012) 
IBS to IBS 0.999804414 Agreus (2001) 
Death rate uncomplicated diarrhoea 0.000195968 Werber (2013), Mangen (2015) 
Death rate hospitalising diarrhoea 0.000195968 Werber (2013), Mangen (2015) 
Death rate febrile convulsions 0.000195968 Werber (2013), Mangen (2015) 
All cause mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
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Salmonella 
Transition Probability 
Point Estimate 
Value Sources and assumptions 
Healthy to Uncomplicated 0.000513285 From IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated diarrhoea 0.359311513 Dworkin (2001), Giraudon (2009), Helms (2006) 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.041047459 
Kramer (1996), Dworkin (2001), Olesen (2005), Ruzante (2011), 
Giraudon (2009), IID2 (Tam et al 2014), HSCIC (2015) 
Uncomplicated diarrhoea to febrile convulsions 0.011377269 Lack of data, see Norovirus 
Uncomplicated diarrhoea to osteomyelitis 0.022948092 Ispahani (2000) 
Uncomplicated diarrhoea to septicaemia 0.011568465 Matheson (2010), Helms (2006) 
Uncomplicated diarrhoea to IBS 0.035372065 Mangen (2015), Helms (2006) 
Uncomplicated diarrhoea to RA 0.005699558 Mangen (2015), Inman (1988), Rudwaleit (2001), Helms (2006) 
Hospitalising diarrrhoea to hospitalising diarrhoea 0.41387664 Dave (2015), HSCIC (2015) 
Hospitalising diarrhoea to IBS 0.032512234 Mangen (2015), Helms (2006) 
   
Hospitalising diarrhoea to RA 0.005232272 Mangen (2015), Inman (1988), Rudwaleit (2001), Helms (2006) 
Febrile convulsions to febrile convulsions 2.67276E-51 See Norovirus 
Febrile convulsions to IBS 0.054088205 Mangen (2015), Helms (2006) 
Febrile convulsions to RA 0.008786804 Mangen (2015), Inman (1988), Rudwaleit (2001), Helms (2006) 
Osteomyelitis to osteomyelitis 0.738413045 Helms (2006) 
Osteomyelitis to IBS 0.015286587 Mangen (2015), Helms (2006) 
Osteomyelitis to RA 0.002441997 Mangen (2015), Inman (1988), Rudwaleit (2001), Helms (2006) 
Septicaemia to septicaemia 0.738413045 Helms (2006) 
Septicaemia to IBS 0.015286587 Mangen (2015), Helms (2006) 
Septicaemia to RA 0.002441997 Mangen (2015), Inman (1988), Rudwaleit (2001), Helms (2006) 
IBS to IBS 0.999804414 Agreus (2001) 
RA to RA 0.896291883 Helms (2006), Inman (1988) 
Uncomplicated diarrhoea death rate 0.00046833 
Mangen (2015), Calvert (2007), Kramer (1996), Werber (2013), 
Ruzante (2011), Scallan (2011) 
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Hospitalising diarrhoea death rate 0.00046833 
Mangen (2015), Calvert (2007), Kramer (1996), Werber (2013), 
Ruzante (2011), Scallan (2011) 
Febrile convulsions death rate 0.00046833 
Mangen (2015), Calvert (2007), Kramer (1996), Werber (2013), 
Ruzante (2011), Scallan (2011) 
Ostemyelitis death rate 0.00046833 
Mangen (2015), Calvert (2007), Kramer (1996), Werber (2013), 
Ruzante (2011), Scallan (2011) 
Septicaemia death rate 0.00046833 
Mangen (2015), Calvert (2007), Kramer (1996), Werber (2013), 
Ruzante (2011), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables, 40 year olds (2014) 
 
Shigella spp. 
Transition probability 
Point Estimate 
Value Sources and Assumptions 
Health to uncomplicated diarrhoea 1.86387E-05 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated diarrhoea 0.502464018 Givney (1998) 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.031019031 
Levine (1990), Frost (1995), Papasian (1995), Helms 
(2006), IID2 (Tam et al 2014), HSCIC (2015) 
Uncomplicated diarrhoea to febrile convulsions 0.008924349 No data, see Norovirus 
Uncomplicated diarrhoea to osteomyelitis 0.001257447 Helms (2006), Lewis (2009) 
Uncomplicated diarrhoea to septicaemia 0.012081616 Helms (2006) 
Uncomplicated diarrhoea to IBS 0.002831421 Helms (2006) 
Hospitalising diarrhoea to hospitalising diarrhoea 0.531063588 Baka (2013), Helms (2006), HSCIC (2015) 
Hospitalising diarrhoea to HUS 0.252352667 Houdoin (2004) 
Hospitalising diarrhoea to IBS 0.002677694 Helms (2006) 
Febrile convulsions to febrile convulsions 2.67276E-51 No data, see Norovirus 
Febrile convulsions to IBS 0.005572755 Helms (2006) 
Osteomyelitis to osteomyelitis 0.731224897 Helms (2006), Altman (1994) 
Osteomyelitis to IBS 0.001587147 Helms (2006) 
Septicaemia to septicaemia 0.430059654 Helms (2006), Beigelm (2002) 
Septicaemia to IBS 0.003228583 Helms (2006) 
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HUS to HUS 0.731224897 Houdoin (2004), Helms (2006) (from diarrheagenic e.coli) 
HUS to IBS 0.001591224 Helms (2006) 
IBS to IBS 0.999804414 Agreus (2001) 
Uncomplicated diarrhoea death Rate 7.64131E-05 Thomas (2015), Scallan (2011) 
Hospitalising diarrhoea death rate 7.64131E-05 Thomas (2015), Scallan (2011) 
Febrile convulsions death rate 7.64131E-05 Thomas (2015), Scallan (2011) 
Osteomyelitis death rate 7.64131E-05 Thomas (2015), Scallan (2011) 
Septicaemia death rate 7.64131E-05 Thomas (2015), Scallan (2011) 
HUS death rate 7.64131E-05 Thomas (2015), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables (2014), 40 year olds 
 
VTEC O157 
Transition Probabilities 
Point Estimate 
Value Sources and Assumptions 
Healthy to uncomplicated diarrhoea 0.000153162 IID2 (Tam et al 2014) 
Uncomplicated diarrhoea to uncomplicated diarrhoea 0.323557276 
Goh (2002), Aldabe (2011), Byrne (2015), Havelaar (2004), Lee 
(1997) 
Uncomplicated diarrhoea to hospitalising diarrhoea 0.146219897 
Herwaldt (1991), Ruzante (2011), Goh (2002), Byrne (2015), 
Dundas (2001), Launders (2016), Toljander (2012), IID2 (Tam et 
al 2014) 
Hospitalising diarrhoea to hospitalising diarrhoea 0.323557276 Byrne (2015), Havelaar (2004) 
Hospitalising diarrhoea to HUS 0.037024071 
Herwaldt (1991), Mangen (2015), Goh (2002), Byrne (2015), 
Dundas (2001), Launders (2016), Rowe (1998), Toljander (2012) 
Hospitalising diarrhoea to TTP 0.028638338 Griffin (1991) 
HUS to HUS 0.53684001 Aldabe (2011), Delmas (2014), Bowles (2011) 
HUS to renal failure 0.067181344 Mangen (2015) 
HUS to neurological damage 0.204329484 Dundas (2001) 
TTP to TTP 0.53684001 Assumed same as HUS 
Renal failure to renal failure 0.974654609 Krogvold (2011) 
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Neurological damage to neurological damage 0.997033908 Assumption, permanent damage 
Uncomplicated diarrhoea death rate 0.000680992 
Herwaldt (1991), Mangen (2015), Byrne (2015), Dundas (2001), 
Launders (2016), Toljander (2012), Scallan (2011) 
Hospitalising diarrhoea death rate 0.000680992 
Herwaldt (1991), Mangen (2015), Byrne (2015), Dundas (2001), 
Launders (2016), Toljander (2012), Scallan (2011) 
HUS death rate 0.000680992 
Herwaldt (1991), Mangen (2015), Byrne (2015), Dundas (2001), 
Launders (2016), Toljander (2012), Scallan (2011) 
TTP death rate 0.000680992 
Herwaldt (1991), Mangen (2015), Byrne (2015), Dundas (2001), 
Launders (2016), Toljander (2012), Scallan (2011) 
Renal failure death rate 0.000680992 
Herwaldt (1991), Mangen (2015), Byrne (2015), Dundas (2001), 
Launders (2016), Toljander (2012), Scallan (2011) 
Neurological damage death rate 0.000680992 
Herwaldt (1991), Mangen (2015), Byrne (2015), Dundas (2001), 
Launders (2016), Toljander (2012), Scallan (2011) 
All cause mortality 0.001229 ONS Life Tables (2014), 40 year olds 
 
Long Term Sequelae 
Transition Probability Point Estimate Value Sources 
GBS to GBS 0.945451367 Vedeler (1997), Dornonville de la Cour (2005), Bersano (2006), Koeppen (2006) 
RA recurrence rate 0.275 Nordstrom (1996) 
Rate of chronic RA 0.175 Nordstrom (1996) 
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Utility Values 
Symptom Disutility Clinical Sources of Symptom or Proxy 
Symptom 
Sources 
Flu-like Illness -0.026 Cancer drug side effect, flu vaccination Beusterien (2009), Chit (2015), Newall (2013), 
Chyongchiou (2015), Tarride (2012), Pitman (2013), 
Lavelle (2012) 
Uncomplicated 
Diarrhoea 
-0.092 Cancer drug side effect, gastro-intestinal 
infection, anti-depressant side effect, 
osteoarthritis drug side effect, rotavirus 
vaccination, rotavirus infection 
Beusterien (2009), Beusterien (2010), Nafees (2008), 
Kuchuk (2013), Maniadakis (2013), Wielage, Bakir (2013), 
Melliez (2008), Peasgood (2010) 
Mild Jaundice -0.109 Hepatitis C, Choleycystitis Samp (2015), Johner (2013) 
Febrile 
Convulsions 
-0.140 Epilepsy, refractory seizures, meningitis B 
vaccination 
Kang (2014), Lee (2013), Helmers (2012), Vera-Llonch 
(2013), Forbes (2003), Messori (1998), Tu (2014) 
Hospitalising 
Diarrhoea 
-0.167 Cancer drug side effects, rotavirus infection Shiroiwa (2001), Kuchuk (2013), Melliez (2008) 
Irritable Bowel 
Syndrome  
-0.181 IBS, coeliac disease Canavan (2015), Huang (2015), Stamuli (2012), Bracco 
(2007), Brazier (2006), Porter (2015), Spiegel (2009), 
Hershcovivi (2010) 
Severe Jaundice -0.246 Hepatitis C Samp (2015), Stepanova (2014), Hsu (2012), Petta 
(2014), Saab (2014) 
Mesenteric 
Adenitis 
-0.385 Appendicitis Wu (2015), Wan (2009) 
Reactive Arthritis -0.388 Rheumatoid arthritis, osteoarthritis, reactive 
arthritis 
Ariza-Ariza (2006), Marra (2004), Bruyere (2009), 
Torrance (2004), Duff (2003) 
Thrombotic 
Thrombocytopenic 
Purpura 
-0.403 Immune thrombocytopenic purpura, 
myelodysplastic syndrom 
Szende (2009), Szende (2010), Sanz (2011) 
Neurological 
Damage 
-0.436 Stroke Pickard (2004), Haacke (2006) 
Osteomyelitis -0.448 Chemotherapy side effect, Staphylococcus 
vaccination, screening for Staphylococcus, 
surveillance for Staphylococcus 
Stevenson (2014), Song (2012), Lee (2010), Lee (2011) 
Guillain-Barré 
Syndrome  
-0.497 C. Difficile prevention, influenza vaccine Duff (2003), Skedgel (2011), Myers (2011), Prosser 
(2011) 
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Renal Failure -0.587 Diabetes Huang (2007), Morgan (2006), Lung (2011), Zhang 
(2012), Coffey (2002) 
Septicaemia -0.606 Cancer complications, bacterial infection, cancer 
drug side effects, sepsis, Staphylococcus 
vaccination, surveillance for Staphylococcus 
Peasgood (2010), Westwood, Fowler (2003), Stevenson 
(2014), McComb (2014), Song (2012), Lee (2010) 
Meningitis -0.827 Influenza vaccination, lyme disease Gomez (2013), Melegaro (2004), Shadick (2001) 
Haemolytic 
Uremic Syndrome 
-0.840 Prevention of foodborne illness, E.Coli 0157 Duff (2003), Batz (2014) 
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APPENDIX E: INTEGRATE DATA AND VALIDATION OF MTM 
UTILITY VALUES 
 
The project used patient completed health ratings, during and after an episode of 
diarrhoea and vomiting (D&V) to validate the utility values used in the Markov 
Transition Models (MTMs) developed in the project. The data came from the on-
going Integrate project (http://www.integrateproject.org.uk/ - HICF-T5-354); a study 
funded by the Department of Health (DoH) and the Wellcome Trust which samples 
from the North West of England, an area containing 1/7 of the population. 
 
The data comes from questionnaires completed by patients presenting FBD 
symptoms with their GP.  The patients were recruited into the Integrate study when 
they present at their GPs with incidents of diarrhoea and vomiting (D&V).  As well as 
providing stool samples which allow, in some cases, for the pathogen causing the 
illness to be identified, the patients complete a questionnaire initially (survey 1) which 
includes information about  them (demographics) and asks them to rate their health 
using the EQ-5D-3L. In most cases this will be completed when they are ill5 (more 
details below). 
 
Patients are also invited to complete a second questionnaire initially (survey 2) 2-3 
weeks later.  Questions concern their symptoms, contact with medical services and 
whether they are still ill or the duration of the illness. They again rate their health 
using the EQ-5D-3L format.  In most cases this will be completed when they are no 
longer ill (more details below). 
 
These data provide the basis for an analysis of the impact of their illness on self-
reported EQ-5D-3L health state, and hence, their Utility.  This involves mapping from 
the EQ5D scores to Utility scores and analysing the impact of the presence of the 
illness on that Utility.  
 
The Markov Transition Models (MTMs) used within this project estimate QALY 
burden estimates of FBD for the UK, based on utility scores from literature and 
experts. Many of the literature derived parameter values are from patients’ own 
assessment of health impacts, but many come from non–UK studies.  The 
contemporaneously reported, UK-based, data from Integrate allows a cross-check 
with the Utility scores (and hence QALY values) in the MTMs. 
  
E.1 Summary statistics 
The Integrate data set was extracted on 7/11/2016 with the data collected between 
September 2015 and October 2016.  It contained 384 observations, not all of which 
were complete, or suitable for analysis. 321 respondents (patients) completed EQ5D 
scores for Survey 1, and 340 patients completed EQ5D scores for Survey 2.  308 
completed both survey 1 and 2.   
 
                                            
5 For our purposes ‘ill’ refers to the presence of symptoms related to the diarrhoeal illness which caused them to 
be recruited into the study. 
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A core sample of 280 was retained after children and people with missing data were 
excluded.  88% were ill at the point of completing the first survey (ills1=1), and 31% 
(87 out of 280 respondents) were still ill at the second survey (which is carried out 2-
3 weeks later).  A relatively small number (2%) were not ill at survey 1 but were so at 
survey 2 (i.e. 6 of out of 280 respondents). 
 
Table E.1:  Respondent or carer (n=280) 
 Ill at survey 2 
 
Ill at survey 1 
 No Yes 
No 27 6 
Yes 160 87 
 
Respondents reported in the Survey 1 the symptoms experienced during the illness.  
Only a few (5/280) did not report diarrhoea, 19% reported having experienced 
vomiting and 9% had had blood in their stools.  
 
The number of people reporting each of these symptoms in Survey 1 is shown in 
Table E.2. 
 
Table E.2:  Reported symptoms of illness (n=280) 
 N % 
Diarrhoea 275 98.2 
Blood in stools 25 8.9 
Vomiting  54 19.3 
 
There was some data on patients’ contact with medical services (e.g. GP, hospitals). 
These are reported as the number of contacts for each category. There are 
significant numbers of missing values for these variables. Categorical variables are 
also created for they attended A&E or hospital or not (0/1). These categorical 
variables are be used in analysis below. 
 
Table E.3:  Descriptive Statistics - contact with medical services 
 n mean st.dev min max 
No. of visits or phone calls to GPs 278 1.759 1.326 0 10 
No. of consultations GP out of hours surgery 257 0.093 0.374 0 3 
No. of GP visits at home 255 0.054 0.315 0 3 
No. of times speaking with GP on phone 265 0.777 1.016 0 7 
No. of times attending A&E 257 0.101 0.683 0 10 
No. of nights staying in hospital 257 0.221 1.417 0 13 
No. of visits to NHS walk-in-centre 256 0.043 0.269 0 3 
No. of consultations with community pharmacist 259 0.185 0.547 0 3 
No. of times dialled 999 256 0.043 0.479 0 7 
No. of times dialled 111 256 0.070 0.324 0 3 
No. of times requiring home care  254 0.004 0.063 0 1 
Have any attendance at A&E (0/1) 257 0.054 0.227 0 1 
Have any nights in hospital (0/1) 257 0.031 0.174 0 1 
Note: Not all respondents completed these question: non-completion was treated as missing, rather than a zero. 
 
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                    Final Report  
 
eftec 116 March 2017 
Respondents reported their current health status using the EQ-5D-3L framework. 
These are converted to a Utility Score using the Great Britain tariff, as programmed 
within the Stata eq5d command (Ramos-Goñi, J.M. and O. Rivero-Ariaseq 2011).  
Figure 1 is a histogram of Utility Scores from Survey 1.  Only 17% report have a 
score of 1 (scoring 1 on all 5 dimensions of health), whereas in a general sample of 
the population this would be closer to 55% (Feng, Y., Devlin, N. and Herdman, M., 
2015).  
 
Figure E.1:  Histogram of EQ5D scores, Survey 1.  N=280 
 
In Survey 2 (see Figure E.2), the EQ5D has a higher proportion at full health (48%).  
Of those who report that they no longer have symptoms, 60% have an EQ5D score 
of 11111.  
 
It is possible to scatter the two EQ5D scores against each other (Figure E.3). One 
would anticipate that most respondents would lie below the 450 line, ie that their 
status improved over the period.  This is largely true, and it is notable the large 
number who shifted from <1 to 1 (full health).   
 
Those who still had symptoms at the second survey are marked with a circle, and it 
is notable that this group makes up the majority of respondents who lie above the 
line, ie who report a worse state at the second survey.  
 
One can summarise the EQ5D scores by status in the two surveys as presented in 
Table E.4.   
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Figure E.2: Histogram of EQ5D scores, Survey 2.  N=280 
 
 
 
Figure E.3: Scatter plot of EQ5D scores across two survey points (jitter 
applied). N=280
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Table E.4: Change in EQ5D utility score (Survey 1-Survey 2) 
 n Mean Std.dev 
All sample 280 -0.109 0.260 
Ill in Survey 1, well in survey 2  160 -0.183 0.249 
Ill in Survey 1, ill in survey 2 87 0.001 0.256 
 
The aggregate decrement is 0.1 across all, 0.18 for those that are ill in survey 1 but 
get better. And zero for those who were ill in both.  What is notable is the wide range 
of values, including some whose scores improved.  But this does not take account of 
other conditions which might affect self-reported health. 
 
E.2  Modelling utility scores 
 
To control for this, we conduct a simple statistical analysis: estimating a double 
bounded Tobit model.  Because of definition of EQ5D there is an upper limit of 1, 
and a gap between that and the next lowest value (0.883).  Here we use a Tobit 
model and define it as having an upper limit for any value >= 0.884, to overcome the 
issue of modelling the gap.  A lower limit of -0.594 is applied (generated if an EQ5D 
assessment of 33333 is given) although no one in the sample reports this value. 
 
We assume that the primary explanation of the underlying EQ5D utility score in 
survey 1 will be the respondents ‘normal’ EQ5D score, which we assume is recorded 
in the second survey. The illness then causes deviations from that ‘normal’ level. We 
expect that respondents who are well at the time of the first survey to not deviate 
from the score in the second survey (as they are required to describe their illness on 
the day of the survey, not recall their state during illness). 
 
We include an interaction for whether they are currently ill and have blood in stools 
(we would expect that it is only significant for those who are ill at time of survey).  We 
also include a number of interactions based on the two illness states:  
 ill at the first survey, but well at the second (which  we expect to generate the 
maximal effect);  
 well at the first survey and well at the second (which we would expect to see 
generate no impact);  
 ill at the second but not at the first (where one may expect to see the EQ5D score 
in survey 1 to be higher than that in survey 2).   
 
We estimate two models, one using alternative indicators of a severe case: A. blood 
in stools (Table E.5) and B. attendance at A&E (Table E.6). Demographic and other 
symptom variables such as vomiting, gender, age etc were included in the model but 
were not significant.  
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Table E.5:  Tobit Model - Survey1 EQ5D Scores, using ‘blood in stools’ as 
indicator of severity – N= 280 
eq5d1 
Coef. Std. Err. t P>t 
[95% Conf. 
Interval] 
EQ5D Survey2 0.570 0.060 9.56 0 0.452 0.687 
Not ill Survey1:blood 0.177 0.207 0.85 0.394 -0.231 0.584 
Ill Survey1: blood  -0.088 0.052 -1.68 0.093 -0.190 0.015 
Ill Survey1: not ill 
Survey2 -0.174 0.055 -3.15 0.002 -0.283 -0.066 
Ill Survey1: ill Survey 2 -0.060 0.059 -1.01 0.315 -0.177 0.057 
Not ill Survey1: ill 
Survey2 -0.111 0.118 -0.94 0.347 -0.344 0.121 
_cons 0.378 0.074 5.1 0 0.232 0.523 
       /sigma 0.233 0.011 
  
0.212 0.255 
Log likelihood = -29.647383      
0  left-censored observations; 231     uncensored observations; 49 right-censored observations at eq5d1 >= .884 
 
As expected: 
 There is a strong relationship between the EQ5D score reported in the second 
survey, and the first: this will account for any individual specific idiosyncrasies 
in health state.   
 The impact of blood in stools causes a reduction in score only for those who 
are ill at the time of the first survey: -0.088 (although only marginally 
significant).   
 Those who are ill at the first survey but well at the second show a significant 
deviation from their second survey EQ5D score: a coefficient of -0.174.   
 Those who were ill at both survey dates, or who were will at the second but 
not the first, show no additional  impact (NB the base line case are those who 
are not ill at either survey).   
 
The raw parameters reported above cannot be taken as the impact of being ill, as 
the Tobit model is non-linear, with censoring, and this influences the expected value 
of a respondent’s utility scores.   
 
There are a variety of marginal effects that can be estimated: we report the marginal 
effects on the expected value of the censored outcome (i.e. accounting for the 
censoring in the Tobit model).  These marginal effects vary according to the point in 
the distribution they are measured at: conditioning on points close to the censoring 
points reduces the marginal effect.  We report values conditioned at a value of 
EQ5D=1 in the second survey. 
 
The estimated reduction in EQ5D utility score from being ill (with no further 
complications) is -0.11 (Std.err=0.03), while the additional effect of having blood in 
stools is -0.053 (Std.err=0.03). The second model uses whether the respondent 
presented to A&E as an indication of severity.  This leads to some reduction in 
sample due to missing values, but the estimated effect is more significant than for 
blood in stools (the two are correlated and cannot be included in the same model). 
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As all who reported attending A&E were still ill at the time of the first survey, there 
are no interaction effects on this variable.  Other effects are very similar. 
 
Table E.6:  Tobit Model - Survey1 EQ5D Scores, using A&E attendance as 
indicator of severity N= 257 
eq5d1 
Coef. Std. Err. t P>t 
[95% Conf. 
Interval] 
EQ5D Survey2 0.568 0.061 9.33 0 0.448 0.687 
Attend A&E -0.135 0.065 -2.07 0.04 -0.263 -0.006 
Ill Survey1: not ill 
Survey2 
-0.193 0.056 -3.44 0.001 -0.303 -0.082 
Ill Survey1: ill Survey 2 -0.065 0.060 -1.08 0.282 -0.183 0.053 
Not ill Survey1: ill 
Survey2 
-0.132 0.119 -1.11 0.268 -0.366 0.102 
_cons 0.391 0.075 5.22 0 0.244 0.538 
/sigma 0.231 0.011   
0.208 0.254 
Log likelihood = 25.160443      
0  left-censored observations; 212     uncensored observations; 45 right-censored observations at eq5d1 >= .884 
 
Calculating the marginal effects, as above gives estimates of -0.12 (Std.err=0.03) 
and -0.08 (Std err. =0.04), suggesting that the A&E presentation represents a more 
significant illness state than reporting ‘blood in stools’. 
 
E.3 Comparison with Markov Transition models 
We find significant effects of being ill on respondent’s EQ5D Utility Scores, 
controlling for individual level effects. There is no effect of demographics (age, 
gender) on those illness-utility impacts. Vomiting does not generate additional utility 
decrements over and above that of the baseline condition of diarrhoea. The 
presence of blood in the patient’s stools does have a significant impact on utility, as 
does them having attended A&E. Of these 2 definitions of more serious cases, 
attendance at A&E fits better with the MTMs which use hospital attendance to 
delineate uncomplicated D&V from more serious illness. 
 
As reported in the Introduction, the Markov Transition Models used within this project 
estimate QALY burdens, based on utility scores from literature and experts with the 
former comprising studies from around the world. 
 
The analysis reported here using Integrate project data provides a UK cross check 
with the Utility scores (and hence QALY values) in the Markov Transition Models.  
Table 7 compares the estimated Integrate utility impacts with the estimates in the 
MTMs. 
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Table E. 7:  Comparison of EQ5D Utility Impacts between Tobit Models 
estimated on Integrate study data and MTM parameterised in this study 
 
MTM Integrate Data Models 
  
Model A 
“Blood in stools” as 
indicator of severe case  
Model B 
“A&E” as 
indicator of 
severe case  
Mild 
 
-0.092  
(0.057) 
-0.105 
(0.033) 
-0.117 
(0.030) 
Additional Severity 
 
-0.053 
(0.032) 
-0.081  
(0.040) 
Severe 
 
 
-0.167  
(0.079) 
 
-0.158 
 
 
-0.198 
st. errors reported in parentheses 
 
The utility decrements based on Tobit models estimated on Integrate data for mild 
and severe diarrhoeal illness are close to those values being used in the MTMs 
developed in the project, which are derived from many, international, studies. 
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APPENDIX F: WTP SURVEY: FOCUS GROUPS, COGNITIVE 
INTERVIEWS AND EXAMPLES OF 
VALUATION QUESTIONS – ADULT & CHILD 
ILLNESS, SHORT & LONG TERM 
 
 
F.1 Focus Groups 
This section summarises the key elements of and findings from the focus groups. 
Focus groups are semi-structured discussion groups led by a moderator in which 
participants are presented with cues and prompts about the topic of interest. The 
main aim of the focus groups, in this case, was to help ensure that the proposed 
wording of the key parts of the main survey instrument was clear to participants. 
They were also an opportunity to test how participants could be encouraged to think 
about pain, grief and suffering in isolation of the other attributes FBDsuch as loss of 
income, cost of alternative child care, and so on.  
 
Group 
details 
Focus Groups  
1 & 2 
Focus Groups  
3 & 4 
Focus Groups  
5 & 6 
City Manchester London Cardiff 
Date 11 May 2016 17 May 2016 24 May 2016 
Time 5.30pm-7.30pm and 
7.45pm-9.45pm 
5.30pm-7.30pm and 
7.45pm-9.45pm 
5.30pm-7.30pm and 
7.45pm-9.45pm 
Viewers Dan Rigby and 
Michael Burton from 
University of 
Manchester 
 
Michael Burton from 
University of Manchester, 
Ece Ozdemiroglu from 
eftec and Nicholas Daniel 
and Alice John from the 
FSA 
None 
 
In each location, the first group was with adults to discuss FBD risk to their own 
health, and the second group was with adults to discuss FBD risk to their children 
(not babies). Six groups were deemed to be sufficient, and this was evidenced as 
new learning started to decline.  
 
Focus group participants were selected to achieve a mix of both socio-economic 
groups and answers to the following questions: 
 
1. Have you or any member of your family or close friends been employed in any 
of the following roles? 
2. Note gender 
3. What was your age at your last birthday? 
4. Do you have any children? 
5. Can you tell me how many children you have in each of the following age 
groups? Please note that the parent group in particular need to be made 
aware that there may be some sensitive materials shown and sensitive 
discussions about the impact of these diseases on children 
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6. Which of the following best describes your ethnic background? 
 
Potential participants were also asked how many focus groups they had previously 
participated in, and when they had last participated in a focus group. Participants 
were selected amongst the group with low (1-3 groups) and past participation (more 
than 6 months ago).  
 
On the whole the six groups covered a fair combination of the possibilities, and 
socio-economic and age groups were kept together to ensure that each group was 
harmonious in these respects.  
 
The recruitment of participants, moderation of the groups, video and voice recording, 
and subsequent transcription of the group discussions were undertaken by Facts 
UK.  
 
The adults–own risk and adults–parents groups followed the same protocol. The only 
difference was that risks to adults were described in the former, and risks to children 
(participants’ own children) were described in the latter.  
 
The protocols on all six groups followed the same structure, but the wording and 
focus on specific issues were tested then changed after each pair: the learning in 
each pair was reflected in the next protocol.   
 
All the focus groups tested both understanding of short term mild cases versus long 
term more serious cases, and WTPfor risks to their own health and to the health of 
their children.  
 
The focus groups started with the moderator explaining the topic and purpose of the 
research. It was made particularly clear that the research was for the FSA and not 
for a private medical or pharmaceutical company. Participants were also reassured 
that there were no right or wrong answers and that their responses would help the 
research team to improve the questionnaire for a national survey. Finally, 
participants were told that the groups would be audio and video recorded, and in the 
case of Manchester and London, also viewed. However, confidentiality was 
guaranteed, therefore the transcripts are included in the Annexes to this report but 
the video recordings are not.  
 
The first section of the protocol covered what is involved in food poisoning. The 
purpose was to warm up the participants and help them recall and share their 
experience and knowledge about food poisoning. The moderator was instructed to 
prompt if the discussion did not progress or an important aspect that expected 
someone to mention was not mentioned.  
 
The second section of the protocol involved testing the concept and wording of 
vignettes. Vignettes listed descriptions of a series of different symptoms of food 
poisoning, including whether the person would feel the need to visit a doctor. The 
discussion about whether the wording was clear was followed by a few willingness to 
pay (WTP) questions. Again, testing to ensure questions were clear to the 
participants was more important than their actual answers. A dichotomous 
contingent valuation approach was used, whereby participants answered on their 
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own (on paper) whether they would be willing to pay £x, if yes, they were directed to 
a WTP question with double £x; if no, they were directed to an amount half £x. They 
were also asked what their maximum WTP was.  
 
While answering both WTP questions, participants were encouraged to think about 
precisely what they were being asked to pay: pain, grief and suffering. They were 
asked not to think about their loss earnings, cost of alternative child care and so on.  
 
The next section of the protocol used the EQ5D scale to describe the health state of 
the participant and also similar wording was used to describe the health state with 
food poisoning. In this approach we asked respondents to make choices which allow 
direct valuation of generic EQ-5D states (for appropriate durations) and then use 
those value components to construct the value of particular pathogen/severity states 
as required.   
 
In the next section of the protocol, participants were told about some likely long term 
symptoms or illnesses from food poisoning. Once the clarity of these descriptions 
was established, they were then asked to respond to a dichotomous contingent 
valuation question about these illnesses. Again both vignettes and EQ5D 
presentations were tested.  
 
Key Findings 
 
Participants in all six groups had previously experienced varying degrees of food 
poisoning. They were much less aware of the more serious sequelae of FBD.  
 
What was being asked was also clear: trading off money vs. a case of food 
poisoning with described symptoms, or trading off money (and life years) vs. a case 
of food poisoning and sequelae. Even those who could not decide on the amount 
they would be willing to pay were clear what they were being asked about. Even in 
the parents groups, risks to children’s health could be discussed, and trade-off could 
be made – in particular participants had different reactions to short term mild cases 
vs. long term serious symptoms.  
 
On the whole participants found the vignette approach more intuitive. EQ5D were 
found to be too general. The exercise of taking participants through an EQ5D survey 
before asking their WTP to avoid an option described using EQ5D was also 
confusing, partly because EQ5D asks about how the participant feels on that day, 
whereas WTP is asked about a hypothetical time. Participants found it particularly 
difficult to link EQ5D to food poisoning when considering short term and mild cases.  
 
Mentioning the names of pathogens did not make a difference to participants’ 
consideration of health impacts.  
 
The likelihood of the presence of the following biases in responses were tested 
through the focus groups:  
 
 Hypothetical bias – when respondents do not take the trade-off questionnaire 
seriously 
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Participants were sufficiently aware of FBD– for ease of identification called ‘food 
poisoning’ during the group discussions and materials. The task of trading off money 
and symptoms was clear and participants engaged in this trade off. 
 
They were also observed to engage in the exercise realistically. Even in the parents 
groups, although the discussion started with paying anything for the health of their 
child, it then moved on to considering the severity of the illness and WTP for mild 
illnesses was lower than that for severe illnesses.  
 
How the different symptoms of FBD could be linked to EQ5D was less clear. But the 
task of expressing willingness to pay to avoid FBD was clear. EQ5D scores for risks 
to children’s health was also found confusing as it had severe symptoms like 
difficulty washing and getting dressed etc.  
 
In some groups, participants were offered a pill to make the symptoms to go away. 
There was a lot of discussion about what this pill would contain, any side effects, 
how and when and from where it could be obtained. Therefore, it added to the 
hypothetical nature of the valuation scenario and it was removed from the 
questionnaire.  
 
Finally, the ‘cheap talk’ presented to the group participants seem to have worked 
reminding them that there are other risks to protect from and limited funds. The 
maximum WTP (open ended) question did not result in unrealistically high numbers.  
 
 Protest responses – when respondents give an answer that does not reflect 
their true preference (e.g. zero, no WTP response to protest being asked to trade 
off not because they do not value what they are being asked to trade off). 
 
At the start of focus groups protocols, the trade-off context was set as for the policy 
analysis of the FSA, and not for a private medical or pharmaceutical company. This 
seemed to make the context less prone to protest answers.  
 
Participants were, on the whole, not familiar with the more severe illnesses that 
could be caused by food poisoning. They were reassured that the information 
provided was real. The main questionnaire needs to be clear that such severe cases 
could occur, even if they are unlikely.  
 
 Embedding (part-whole bias) – this part of the discussion tested whether 
participants could isolate, and focus on, pain and suffering associated with FBD.  
 
The participants were able to identify other impacts of FBD like loss of income, work 
days lost, medical expenses, extra childcare expenses and so on. Once these were 
identified, they could think of pain and suffering in isolation.  In the parents groups, 
participants mentioned that there is also cost and stress to them from anxiety and 
worry, but also sleepless nights and so on.  
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F.2 Cognitive Interviews 
 
This section presents the main findings from the cognitive testing interviews carried 
out from 29 June – 1 July 2016 as part of the design phase for the main valuation 
questionnaires. The cognitive testing interviews were conducted on a sample of ten:  
five adults considering risks to their own health and five adults considering (as 
parents) risks to the health of their child. The draft questionnaire was administered to 
respondents in a Computer Assisted Personal Interview (CAPI) and this was then 
followed by a separate set of debriefing questions. The debriefing permits the testing 
of a number of issues concerning the design of the questionnaire, including 
respondent comprehension and retrieval of information (eg questions and other 
survey materials, such as showcards) and respondent decision processes (eg 
mental effort, motivations behind choices, truth telling). Cognitive interviews are 
therefore highly useful in evaluating the validity of questionnaires, especially when 
the questions and issues presented to respondents are complex.  
 
The debriefing questions and summary of responses are provided below. Text to be 
read out loud is in bold. Some questions are worded differently depending on the 
version of the questionnaire. 
 
DQ0. Please record any observations you have made during the CAPI part of the 
interview, such as any signs of difficulty, hesitation, speeding up (not reading) 
responds showed. If possible record where in the questionnaire you observed such 
signs.  
 
Please also record any questions the respondent asked you during the CAPI part of 
the interviews. Please answer “The researchers would like you to answer the 
questions as best you as without further information or clarification at this 
stage. So please continue and we can discuss the details after you completed 
the survey” 
 
 Most respondents had little difficulty with the questionnaire overall. A couple 
of respondents (2/10) asked about the frequency of the payments, or whether 
they were one-off payments.  
 
I now want to ask you about the questions you have just answered and what you 
thought of them. There are no right or wrong answers and your responses will be 
used to help us improve the survey. 
 
DQ1. First, please could you tell me in your own words what you were asked 
to do in this questionnaire? 
 Nearly all respondents (8/10) understood that they were being asked to make 
a trade-off between “different amounts of money” and avoiding illness as 
described in “different scenarios”. Two respondents seemed to interpret the 
purpose of the exercise as being to “put a value on preventative measures” 
and “potential treatment costs for myself and my child”. The purpose behind 
the survey will be made more explicit in further iterations of the CAPI survey. 
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DQ2. The main part of the survey asked you about food poisoning and its 
impacts on health. How clear / unclear were the descriptions?   
 
 Most respondents (8/10) found the survey clear and “straightforward”. Two 
respondents explained that the long-term illness descriptions were more 
difficult to understand. 
DQ3. Did you think, on the whole, the description of the health impacts was 
realistic or not?   
 
NOTE TO INTERVIEWER: Here we mean the symptoms (common to both 
Vignette and EQ5D versions of the questionnaire): both short term 
like vomiting, diarrhoea and long term like the GBS, IBS, reactive 
arthritis, chronic renal failure, meningitis, septicaemia.  
 
PROBE: for both short term and long term symptoms. Refer to the relevant pages 
where necessary. Please note if reminding the symptoms has been necessary.  
 Most respondents (7/10) found the descriptions realistic. Three respondents 
commented that health issues are not as “cut and dry” as the descriptions 
suggest. One respondent suggested that the idea that a person would return 
to their current state of health after a long-term illness was unrealistic.  
DQ4. ADULT VERSION When making choices, did you think you could 
possibly suffer the symptoms described? In other words, did you think “this 
could happen to me”? 
 
DQ4. PARENT VERSION When making choices, did you think your child 
could possibly suffer the symptoms described? In other words, did you think 
“this could happen to him or her”?  
 
NOTE TO INTERVIEWER: Here we mean the symptoms (common to both 
Vignette and EQ5D versions of the questionnaire): both short term 
like vomiting, diarrhoea and long term like the GBS, IBS, reactive 
arthritis, chronic renal failure, meningitis, septicaemia.  
 
PROBE: for both short term and long term symptoms 
 Nearly all (9/10) respondents reported that the symptoms described could 
happen to them. 
DQ5. What did you think you were being asked to pay for?   
NOTE TO INTERVIEWER: They should have mentioned this in DQ1 but still ask 
them to repeat. PROBE: Did you think about how paying this amount would avoid 
the food poisoning? Did you think about to whom you’d pay and so on?  
 
 Most respondents understood that they were being asked to avoid pain and 
suffering as described in the scenarios presented. Some respondents 
thought about the question more generally, while others thought more 
specifically about what they were paying for such as “drugs” or 
“immunisation”.  
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DQ6. Did you think this was a one-off payment or an annual payment?    
 Nearly all respondents (9/10) thought the payment was a one-off payment, 
although a few respondents (3/10) commented that they found this 
confusing and couldn’t be certain. The payment frequency will be addressed 
more explicitly in further iterations of the CAPI questionnaires. 
DQ7. When did you think you would make this payment? Now or in the 
future? If future when?     
 Most respondents (8/10) thought that they would make the payment now or 
“immediately”. One respondent was unsure and another thought the 
payment would be “in the future, after the remedy”. 
DQ8. Did you state the £ payment on your behalf or on behalf of your 
household?  
 
 Most respondents (6/10) stated the payment on their behalf. 
 
 
 
 
 
DQ9. How do you think other people like you would answer these questions 
about paying to avoid the health impacts of food poisoning? 
 
 Most respondents (7/10) indicated that they believed other people like them 
would answer in a similar way.  
 
DQ10. ADULTS VERSION 
 
When making choices about paying to avoid the health impacts of food 
poisoning, did you also consider how much it would cost you to take sick 
leave; to pay for extra child care and for the medical expenses?  
  
DQ10. PARENTS VERSION 
 
When we asked you about your child having food poisoning, did you think 
you’d also be ill at the same time or did you think you’d be healthy? Did you 
include the possibility that you may need to take time off work to look after 
your child into account?  
   
PROBE if the answer is no: We did not want you to think about these. We wanted 
you to focus only on the ‘pain and suffering’. What was it that made this clear to 
you?  
 
PROBE if the answer is yes: We did not want you to think about these. We wanted 
you to focus only on the ‘pain and suffering’. How could we have made this 
clearer? 
 
 Three of the ‘adult version’ respondents did not think about taking time off 
from work while the other two are retired and so this question was not 
applicable. Most of the parent respondents (4/5) indicated that they did not 
think they would be ill and that they did not include time off work in their 
decisions. 
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DQ11. FOR ADULT_EQ5D VERSION ONLY: What did you think about the 
questions about your current general health state? 
 
DQ11. FOR PARENT EQ5D VERSION ONLY: What did you think about the 
questions about your child’s current general health state? 
 
NOTE TO INTERVIEWER: This is the set of questions about ‘walking about, self-
care, usual activities, pain / discomfort, anxiety / depression’. This is the page that 
that starts with the ‘EQ5D explain’ box. 
 
PROBE: How easy / difficult / specific / general? 
 Most respondents (8/10) found the questions “general” and 
“straightforward”. 
 
DQ12. FOR EQ5D VERSION ONLY: How relevant did you think these 
questions were in general? How relevant did you think they were in relation 
to food poisoning?  
 
 Most respondents (6/10) thought the questions were relevant while four 
respondents did not answer the question. 
 
DQ13. VIGNETTES VERSION:  
 
When making choices about the short term illnesses that can be caused 
because of food poisoning, could you give a short description of the thought 
processes that you used to make the decision?  
 
PROBE: See if all types of information are mentioned, if not probe to make sure we 
know what they thought of all the following (even if they did not consider them). 
Description of the symptoms? Number of days? Number of days spent in bed? 
Whether you felt the need to visit the GP or not?  The amount of money you were 
being asked to pay?  
 
Parents should answer about the choices they made thinking of their child. 
 
DQ13. EQ5D VERSION:   
 
Did you recognise that what was being shown as ‘current’ health was the 
answers you had given earlier to the health rating question? 
 
Parents should answer about the choices they made thinking of their child. 
 Only three vignette version respondents provided adequate answers to this 
question, of which two thought about the short term illness in terms of “how 
long they could cope with those symptoms”, and the remaining respondent’s 
thought process was based on “on available medication like ibuprofen. How 
much would I pay to have a cure all, my own money circumstances came 
into it”. Only three EQ5D respondents answered this question, two 
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recognising that their ‘current’ health was based on their answers to health 
questions, while one did not know. 
 
DQ14. How certain are you of the choices you made about the short term 
health impacts of food poisoning? 
 
1: Very certain, 2: Certain, 3: Not sure, 4: Uncertain, 5: Very uncertain 
 Most respondents (6/10) were ‘certain’ about their choices, one respondent 
was ‘very certain’, one respondent was ‘uncertain’, one respondent was ‘not 
sure’ and one respondent answered that they “did not know”. 
 
DQ15. VIGNETTES VERSION 
 
When making choices about the long term illnesses that can be caused 
because of food poisoning, could you give a short description of the thought 
processes that you used to make the decision?  
PROBE: See if all types of information are mentioned, if not probe to make sure we 
know what they thought of all the of following (even if they did not consider them) 
Description of the symptoms? Number of days? Number of days spent in bed? 
Whether you felt the need to visit the GP or not?  The cost to avoid the illness? 
Parents should answer about the choices they made thinking of their child. 
 
 Two vignette version respondents described the thought process as being 
“quick” and “obvious”. The other three respondents mentioned the “impact on 
external family members”, “work and living standards”, and “education” as 
being part of their thought process. 
 
DQ16. EQ5D VERSION 
 
When making choices about the long term illnesses that can be caused 
because of food poisoning, could you give a short description of the thought 
processes that you used to make the decision?  
PROBE: See if all types of information are mentioned, if not probe to make sure we 
know what they thought of all the following (even if they did not consider them)   
descriptions of the health state (walking about, self-care, usual activities, pain or 
discomfort, anxiety or depression)? The number of months / years you’d have the 
illness? The number of years you will have current health state in Life A (with illness)? 
The number of years you will have current health state in Life B (without illness)? The 
average yearly income until death in Life A? The average yearly income until death in 
Life B? 
Show a copy of the DECLongIntro page 
Parents should answer about the choices they made thinking of their child. 
 
 The five EQ5D respondents listed “length of time” and “severity” of illness as 
being weighted against the cost. One respondent also mentioned a prior 
illness and not wanting “to have long term illness for any considerable period 
of time”. Another respondent highlighted that “if you are in pain (your child) no 
amount of time would be relevant you would want to prevent it”. 
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DQ17. How certain are you of the choices you made about the long term 
illnesses that can be caused because of food poisoning? 
 
1: Very certain, 2: Certain, 3: Not sure, 4: Uncertain, 5: Very uncertain 
 
 Of the eight responses to this question, most (5/8) were certain about their 
choices, while two were not sure and one was uncertain. 
DQ18. If you said yes to at least one £ amount in the many choices you made, 
what were the main reasons for doing this? Why were you willing to pay to the 
amount(s) given?  
 
PROBE: please get them to say as many reasons as possible and record all 
verbatim.  
 Most adult respondents answered that they were willing to pay certain 
amounts because it was worth not experiencing the pain or symptoms 
described. All parent respondents (5/10) indicated payment was worth it to 
avoid their child from being in any pain.  
 
DQ19. Overall, would you say that you were presented with enough 
information to make the choices you were asked to make?  
 
PROBE: Was there too much to take in? Was it relevant? Was anything missing? 
Was it too detailed? Not detailed enough?  
 Nearly all respondents (9/10) reported that they were presented with enough 
information to make the choices, while one respondent thought there was too 
much information given. 
 
DQ20. Were there any other issues that influenced your any of your answers 
to the survey in any way at all?  
 Of the five respondents that answered this question, three responded that 
their income and “ability to pay” influenced their choices, with the remaining 
two respondents answering “the fact I have already paid into NHS my 
working life” and “the amount of days ill and the amount of days that you 
would be healthy for” respectively. 
 
INTERVIEWER DEBRIEFING: Any other observations / suggestions you wish to 
share with us? 
 
 Of the three interviewers who answered, one noted that the questionnaire 
“worked quite well” was “challenging” and “not obvious, which not good”. 
Another answered that “health is not black and white” while the remaining 
interviewer found the exercise “interesting”. 
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F.3 Examples of Valuation Questions – adult & child illness, short & long 
term 
Figure F.1:  Example of an adult illness short term choice question 
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Figure F.2:  Example of a child illness short term choice question 
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Figure F.3: Example of a long term vignette for adult illness: meningitis  
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Figure F.4: Example of a long term vignette for child illness: meningitis  
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Figure F.5: Example of an EQ-5D-3L short term adult illness choice question  
 
 
Figure F.6: Example of an EQ-5D-3L short term child illness choice question  
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Figure F.7: Example of an EQ-5D-3L long term adult illness choice question  
 
 
 
  
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                    Final Report  
 
eftec 138 March 2017 
APPENDIX G: LONG TERM ILLNESS (INCLUDING 
SEQUELAE) VALUATION – DESIGN 
INFORMATION  
 
G.1 Cost Levels - long term valuation questions 
A respondent was assigned (at random) one of sic cost levels in each of the long 
term valuation questions.  Below we report, alongside the illness descriptions, the 
minimum and maximum values for the ‘standard’ design - this would be seen by 
someone with an income level of £35,000 - £44,999.   
 
The costs faced by respondents whose household income level fell in to another 
category were modified using the formula: 
 
£X2-6 *(1 + (Z-6)*0.18) 
 
where X is the standard value, and Z is a variable associated with their self-reported 
income level (see Table G.1) i.e. there is an 18% change in cost associated with 
each change in income category. The value used for the minimum level £X1 was not 
changed. 
 
Table G.1: Questionnaire Household Income Bands  
income category    Z 
Below £6,500 1 
£6,500 - £11,499 2 
£11,500 - £17,499 3 
£17,500 - £24,999 4 
£25,000 - £34,999 5 
£35,000 - £44,999 6 
£45,000 - £54,999 7 
£55,000 - £74,999 8 
£75,000 - £99,999 9 
£100,000 - £124,999 10 
£125,000 - £149,999 11 
£150,000 - £199,999 12 
more than £200,000 13 
 
G.2 Descriptions, Durations, Costs - long term vignettes – adult illness 
Below we report the text used to describe the 11 conditions used. For some 
conditions the duration of the illness varies within the survey (values drawn from 
range of predefined values). This is identified in parenthesis {..}, and the range of 
durations are reported below the description. The costs are based on results from 
Focus Groups, Cognitive Interviews and Pilot surveys - the cost ranges needed to 
induce sufficient variation in the Pay/No Pay responses. 
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1. Guillain-Barre Syndrome  
2. Irritable Bowel Syndrome 
3. Reactive Arthritis 
4. Mesenteric Adenitis 
5. Septicaemia 
6. Jaundice 
7. Osteomyelitis 
8. Thrombotic thrombocytopenic purpura (TTP) 
9. Chronic Renal Failure 
10. Meningitis 
11. Brain damage 
 
Guillain-Barre Syndrome  
You become ill with food poisoning and this leads to more serious symptoms. 
You suffer from difficulty in moving your legs and arms, and find it hard to speak. 
You have Guillain-Barre Syndrome (GBS) which means your body's immune system 
attacking your own nervous system. 
You spend 3 weeks in hospital. 
The GBS damages your nervous system so severely that you lose the use of your 
legs, meaning that you are restricted to a wheelchair. 
There will be long term pain and tiredness for {2} years before you recover to feel 
like your normal self. 
Length: 2,4,10 years  
Cost range:  £1-160k 
 
Irritable Bowel Syndrome  
You become ill with food poisoning and from which you seem to recover normally. 
About a month later you develop stomach cramps and severe constipation, and 
sometimes you experience an urgent need to go to the toilet.   
You have Irritable Bowel Syndrome (IBS). 
This involves symptoms affecting you for 5-6 days, every 2 months. 
It is expected to last for the rest of your life. 
Cost range:  £0.5-40k 
 
Reactive arthritis 
You become ill with food poisoning during which you develop symptoms which fail to 
clear up. 
You have reactive arthritis, which means your joints (knees feet and ankles) become 
inflamed, red and sore. 
You are prescribed painkillers and anti-inflammatory drugs to reduce the pain.   
It takes {6} months before you will feel like your normal self. 
Length:  0.5, 1, 10 years  
Cost range:  £0.5-40k 
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Mesenteric Adenitis 
After a case of food poisoning that lasts a few days you develop MA. 
This is an inflammation in the lymph glands in the gut. This causes pain in the 
abdomen, high temperature (fever) and feeling generally unwell; you may be 
nauseous and/or have diarrhoea. 
The symptoms will improve within a 3 days, and will clear up completely within two 
weeks. 
No treatment is needed other than painkillers. However, MA can be difficult to 
distinguish from acute appendicitis or ectopic pregnancy. You need a small operation 
to look inside your abdomen to make sure other important problems, like 
appendicitis, are not missed. You will feel some pain and discomfort where the 
incisions were made for a few days after the procedure. You’ll be given painkillers to 
ease the pain. You will be able to resume your normal activities after a week.  
Cost range:  £0.1-5k 
 
Septicaemia 
After a case of food poisoning that lasts a few days you experience a very high 
temperature (fever), chills and shivering, a fast heartbeat and fast breathing. You 
may start to feel dizzy or faint, confused or disorientated. Your speech becomes 
slurred and you develop severe muscle pain and severe breathlessness.  
You are told you have septicaemia. This means that your immune system is fighting 
the infection so much that they blood supply to vital organs such as the brain, heart 
and kidneys is restricted. 
You are admitted to the Intensive Care Unit (ICU) where you are given antibiotics 
and fluids straight in to a vein (intravenously) and given oxygen.  
You are in the intensive care unit for 5 days and in hospital on an ordinary ward for 
another 5 days. 
It takes {18} months before you feel like your normal self. 
Length:  1.5, 3, 10 years  
Cost range:  £0.5-120k 
 
Osteomyelitis 
You think that you have recovered from a bout of food poisoning when you suddenly 
develop a very high temperature.  
You experience severe pain in your leg and you notice that it is swollen, red and 
warm at one spot.  
It is very tender to the touch and hurts a lot when you try to move it.  
You have acute osteomyelitis – a condition which affects the bones.  
You are in hospital for 1 week so that antibiotics can be given intravenously (directly 
into a vein).  
You also need to take painkillers.  
You are fitted with a splint to restrict movement whilst the bone heals. 
It takes {2} months before you feel like your normal self. 
Length:  2 months, 4 months, 2 years  
Cost range:  £0.5-20k 
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TTP 
Following a bout of diarrhoea you start to feel more unwell.  
You have a bad headache and feel confused.  
You have kidney damage, and are admitted as an emergency to hospital. 
You spend the first few days on a ventilator to aid your breathing. 
You spend a further month in hospital having blood transfusions on most days.  
You are allowed home after seven weeks in hospital but are very weak. 
You need regular follow-up visits to hospital.  
It takes {6} months before you feel like your normal self. 
 
Length:  0.5, 1, 3 years  
Cost range:  £0.5-40k 
 
Chronic renal failure  
You become ill with food poisoning which leads to your kidneys being damaged.  
The damage means your kidneys cannot clean the blood.  
This means having to have dialysis whilst you wait for a kidney transplant. 
You will have to visit a hospital 3 times a week for dialysis, where your blood is 
drawn from your body, cleaned, and returned to your body.   
A kidney transplant becomes available after {3} years. 
 
It will involve 3 hours of surgery, followed by 4 days in hospital and 4 weeks of 
recovery at home, when mobility is reduced.   
After surgery you will need to take drugs to prevent rejection of the transplanted 
kidney, which will lead risk of infections, and diabetes in the future.   
It takes 3 months after the surgery before you start to feel like your normal self. 
Length: 1, 3, 6, 10 years  
Cost range:  £0.5-300k 
 
Meningitis 
After a case of food poisoning that lasts a few days you experience a very high 
temperature (fever), chills and fast breathing. At first you think you have got ‘flu. 
Then you start to feel confused or disorientated and lose your balance. You have a 
terrible headache and a very stiff neck. 
You are told you have meningitis. 
You are in hospital for 2 weeks so that antibiotics can be given directly into a vein.  
It takes {6} months for you to recover. 
Length:  0.5, 1, 3 years  
Cost range:  £0.5-50k 
 
Jaundice 
You start to feel unwell - eventually feeling sick and not wanting to eat. You have 
pain in the upper part of your stomach and your skin and the whites of your eyes turn 
yellow. You visit the GP who tells you this is called Jaundice. Your skin becomes 
itchy, your stomach swells and you start to feel confused and very sleepy. You are 
admitted to hospital. 
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Doctors explain that you have Hepatitis E infection. Your liver has failed and you will 
need a liver transplant. It takes {6} months before a donor liver is found – during 
which time you are unwell.  You stay in hospital for two weeks after the transplant.  
You start to feel better after transplant, and it takes 6 months before you feel like 
your normal self. You need tablets every day for the rest of your life to stop your 
body rejecting your new liver. 
Length:  0.5, 1, 2, 4 years  
Cost range:  £0.5-60k 
 
Brain Damage 
You become ill with food poisoning. You start to feel dizzy, and you notice that you 
are confused and disorientated. The bacteria that caused the food poisoning and 
damaged your kidneys has also caused brain damage. This damage is permanent, 
and makes you very disabled. You cannot walk, talk or concentrate. You are unable 
to go to work. You will need specialist equipment at home to help you to cope. The 
consequences from the brain damage will last for the rest of your life. 
Cost range:  £0.5-500k 
 
G.3 Descriptions, Durations, Costs - long term vignettes – child illness 
Below we report the text used to describe the 12 conditions used for children’s long 
term conditions.  For some conditions the duration of the illness varies within the 
survey (values drawn from range of predefined values).  This is identified in 
parenthesis {..}, and the range of durations are reported below the description.  The 
costs are based on results from Focus Groups, Cognitive Interviews and Pilot 
surveys - the cost ranges needed to induce sufficient variation in the Pay/No Pay 
responses. 
 
1. Guillain-Barre Syndrome 
2. Irritable Bowel Syndrome  
3. Reactive arthritis  
4. Mesenteric Adenitis 
5. Septicaemia 
6. Osteomyelitis 
7. Haemolytic Uraemic Syndrome  
8. Chronic renal failure  
9. Complicated jaundice  
10. Meningitis  
11. Brain damage 
12. Febrile convulsions 
 
Guillain-Barre Syndrome  
Your child becomes ill with food poisoning and this leads to more serious symptoms. 
They suffer from difficulty in moving their legs and arms, and find it hard to speak. 
They have Guillain-Barre Syndrome (GBS) which means their body's immune 
system attacking their own nervous system. 
They spend 3 weeks in hospital. 
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The GBS damages their nervous system so severely that they lose the use of their 
legs, meaning that they are restricted to a wheelchair. 
There will be long term pain and tiredness for {2} years before they recover to feel 
like their normal self. 
Length 2, 4, 10 years 
Cost range: £1-160k 
 
Irritable Bowel Syndrome  
Your child becomes ill with food poisoning and from which they seem to recover 
normally. 
About a month later they develop stomach cramps and severe constipation, and 
sometimes they experience an urgent need to go to the toilet.   
They have Irritable Bowel Syndrome (IBS). 
This involves symptoms affecting them for 5-6 days, every 2 months. 
It is expected to last for the rest of their life. 
Cost range 1-20k 
 
Reactive arthritis  
Your child becomes ill with food poisoning during which they develop symptoms 
which fail to clear up. 
They have reactive arthritis, which means their joints (knees feet and ankles) 
become inflamed, red and sore. 
They are prescribed painkillers and anti-inflammatory drugs to reduce the pain.   
It takes {6} months before they will feel like their normal self. 
Length:  6 months, 1 year 10 years  
Cost range: £ 0.5-40k 
 
Mesenteric Adenitis 
After a case of food poisoning that lasts a few days your child develops MA. 
This is an inflammation in the lymph glands in the gut. This causes pain in the 
abdomen, high temperature (fever) and feeling generally unwell; they may be 
nauseous and/or have diarrhoea. 
The symptoms will improve within a 3 days, and will clear up completely within two 
weeks. 
No treatment is needed other than painkillers. However, MA can be difficult to 
distinguish from acute appendicitis. They need a small operation to look inside their 
abdomen to make sure other important problems, like appendicitis, are not missed.  
They will feel some pain and discomfort where the incisions were made for a few 
days after the procedure. They will be given painkillers to ease the pain. They will be 
able to resume their normal activities after a week.  
Cost range: £0.1-5k 
 
Septicaemia 
After a case of food poisoning that lasts a few days your child experiences a very 
high temperature (fever), chills and shivering, a fast heartbeat and fast breathing. 
They start to feel dizzy, confused or disorientated. Their speech becomes slurred 
and they develop severe muscle pain and severe breathlessness.  
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You are told they have septicaemia. This means that their immune system is 
fighting the infection so much that their blood supply to vital organs such as the 
brain, heart and kidneys is restricted. 
They are admitted to the Intensive Care Unit (ICU) where they are given antibiotics 
and fluids straight in to a vein (intravenously) and given oxygen.  
They are in the intensive care unit for 5 days and in hospital on an ordinary ward for 
another 5 days. 
It takes {18} months before they feel like their normal self. 
Length:  18 months, 3 years 10 years  
Cost range:  £0.5-120k 
 
Osteomyelitis 
You think that your child has recovered from a bout of food poisoning when they 
suddenly develop a very high temperature.  
They experience severe pain in their leg and you notice that it is swollen, red and 
warm at one spot.  
It is very tender to the touch and hurts a lot when they try to move it.  
They have acute osteomyelitis – a condition which affects the bones.  
They are in hospital for 1 week so that antibiotics can be given intravenously (directly 
into a vein).  
They also need to take painkillers.  
They are fitted with a splint to restrict movement whilst the bone heals. 
It takes {2} months before they feel like their normal self. 
Length:  2 months, 10 years  
Cost range:  £1-20k 
 
Haemolytic Uraemic Syndrome  
Your child becomes ill with food poisoning which leads to their kidneys being 
damaged.  
The damage means their kidneys cannot clean the blood.  
They go to hospital where you are told they have Haemolytic Uraemic Syndrome. 
They spend a month in intensive care, and you are taught how to conduct dialysis, 
where their blood is drawn from their body, cleaned, and returned to their body each 
night.   
Your child returns home, and you have to continue dialysis for 4 months. 
A kidney transplant becomes available after {3} years. 
It will involve 3 hours of surgery, followed by 4 days in hospital and 4 weeks of 
recovery at home, when mobility is reduced.   
After surgery they will need to take drugs to prevent rejection of the transplanted 
kidney, which will lead risk of infections, and diabetes in the future.   
It takes 3 months after the surgery before they start to feel like their normal self, but 
they do not achieve normal growth milestones. 
Length:  1, 3, 6,10 years  
Cost range:  £1-300k 
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Chronic renal failure  
Your child becomes ill with food poisoning which leads to their kidneys being 
damaged.  
The damage means their kidneys cannot clean the blood.  
This means having to have dialysis whilst they wait for a kidney transplant. 
They will have to visit a hospital 3 times a week for dialysis, where their blood is 
drawn from their body, cleaned, and returned to their body.   
A kidney transplant becomes available after {3} years. 
It will involve 3 hours of surgery, followed by 4 days in hospital and 4 weeks of 
recovery at home, when mobility is reduced.   
After surgery they will need to take drugs to prevent rejection of the transplanted 
kidney, which will lead risk of infections, and diabetes in the future.   
It takes 3 months after the surgery before they feel like their normal self. 
Length:  1, 3, 6, 10 years  
Cost range:  £1-300k 
 
Complicated jaundice  
Your child starts to feel unwell - eventually feeling sick and not wanting to eat.  
They notice pain in the upper part of their tummy and their skin and the whites of 
their eyes turn yellow. You visit the GP who tells you this is called Jaundice. 
Their skin becomes itchy, their tummy swells and they start to feel confused and very 
sleepy.  
They are admitted to hospital. 
Doctors explain that they have a rare complication of Hepatitis E infection. 
Their liver has failed and they will need a liver transplant.  
It takes 6 months before a donor liver is found – during which time they are unwell. 
They stay in hospital for two weeks after the transplant.  
They start to feel better after transplant, and it takes {6} months before they feel like 
their normal self.  
They take tablets every day for the rest of their life to stop their body rejecting their 
new liver. 
Length:  6 months 2 years  
Cost range:  £1-200k 
 
Meningitis  
After a case of food poisoning that lasts a few days your child experience a very high 
temperature (fever), chills and fast breathing. At first you think they have got ‘flu. 
Then they start to feel confused or disorientated and lose their balance. They have a 
dreadful headache and a very stiff neck. 
You are told they have meningitis.  
They are in hospital for 2 weeks so that antibiotics can be given directly into a vein.  
It takes 6 months before you feel like their normal self. 
Length:  6 months, 1, 3 years  
Cost range:  0.5-300k 
 
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                    Final Report  
 
eftec 146 March 2017 
Brain damage  
Your child starts to feel dizzy, and you notice that they are confused and 
disorientated. They cry a lot and you cannot console them. 
The bacteria that caused their food poisoning and damaged their kidneys has also 
caused brain damage. This damage is permanent, and makes your child very 
disabled. They cannot walk, talk or concentrate. They are unable to go to nursery or 
school. They will never be able to work or to look after themselves. You will need 
specialist equipment at home to help you to cope. 
The consequences from the brain damage will last for the rest of their life. 
Cost range:  £1-500k 
 
Febrile convulsions  
Your child becomes ill with diarrhoea and vomiting. They develop an infection and a 
very high temperature.  Your notice that suddenly your child’s body becomes stiff, 
and their arms and legs begin to twitch. They lose consciousness and they wet 
themselves. They vomit and foam at the mouth. Their eyes roll back in their head. 
Although the seizure lasts for less than five minutes it feels like a lifetime to you. You 
rush your child to A&E. Your child is still very sleepy. 
They tell you that your child has had a febrile convulsion. They show you how to put 
your child in the recovery position if they have another seizure and they tell you how 
to bring your child’s temperature down. They make sure that you child is not 
dehydrated. 
They allow you to go home once your child has recovered. 
Cost range:  £0.5-20k 
 
 
APPENDIX H: VIGNETTE SURVEY (ADULTS) 
 
This Appendix presents a pdf version of the survey for adults. It is provided as a 
separate file accompanying this report.  
APPENDIX I: VIGNETTE SURVEY (PARENTS) 
 
This Appendix presents a pdf version of the survey for parents. It is provided as a 
separate file accompanying this report.  
APPENDIX J:  EQ-5D-3L SURVEY (ADULTS) 
This Appendix presents a pdf version of the survey for parents. It is provided as a 
separate file accompanying this report.  
 
APPENDIX K: EQ-5D-3L SURVEY (PARENTS) 
This Appendix presents a pdf version of the survey for parents. It is provided as a 
separate file accompanying this report.  
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APPENDIX L: DATA ANALYSIS (VIGNETTE SAMPLE)  
 
L.1 Econometric Models and Results 
 
Short term - Adults 
The valuation tasks for short term conditions (Adult, Parent) comprise a discrete 
choice experiment. They are analysed via estimation of random utility models, 
specifically conditional logit models with an error component specification to allow for 
differing error variance between the illness and no illness options which comprise 
each set. 
 
Estimation of these models gives estimates of the marginal utilities or preference 
weights (βs) implicitly assigned by respondents to each of the constituent attributes 
(e.g. symptoms, duration, cost). The WTP for a marginal change in attribute j is given 
by (-βj/ βcost) where βj is the estimated marginal utility of the attribute j, and βcost is the 
estimated preference weight on the cost term. 
 
We assume that the impact of symptoms is moderated by their duration, i.e. vomiting 
for 3 days will be treated differently to vomiting for 1 day. Some attributes are treated 
as independent of duration: uncontrolled vomiting (which had a fixed duration of two 
days) and the number of doctor visits.    
 
Results from estimating the model are reported in Table L.1. The model includes 
duration, doctor visits, uncontrolled vomiting, vomiting*days and blood in 
stools*days. Stomach cramps were consistently insignificant and excluded from the 
models. Doctor visits were found to increase the disutility of the illness but were 
collapsed into a yes/no variable as there was no differentiation between 1 or 2 visits. 
The model includes interaction terms between (i) cost and household income6 (to 
accommodate wealthier people being willing to pay more) and (ii) duration and the 
costs7 the respondent indicated would be incurred if they missed work (to test if this 
has any unintended influence on their WTP for pain and suffering). 
 
Short Term - Parents 
Parents’ income influenced the marginal value of the cost attribute (Cost*Incxmd, 
income defined as deviation from £31 655), but no other interaction effects were 
found to be significant (i.e. child age, child gender, lost earnings). Also, a smaller 
number of the attributes used to describe the illness were significant. The presence 
of vomiting, cramps or visits to a doctor did not influence WTP to avoid the illness.  
The duration of the illness, whether there was blood in the stools and the extreme 
vomiting all increased the disutility of the child’s illness (see Table L.2). 
  
                                            
6
 incxmd is the deviation of respondent’s household income from £31 655.  
7
 lostearn is the respondent’s daily cost (lost wages, childcare, etc) of being too ill to work.  
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Table L.1:  Conditional logit estimates for short term adult illness 
 
Coef. Std. Err. z P>z [95% Conf. Interval] 
Cost -0.019241 0.000749 -25.68 0 -0.020709 -0.017772 
Cost * incxmd 0.000033 0.000014 2.28 0.023 0.000005 0.000061 
Days  -0.076599 0.009002 -8.51 0 -0.094242 -0.058956 
Days * vomiting -0.032329 0.011720 -2.76 0.006 -0.055301 -0.009358 
2 days 
uncontrolled 
vomiting  -0.514935 0.114023 -4.52 0 -0.738415 -0.291455 
Days *blood -0.057032 0.016776 -3.4 0.001 -0.089913 -0.024152 
Dr visit -0.333834 0.073010 -4.57 0 -0.476931 -0.190738 
Days*lostearn -0.000133 0.000042 -3.2 0.001 -0.000214 -0.000052 
ASC * incxmd 0.000015 0.000003 5.18 0 0.000010 0.000021 
ASC 0.831096 0.114844 7.24 0 0.606006 1.056186 
Error variance effect 
   σ 2.401816 0.092016 26.1 0 2.221469 2.582163 
ASC is an alternative specific constant for the no illness option 
Number of choices = 7816 
Number of respondents = 977 
Log likelihood = -3756.8444 
 
 
Table L.2: Conditional logit estimates for short term child illness - Parents 
 
Coef. Std. Err. z P>z [95% Conf. Interval] 
Cost -0.02033 0.00091 -22.44 0 -0.02211 -0.01856 
Cost*Incxmd 0.00003 0.00001 2.16 0.031 2.87E-06 6.04E-05 
Days  -0.09895 0.01101 -8.98 0 -1.21E-01 -7.74E-02 
Days *blood -0.10251 0.02158 -4.75 0 -0.1448 -0.06021 
2 days extreme 
vomiting -0.35420 0.12367 -2.86 0.004 -0.5966 -0.11181 
ASC 2.55710 0.17436 14.67 0 2.215368 2.898838 
Error variance effect 
   σ 2.68084 0.14425 18.58 0 2.398114 2.963561 
ASC is an alternative specific constant for the no illness option 
Number of choices     =     4488 
Number of respondents = 561  
Log likelihood = -1942.3589                     
 
Long Term – Adults 
The long term vignettes are single items to be valued, rather than being composed of 
constituent attributes. The elements which varied in the long term sets were the 
duration8 and cost to avoid. The respondents’ decisions to pay /not pay (1,0) were 
analysed via estimation of a logit model for each condition. Explanatory variables 
included the cost to the respondent, and (where appropriate) the duration of the 
illness.   
                                            
8
 Durations did not vary for IBS, MA, or brain damage. 
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As with the short term condition model the cost was interacted with the income level 
of the household (defined as deviation from the household income of £31,655). The 
age of respondent was included as an interaction term with duration (ageoemd) as 
age was thought likely to influence willingness to pay to avoid long duration illnesses. 
Results are reported in Table L.3. 
   
Table L.3:  Logit estimates for 11 conditions: adults 
 cost Cost 
*incxmd 
Duration ageoemd constant N 
GBS -9.29e-6 
(7.46) 
1.10e-7 
(5.31) 
0.070 
(4.20) 
-0.0.01 
(2.29) 
ns 936 
IBS -0.317e-5 
(3.95) 
3.45e-7 
(3.40) 
na -0.012 
(2.45) 
0.432 
(3.40) 
710 
RA -0.615e-4 
(12.04) 
5.05e-7 
(6.99) 
0.097 
(5.80) 
ns ns 933 
MA -0.49e-3 
(5.92) 
6.19e-6 
(4.98) 
na ns -0.186 
(1.17) 
473 
Septicaemia  -0.16e-4 
(7.70) 
1.72e-7 
(6.18) 
ns ns 0.318 
(3.03) 
935 
Osteomyelitis -0.67e-4 
(5.63) 
6.97e-7 
(4.85) 
0.538 
(5.94) 
ns -0.267 
(2.10) 
935 
TTP -0.376e-4 
(7.07) 
4.31e-7 
(6.26) 
0.198 
(3.08) 
ns 0.227 
(1.87) 
1162 
CRF -6.73e-6 
(8.04) 
5.93e-8 
(5.69) 
ns ns 0.308 
(2.81) 
935 
Meningitis -3.60e-5 
(7.86) 
3.51e-7 
(5.50) 
0.184 
(3.30) 
ns ns 711 
Jaundice  -2.03e-5 
(5.25) 
1.76e-7 
(3.85) 
0.104 
(2.03) 
ns 0.542 
(3.74) 
936 
Brain damage -3.29e-6 
(4.77) 
3.65e-8 
(3.66) 
na -0.015 
(2.48) 
0.737 
(4.58) 
463 
Note:  
values in parentheses are z-statistics 
‘na’ indicates not available in the model,  
‘ns’ indicates not significant and dropped from the model. 
 
Long Term – Parents 
Table L.4 reports the results of the logit model estimation for the child illness sample. 
The cost term is significant in all models, and the income effect on cost is significant 
for all but one of the conditions (mesenteric adenitis). The age of the “nominated 
child” the respondent was asked to think about when answering all of the valuation 
questions was not significant. In contrast to the Adult results, many duration effects 
were not significant although there were duration effects for GBS, Reactive Arthritis 
and Osteomyelitis.  
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Table L.4:  Logit estimates for 11 conditions: child illness sample 
 cost Cost 
*incxmd 
duration constant N 
GBS -9.25e-6 
(4.73) 
8.81e-11 
(3.92) 
0.065 
(1.98) 
0.591 
(2.84) 
489 
IBS -5.31e-5 
(3.42) 
3.95e-10 
(2.49) 
na 1.207 
(6.71) 
489 
RA 4.12e-5 
(5.34) 
2.69e-10 
(3.79) 
0.091 
(3.16) 
0.609 
(3.56) 
489 
MA -3.21e-4 
(3.79) 
8.54e-10 
(1.10) 
na 0.562 
(2.60) 
263 
Septicaemia  -9.80e-6 
(3.62) 
7.34e-11 
(2.86) 
ns 0.961 
(5.97) 
489 
Osteomyelitis -5.79e-5 
(3.73) 
5.31e-10 
(3.16) 
0.334 
(2.26) 
0.513 
(2.74) 
460 
HUS -4.33e-6 
(4.24) 
2.88e-11 
(2.80) 
ns 0.751 
(4.75) 
489 
CRF -5.77e-6 
(5.53) 
4.49e-11 
(3.85) 
ns 0.844 
(5.44) 
489 
Meningitis -1.74e-5 
(4.34) 
1.18e-10 
(3.10) 
ns 1.00 
(6.01) 
489 
Jaundice involving 
a liver transplant 
-1.11e-5 
(4.54) 
9.98e-11 
(3.35) 
na 1.283 
(5.29) 
234 
Brain damage -4.04e-6 
(4.31) 
5.48e-11 
(3.65) 
na 1.425 
(5.58) 
255 
Febrile 
convulsions 
-5.81e-5 
(2.78) 
4.78e-10 
(2.21) 
na 0.464 
(2.07) 
255 
Notes:  
values in parentheses are z-statistics 
na: length of illness not included for the condition 
ns: length of illness was included but not significant & dropped from the model 
 
L.2 Adult Sample – demographics and health 
 
The total sample collected for adults was 1189. Some were removed because their 
speed of completion was so great that the data quality was considered unreliable. 
The active sample was then 1040. The sample was 53-47 split between females and 
males. 
 
Table L.5: Gender 
male Freq. Percent Cum. 
    
male 492 47.31 47.31 
female 546 52.5 99.81 
other 2 0.19 100 
Total 1,040 100  
 
Table L.6: Occupation  
We would like to know about the Chief Income Earner in your household 
This is the person with the largest income. 
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If this person is 
 retired with an occupational pension then answer about their most recent occupation. 
 not in a paid job but has been out of work for less than 6 months, then answer about 
their most recent job. 
The Chief Income Earner is (or was):    
 Freq. Percent Cum. 
Semi or unskilled manual work 108 10.38 10.38 
Skilled manual worker 170 16.35 26.73 
Supervisory or clerical/ junior managerial/ professional/ 
administrative 
269 25.87 52.6 
Intermediate managerial/ professional/ administrative 267 25.67 78.27 
Higher managerial/ professional/ administrative 99 9.52 87.79 
Student 13 1.25 89.04 
Casual worker – not in permanent employment 5 0.48 89.52 
Housewife/ Homemaker 15 1.44 90.96 
Retired and living on state pension 37 3.56 94.52 
Unemployed or not working due to long-term sickness 50 4.81 99.33 
Full-time carer of other household member 7 0.67 100 
Total 1,040 100  
 
The geographical split of the sample is shown in Table L.7. The division between UK 
nations is close to the true population proportions with 8.2% from Scotland 
(nationally 8.4%), 5% from Wales (nationally 4.8%) and 3.1% from Northern Ireland 
(nationally 2.9%).  Ethnicity and Education are summarised in Tables L.8 and L.9. 
 
Table L.7: Region 
region Freq. Percent Cum. 
East Midlands 67 6.44 6.44 
East of England 86 8.27 14.71 
London 140 13.46 28.17 
North East 46 4.42 32.6 
North West 112 10.77 43.37 
South East 163 15.67 59.04 
South West 98 9.42 68.46 
West Midlands 85 8.17 76.63 
Yorkshire & Humber 74 7.12 83.75 
Northern Ireland 32 3.08 86.83 
Scotland 85 8.17 95 
Wales 52 5 100 
Total 1,040 100  
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Table L.8: Ethnicity 
ethnicity Freq. Percent Cum. 
White British 878 84.42 84.42 
White Irish 14 1.35 85.77 
Other White 50 4.81 90.58 
Black or Black British - Caribbean 10 0.96 91.54 
Black or Black British – African 7 0.67 92.21 
Other Black 3 0.29 92.5 
Asian British – Indian 21 2.02 94.52 
Asian British - Bangladeshi 5 0.48 95 
Chinese 7 0.67 95.67 
Other Asian 20 1.92 97.6 
Mixed ethnicity - white & black 
Caribbean 
5 0.48 98.08 
Mixed ethnicity - white & black African 1 0.1 98.17 
prefer not to say 19 1.83 100 
Total 1,040 100  
 
Table L.9: Education 
Which of these best describes the highest educational qualification you have obtained so far? 
education Freq. Percent Cum. 
No formal qualifications 37 3.56 3.56 
GCSE Level education (e.g. GCSE, O-Levels or 
Standards) 
218 20.96 24.52 
A-Level education (e.g. A, AS, S-Levels, Highers) 223 21.44 45.96 
Degree or Graduate education (e.g. BSc, BA) 307 29.52 75.48 
Post-graduate education (e.g. PhD, MSc, MA) 139 13.37 88.85 
Vocational education (e.g. NVQ, HNC, HND) 105 10.1 98.94 
Prefer not to say 11 1.06 100 
Total 1,040 100  
Median household pre-tax income was in the range £25,000 - £34,999. The 2013/14 
Households below average income (HBAI) statistics report from the DWP gives a 
median household income (2 adults) as £23,556. The age distribution is shown in 
Table L.11. 
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Table L.10: Household Income  
Please tell us your Household income group  
This is the amount you earn before tax, and includes the people you live with (partner, 
family) – but do not include people you house/flat share with. 
income        Freq. Percent Cum. 
Below £6,500 42 4.04 4.04 
£6,500 - £11,499 85 8.18 12.22 
£11,500 - £17,499 99 9.53 21.75 
£17,500 - £24,999 159 15.3 37.05 
£25,000 - £34,999 184 17.71 54.76 
£35,000 - £44,999 157 15.11 69.87 
£45,000 - £54,999 99 9.53 79.4 
£55,000 - £74,999 91 8.76 88.16 
£75,000 - £99,999 63 6.06 94.23 
£100,000 - £124,999 25 2.41 96.63 
£125,000 - £149,999 20 1.92 98.56 
£150,000 - £199,999 9 0.87 99.42 
more than £200,000 6 0.58 100 
Total 1,039 100  
 
Table L.11: Age Groups 
agecat Freq. Percent Cum. 
18-19 16 1.54 1.54 
20-29 168 16.15 17.7 
30-39 194 18.65 36.4 
40-49 209 20.1 56.4 
50-59 176 16.92 73.4 
60-69 184 17.69 91.1 
70-79 80 7.69 98.8 
80-89 13 1.25 100 
Total 1,040 100  
 
468 (45%) of the sample reported full being at the best level of health using the 
EQ5D -3L form.  The mean EQ5D utility score value (maximum value of 1) was 
0.802 
 
eq5d utility score Obs Mean Std. Dev. Min Max 
      
eq5dutility 1,040 0.802 0.267 -0.594 1 
 
The distribution of EQ5D utility scores is shown in Figure L.1. A total of 18 people in 
the sample reported a health state less than 0 (worse than death). 
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Figure L.1: Histogram EQ5D utility scores – Adult sample 
 
 
The history of the sample and their family members with diarrhoea and/or vomiting in 
the past year are shown in Table L.12 which shows proportions – e.g. 48% of the 
sample have had mild diarrhoea and/or vomiting lasting less than a day in the last 
year. 
 
Table L.12: History of diarrhoea and/or vomiting in past year 
In the past year please tell us if you or family members have had illnesses like this? 
 
 You Other adults 
in the family 
Children in 
the family 
None 
of 
them 
Mild diarrhoea and/or vomiting  <1 
day 
0.488 0.263 0.0915 0.395 
Mild diarrhoea and/or vomiting  , 1-3 
days, time off work/school, no Dr 
contact 
0.217 0.164 0.080 0.656 
Mild diarrhoea and/or vomiting  , 1-3 
days, time off work/school, Dr 
contact 
0.090 0.072 0.040 0.832 
Severe diarrhoea and/or vomiting, 
time off work/school,  > 1 Dr contact 
0.057 0.049 0.021 0.891 
Severe food poisoning, 1+ nights in 
hospital 
0.037 0.038 0.014 0.921 
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Table L.13: History of long run FBD conditions 
Please indicate if either you, or someone in your close family, has any experience of the 
following illnesses. 
 you member of 
close family 
Guillain-Barre Syndrome  0.018 0.025 
Irritable Bowel Syndrome 0.164 0.181 
Arthritis 0.160 0.265 
Febrile Convulsions 0.013 0.025 
Mesenteric adenitis 0.010 0.021 
Septicaemia 0.017 0.053 
Complicated Jaundice 0.013 0.023 
Osteomyelitis 0.017 0.019 
Hemolytic uremic syndrome (HUS) 0.009 0.009 
Thrombotic thrombocytopenic purpura (TTP) 0.013 0.013 
Renal Failure/ Dialysis 0.013 0.042 
Meningitis 0.029 0.041 
 
L.3. Choices, Task Difficulty & Protests – Adult sample 
Possible protest behaviour were investigated for people who selected a pay, or a no 
pay, option in all of the sets they faced. 
 
People with this pattern of choices in the short term sets were prompted as to why 
that was the case using the responses shown in Tables L.14 and L.15. 
 
Table L.14: Why never chose to pay – short term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad - I could live with 
it. 
36 3.46 3.46 
2. I would get better anyway, so it is not worth paying 
for the treatment. 
46 4.42 7.88 
3. I would like to avoid the illness but I could not 
afford to pay what was asked 
20 1.92 9.81 
4. I shouldn’t have to pay because the government 
should provide health care. 
20 1.92 11.73 
5. I have an ethical/religious objection to taking 
medicines 
2 0.19 11.92 
6. Other [please specify] 10 0.96 12.88 
                n/a 906 87.12 100 
Total 1,040 100  
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Table L.15: Why always chose to pay – short term 
Please select the option that best explains why you always chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was 
realistic so I ignored it 
10 0.96 0.96 
2. The cost was small compared to the pain and 
suffering 
108 10.38 11.35 
3. The cost was small compared to what I would 
lose missing work 
46 4.42 15.77 
4. Other (please specify) 21 2.02 17.79 
                n/a 855 82.21 100 
Total 1,040 100  
 
People choosing options 4-6 in Table L.14, and options 1 or 4 in Table L.15 were 
excluded from the estimation sample. The rates of such ‘protests’ were very low 
considering this was a health-payment study in the UK. 
 
Possible protest behaviour were investigated for people who selected a pay, or a no 
pay, option in all of the sets they faced. 
 
People who selected a pay, or a no pay, option in all of the long term sets were 
prompted as to why that was the case using the responses shown in Tables L.16 
and L.17. 
 
Table L.16: Why never chose to pay – long term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad - I could live with it. 22 2.12 2.12 
2. I would get better anyway, so it is not worth paying for 
the treatment. 
18 1.73 3.85 
3. I would like to avoid the illness but I could not afford to 
pay what was asked. 
91 8.75 12.6 
4. I shouldn’t have to pay because the government should 
provide health care. 
44 4.23 16.83 
5. I may not live for all those years, so not worth paying to 
avoid the illness. 
10 0.96 17.79 
6. I would rather leave money to family/partner than spend 
to avoid the illness. 
12 1.15 18.94 
7. Other [please specify] 23 2.21 21.15 
                n/a 820 78.85 100 
Total 1,040 100  
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Table L.17: Why always chose to pay – long term 
Please select the option that best explains why you always chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was realistic so I 
ignored it 
15 1.44 1.44 
2. The cost was small compared to the pain and suffering 83 7.98 9.42 
3. The cost was small compared to what I would lose 
missing work 
9 0.87 10.29 
4. Other (please specify) 21 2.02 12.31 
                n/a 912 87.69 100 
Total 1,040 100  
 
People choosing options 4-7 in Table L.16, and options 1 or 4 in Table L.17 were 
excluded from the estimation sample. As with the short term sets the rates of such 
‘protests’ were very low. 
 
Respondents were debriefed on how hard to was to understand the sets, and how 
hard it was to make the choices within them 
 
Table L.18: How hard was it to understand the choice questions involving 
illness and money? – short term 
 Freq. Percent Cum. 
very difficult 18 1.73 1.73 
difficult 85 8.17 9.9 
neutral 211 20.29 30.19 
easy 372 35.77 65.96 
very easy 354 34.04 100 
Total 1,040 100  
 
Table L.19: How hard was it to make the choice questions involving illness and 
money? – short term 
 Freq. Percent Cum. 
very difficult 29 2.79 2.79 
difficult 155 14.9 17.69 
neutral 261 25.1 42.79 
easy 357 34.33 77.12 
very easy 238 22.88 100 
Total 1,040 100  
 
The choice tasks were complex, which was why so much effort had been assigned 
to preparation of the materials and testing and refining them in focus groups, 
interviews and pilot surveys.   
 
Rates of 2% and 8% respectively describing the short term sets as very difficult and 
difficult to understand were regarded as validating those efforts. Making the choices 
was more often reported as more difficult than understanding the choices. 
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Table L.20: How hard was it to understand the choice questions involving 
illness and money? – long term 
 Freq. Percent Cum. 
very difficult 46 4.42 4.42 
difficult 94 9.04 13.46 
neutral 199 19.13 32.6 
easy 386 37.12 69.71 
very easy 315 30.29 100 
Total 1,040 100  
 
 
Table L.21: How hard was it to make the choice questions involving illness and 
money? – long term 
 Freq. Percent Cum. 
very difficult 120 11.54 11.54 
difficult 243 23.37 34.9 
neutral 198 19.04 53.94 
easy 290 27.88 81.83 
very easy 189 18.17 100 
Total 1,040 100  
 
The long term conditions included much more information and were more 
demanding. Rates of 4% and 9% respectively describing the sets as very difficult 
and difficult to understand were regarded as not signifying fundamental problems 
with the long term valuation process. Making the choices was more often reported as 
more difficult than understanding the choices, and more often so in the long term 
sets than the short term ones. 
 
L.4 Parents Sample – demographics and health 
The total sample collected within the Vignette design for parents was 653. A similar 
sized sample was collected for parents who were presented with Valuation questions 
using EQ5D information rather than vignettes (not reported here). Some were 
removed because their speed of completion was so great that the data quality was 
considered unreliable. The active sample was then 592. The sample was 60-40 split 
between females and males.  
 
Table L.22: Gender 
male Freq. Percent Cum. 
male 240 40.61 40.61 
female 350 59.22 99.83 
other 1 0.17 100 
Total 591 100  
 
The distribution of occupations and class are shown in Table L.23. 
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Table L.23: Occupation  
We would like to know about the Chief Income Earner in your household 
This is the person with the largest income. 
If this person is 
 retired with an occupational pension then answer about their most recent occupation. 
 not in a paid job but has been out of work for less than 6 months, then answer about 
their most recent job. 
The Chief Income Earner is (or was):    
 Freq. Percent Cum. 
Semi or unskilled manual work 65 11 11 
Skilled manual worker 116 19.63 30.63 
Supervisory or clerical/ junior managerial/ professional/ 
administrative 152 25.72 56.35 
Intermediate managerial/ professional/ administrative 137 23.18 79.53 
Higher managerial/ professional/ administrative 59 9.98 89.51 
Student 6 1.02 90.52 
Casual worker – not in permanent employment 7 1.18 91.71 
Housewife/ Homemaker 18 3.05 94.75 
Retired and living on state pension 7 1.18 95.94 
Unemployed or not working due to long-term sickness 13 2.2 98.14 
Full-time carer of other household member 11 1.86 100 
Total 591 100  
 
The geographical split of the sample is shown in Table L.24. The division between 
UK nations is close to the aggregate national population proportions with 7.8% from 
Scotland (nationally 8.4%), 3.7% from Wales (nationally 4.8%) and 3.6% from 
Northern Ireland (nationally 2.9%). Ethnicity and Education are summarised in 
Tables L.25 and L.26. 
 
Table L.24: Region 
region Freq. Percent Cum. 
East Midlands 41 6.93 6.93 
East of England 47 7.94 14.86 
London 72 12.16 27.03 
North East 29 4.9 31.93 
North West 75 12.67 44.59 
South East 94 15.88 60.47 
South West 47 7.94 68.41 
West Midlands 58 9.8 78.21 
Yorkshire & Humber 40 6.76 84.97 
Northern Ireland 21 3.55 88.51 
Scotland 46 7.77 96.28 
Wales 22 3.72 100 
Total 592 100  
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Table L.25: Ethnicity 
ethnicity Freq. Percent Cum. 
White British 481 81.25 81.25 
White Irish 8 1.35 82.6 
Other White 31 5.24 87.84 
Black or Black British - Caribbean 9 1.52 89.36 
Black or Black British – African 7 1.18 90.54 
Other Black 17 2.87 93.41 
Asian British – Indian 6 1.01 94.43 
Asian British - Bangladeshi 7 1.18 95.61 
Chinese 10 1.69 97.3 
Other Asian 4 0.68 97.97 
Mixed ethnicity - white & black Caribbean 4 0.68 98.65 
Mixed ethnicity - white & black African 8 1.35 100 
prefer not to say 481 81.25 81.25 
Total 592 100  
 
Table L.26: Education 
Which of these best describes the highest educational qualification you have obtained 
so far? 
education Freq. Percent Cum. 
No formal qualifications 17 2.87 2.87 
GCSE Level education (e.g. GCSE, O-Levels or 
Standards) 128 21.62 24.49 
A-Level education (e.g. A, AS, S-Levels, Highers) 128 21.62 46.11 
Degree or Graduate education (e.g. BSc, BA) 163 27.53 73.65 
Post-graduate education (e.g. PhD, MSc, MA) 85 14.36 88.01 
Vocational education (e.g. NVQ, HNC, HND) 63 10.64 98.65 
Prefer not to say 8 1.35 100 
Total 592 100  
 
Median household pre-tax income was in the range £25,000 - £34,999. The 2013/14 
Households below average income (HBAI) statistics report from the DWP gives a 
median household income (2 adults) as £23,556. 
 
The age distribution is shown in Table L.28. 
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Table L.27: Household Income  
Please tell us your Household income group  
This is the amount you earn before tax, and includes the people you live with (partner, 
family) – but do not include people you house/flat share with. 
income        Freq. Percent Cum. 
Below £6,500 12 2.03 2.03 
£6,500 - £11,499 43 7.26 9.29 
£11,500 - £17,499 38 6.42 15.71 
£17,500 - £24,999 79 13.34 29.05 
£25,000 - £34,999 110 18.58 47.64 
£35,000 - £44,999 90 15.2 62.84 
£45,000 - £54,999 66 11.15 73.99 
£55,000 - £74,999 56 9.46 83.45 
£75,000 - £99,999 44 7.43 90.88 
£100,000 - £124,999 23 3.89 94.76 
£125,000 - £149,999 14 2.36 97.13 
£150,000 - £199,999 8 1.35 98.48 
more than £200,000 9 1.52 100 
Total 592 100  
 
 
Table L.28: Age Groups 
agecat Freq. Percent Cum. 
18-19 18 3.04 3.21 
20-29 98 16.55 19.76 
30-39 157 26.52 46.28 
40-49 158 26.69 72.97 
50-59 102 17.23 90.2 
60-69 49 8.28 98.48 
70-79 7 1.18 99.66 
80-89 2 0.34 100 
Total 591 100  
 
Health 
 
The mean EQ5D utility score value (maximum value of 1) was 0.88 
 
eq5d utility score Obs Mean Std. Dev. Min Max 
      
eq5dutility 446 0.882762 0.226135 -0.429 1 
 
The distribution of EQ5D utility scores is shown in Figure L.2. A total of 9 people in 
the sample reported a health state less than 0 (worse than death). 
 
The history of the sample and their family members with diarrhoea and/or vomiting in 
the past year are shown in Table L.29 which shows proportions – e.g. 48% of the 
sample have had mild diarrhoea and/or vomiting lasting less than a day in the last 
year. 
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Figure L.2: Histogram EQ5D utility scores – Adult sample 
 
 
Table L.29: History of diarrhoea and/or vomiting in past year 
In the past year please tell us if you or family members have had illnesses like this? 
 
 You Other adults 
in the family 
Children in 
the family 
None 
of 
them 
Mild diarrhoea and/or vomiting  <1 
day 0.476 0.282 0.390 0.316 
Mild diarrhoea and/or vomiting  , 1-
3 days, time off work/school, no Dr 
contact 0.248 0.228 0.311 0.468 
Mild diarrhoea and/or vomiting  , 1-
3 days, time off work/school, Dr 
contact 0.120 0.096 0.140 0.720 
Severe diarrhoea and/or vomiting, 
time off work/school,  > 1 Dr 
contact 0.074 0.063 0.073 0.828 
Severe food poisoning, 1+ nights 
in hospital 0.049 0.024 0.035 0.905 
 
The long run vignettes included in the valuation study featured a series of conditions 
as shown in Table L.30. 
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Table L.30: History of long run FBD conditions  
Please indicate if either you, or someone in your close family, has any 
experience of the following illnesses. 
 
you 
member close 
family 
Guillain-Barre Syndrome  0.037 0.042 
Irritable Bowel Syndrome 0.159 0.233 
Arthritis 0.110 0.289 
Febrile Convulsions 0.020 0.108 
Mesenteric adenitis 0.012 0.049 
Septicaemia 0.019 0.088 
Complicated Jaundice 0.010 0.069 
Osteomyelitis 0.012 0.042 
Hemolytic uremic syndrome (HUS) 0.010 0.044 
Thrombotic thrombocytopenic purpura (TTP) 0.012 0.037 
Renal Failure/ Dialysis 0.005 0.066 
Meningitis 0.035 0.076 
 
L.5. Choices, Task Difficulty & Protests – Parent sample 
Possible protest behaviour were investigated for people who selected a pay, or a no 
pay, option in all of the sets they faced. 
 
People with this pattern of choices in the short term sets were prompted as to why 
that was the case using the responses shown in Tables L.31 and L.32. 
 
Table L.31: Why never chose to pay – short term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad. 6 1.01 1.01 
2. My child would get better anyway, so it is not 
worth paying for the treatment. 11 1.86 2.87 
3. I would like my child to avoid the illness but I could 
not afford to pay what was asked 7 1.18 4.05 
4. I shouldn’t have to pay because the government 
should provide health care. 7 1.18 5.24 
5. I have an ethical/religious objection to my child 
taking medicines 1 0.17 5.41 
6. Other (please specify) 5 0.84 6.25 
               n/a 555 93.75 100 
Total 592 100  
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Table L.32: Why always chose to pay – short term 
Please select the option that best explains why you always chose to pay to avoid the 
illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was 
realistic so I ignored it 11 1.86 1.86 
2. The cost was small compared to my child's 
pain and suffering 107 18.07 19.93 
3. The cost was small compared to the costs 
involved in caring for my ill child. 18 3.04 22.97 
4. Other (please specify) 7 1.18 24.16 
               n/a 449 75.84 100 
Total 592 100  
 
People choosing options 4-6 in Table L.31, and options 1 or 4 in Table L.32 were 
excluded from the estimation sample. The rates of such ‘protests’ were very low 
considering this was a health-payment study in the UK. 
 
Possible protest behaviour were investigated for people who selected a pay, or a no 
pay, option in all of the sets they faced. 
 
People who selected a pay, or a no pay, option in all of the long term sets were 
prompted as to why that was the case using the responses shown in Tables L.33 
and L.34. 
 
Table L.33: Why never chose to pay – long term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad - I could live with it. 6 1.01 1.01 
2. I would get better anyway, so it is not worth paying for the 
treatment. 12 2.03 3.04 
3. I would like to avoid the illness but I could not afford to pay 
what was asked. 34 5.74 8.78 
4. I shouldn’t have to pay because the government should 
provide health care. 13 2.2 10.98 
5. I have an ethical/religious objection to my child taking 
medicines    
6. Other (please specify) 2 0.34 11.32 
               n/a 525 88.68 100 
Total 592 100  
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Table L.34: Why always chose to pay – long term 
Please select the option that best explains why you always chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was realistic so I 
ignored it 16 2.7 2.7 
2. The cost was small compared to my child's pain and 
suffering 109 18.41 21.11 
3. The cost was small compared to the costs involved in 
caring for my ill child. 20 3.38 24.49 
4. Other (please specify) 20 3.38 27.87 
                n/a 427 72.13 100 
Total 592 100  
 
People choosing options 4-6 in Table L.33, and options 1 or 4 in Table L.34 were 
excluded from the estimation sample. As with the short term sets the rates of such 
‘protests’ were very low. Respondents were debriefed on how hard to was to 
understand the sets, and how hard it was to make the choices within them 
 
Table L.35: How hard was it to understand the choice questions involving 
illness and money? – short term 
 Freq. Percent Cum. 
very difficult 21 3.55 3.55 
difficult 49 8.28 11.82 
neutral 108 18.24 30.07 
easy 195 32.94 63.01 
very easy 219 36.99 100 
Total 592 100 
  
 
Table L.36: How hard was it to make the choice questions involving illness and 
money? – short term 
 Freq. Percent Cum. 
very difficult 36 6.08 6.08 
difficult 114 19.26 25.34 
neutral 127 21.45 46.79 
easy 188 31.76 78.55 
very easy 127 21.45 100 
Total 592 100 
  
The choice tasks were complex, which was why so much effort had been assigned 
to preparation of the materials and testing and refining them in focus groups, 
interviews and pilot surveys.   
 
Rates of 4% and 8% respectively describing the short term sets as very difficult and 
difficult to understand were regarded as validating those efforts. Making the choices 
was more often reported as more difficult than understanding the choices. 
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Table L.37: How hard was it to understand the choice questions involving 
illness and money? – long term 
 Freq. Percent Cum. 
very difficult 36 6.08 6.08 
difficult 63 10.64 16.72 
neutral 101 17.06 33.78 
easy 221 37.33 71.11 
very easy 171 28.89 100 
Total 592 100  
 
 
Table L.38: How hard was it to make the choice questions involving illness and 
money? – long term 
 Freq. Percent Cum. 
very difficult 134 22.64 22.64 
difficult 137 23.14 45.78 
neutral 91 15.37 61.15 
easy 130 21.96 83.11 
very easy 100 16.89 100 
Total 592 100 
  
The long term conditions included much more information and were more 
demanding. Rates of 6% and 11% respectively describing the sets as very difficult 
and difficult to understand were regarded as not signifying fundamental problems 
with the long term valuation process. 
 
Making the choices was more often reported as more difficult than understanding the 
choices, and more often so in the long term sets than the short term ones. 
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APPENDIX M: DATA ANALYSIS (EQ-5D-3L SAMPLE) 
 
M.1 Econometric Models and Results 
 
In the EQ-5D DCE for short term conditions respondents chose between remaining 
in current health at a cost, or experiencing reduced health (defined in terms of EQ-
5D-3L levels) for a defined duration (between 1 and 14 days). The utility functions for 
the two Alternatives are given in (1a) and (1b). 
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Utility is determined by the health level given by the EQ-5D-3L levels. This is 
multiplied by the duration of the health state (T).  EQ5DILLnli are dummy variables 
indicating the health state in the reduced health option, (n=5 dimensions, l= 3 levels) 
 
EQ5DCnli are dummy variables indicating the health state in the current health option, 
(n=5 dimensions, l= 3 levels). The introduction of the current health state is required, 
as otherwise the model would over-state the benefits of avoiding the illness.   
 
Utility in the ill state (1a) is augmented by terms capturing  
(i) the length of the illness, irrespective of health state,  
(ii) the length of illness interacted with the self-reported lost earnings per day 
(LE), and  
(iii) an individual specific Alternative Specific Constant (ASC) to capture any 
baseline aversion to suffering reduced health, irrespective of length and 
severity of the reduced health. 
 
Utility in the current health state (1b) is augmented by terms capturing 
(i) the cost of avoiding the illness state, and  
(ii) an interaction of cost with income (defined as mean deviations) to account 
for a differing marginal utility of money over income levels. 
 
The model is estimated as a Mixed Logit model, with the individual specific constant 
α0i modelled as a normally distributed random parameter that is constant over all 
choices by that individual. Estimation results are reported in Table M.1. 
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Table M.1: Mixed Logit Results - Adult EQ-5D (short term) 
 Coeff SE Z 
T x mobility_D2 -0.02953 0.007997 -3.69 
T x mobility_D3 -0.07657 0.010904 -7.02 
T x selfcare_D2 -0.04879 0.008099 -6.02 
T x selfcare_D3 -0.14504 0.013146 -11.03 
T x usualactivities_D2 -0.03142 0.007535 -4.17 
T x usualactivities_D3 -0.07179 0.010815 -6.64 
T x pain_D2 -0.03988 0.007825 -5.1 
T x pain_D3 -0.17392 0.011282 -15.42 
T x anxiety_D2 -0.00872 0.00815 -1.07 
T x anxiety_D3 -0.11936 0.012935 -9.23 
T -0.10538 0.008967 -11.75 
T x LE -3.5E-05 1.71E-05 -2.04 
Ill -0.47611 0.06874 -6.93 
Cost -0.02006 0.000629 -31.90 
Cost x IncomeMD 7.70E-08 7.64E-09 10.08 
St Dev of random parameter   
ill 2.148459 0.057391 37.44 
Choices=15888;  Individuals =1986; LL=-8160.8101   
 
Cost is significant and negative – respondents took account of the costs in their 
choices. All EQ-5D health parameters are significant and with the anticipated 
ordering, with the exception of T x anxiety_D2.   
Poorer health states reduce utility (apart from anxiety_D2 where there appears to be 
no differentiation between full health and level 2), and there is a significant 
differentiation between state 2 and state 3 for all 5 measures.  
The negative coefficient for T implies that there is an effect of the length of illness in 
addition to that associated with any specific health state, and the negative coefficient 
on ill (the ASC associated with the illness state) implies that there is a negative utility 
associated with illness irrespective of illness state or duration.  The interaction 
between T and lost earnings (LE) is negative which suggests that the ‘duration’ effect 
is larger for those who expect to lose more income per day because of it.   
The structure of the short term EQ-5D- 3L DCE sets for parents answering regarding 
their child’s health states were identical to that for the adults. Parents were asked to 
choose between (i) a specified period of ill health for their child, followed by a return 
to current health and (ii) remaining at current health but at a cost. 
 
Table M.2 reports results from the estimation of a mixed logit model upon the 
parents’ choice data regarding their children’s health states. 
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Table M.2: Parent EQ-5D DCE mixed logit results, short term illness 
 Coeff SE Z 
T x mobility_D2 -0.03437 0.014926 -2.30 
T x mobility_D3 -0.0514 0.019519 -2.64 
T x selfcare_D2 0.012722 0.014598 0.87 
T x selfcare_D3 -0.05669 0.02281 -2.49 
T x usualactivities_D2 -0.02996 0.013879 -2.16 
T x usualactivities_D3 -0.08726 0.019538 -4.47 
T x pain_D2 -0.07250 0.014549 -4.98 
T x pain_D3 -0.17891 0.01975 -9.06 
T x anxiety_D2 0.012692 0.014840 0.86 
T x anxiety_D3 -0.09042 0.023060 -3.92 
Cost -0.01848 0.001136 -16.27 
T 0.076965 0.017190 4.48 
Cost x IncomeMD 4.83E-08 1.15E-08 4.18 
ill -1.47333 0.132799 -11.09 
St Dev of random parameter   
ill 2.2555 0.1077992 20.92 
Choices=5080; Individuals =635; LL = -2521.5993 
 
Cost is significant and negative – parents took account of the costs to them of their 
child avoiding ill health when making their choices. The marginal utility of cost is 
affected by income as economic theory would suggest. 
All EQ-5D health parameters are significant and with the exception of T x 
SelfCareD2 and T x anxietyD2 which are not significantly different from the baseline 
EQ-5D level.  
The negative coefficient for T implies that there is an effect of the length of illness in 
addition to that associated with any specific health state, and the negative coefficient 
on ill (the ASC associated with the illness state) implies that there is a negative utility 
associated with a child’s illness irrespective of illness state or duration. This term is 
specified as random with the St.Dev estimate indicating large heterogeneity in this 
illness aversion. 
The utility function associated with the long run EQ5D model differs since 
respondents are asked to consider two alternative life paths with different health 
states, lasting for different periods. The monetary attribute is not a marginal change 
in income, but the average annual income. 
 
Our starting point for the model is a specific implementation of the general model 
presented by Bleichrodt and Quiggin (1999): 



T
t
thqcvU
1
)()(
         (2) 
Where T is the life span expected, v(c) is the utility over consumption and is strictly 
increasing in c, and q(h) is the utility over the health state h.   
 
Our formal representation of utility takes the form 
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                    Final Report  
 
eftec 170 March 2017 






 
 
5
1
3
2
5exp
n l
Ill
nlinli DEQIncomeTU 

     (3) 
 taking logs gives:  

 

5
1
3
2
5)ln()ln(
n l
Ill
nlinli DEQIncomeTU 
     (4) 
 
We impose the restriction that the coefficient on ln(T) = 1 by using a ‘WTP space 
representation of the model, allowing the error variance to be freely estimated.   
We include an alternative specific constant for the illness alternative, specified as a 
random parameter. We introduce an anchoring effect on the income level since 
analysis indicated that respondents do not place the same value on increases in 
income above their current income, as they do on reductions in income below it.  
This effect appears to be absolute: respondents place no additional utility on income 
levels above their current level, although they do place utility on changes in income 
below it. The behavioural interpretation of this effect is that respondents would not be 
prepared to accept any reductions in length of life, or reductions in health status, if 
the only compensation for that change was an increase in income. They would be 
prepared to accept a reduction in income to achieve an improvement in health status 
or years of life i.e. they are willing to pay to achieve those improvements, but they 
are not willing to accept increases in income above their current income to 
compensate for health/longevity decrements.  
The estimated model is therefore based on the utility function: 
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Where Income’ is the transformed income level, where income levels above the 
respondent’s current level are recoded as that current level. This transformation 
hugely improves model fit and has the behavioural interpretation explained above. 
The results from estimation of this model are reported in Table M.3. 
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Table M.3: Mixed Logit Model, Long Term Adult EQ-5D Sample 
variable coefficient SE Z 
Ln(T) 1 .. .. 
Ln(Income’) 0.420932 0.093394 4.51 
mobility_D2 -0.28457 0.040111 -7.09 
mobility_D3 -1.18728 0.064498 -18.41 
selfcare_D2 -0.15041 0.041118 -3.66 
selfcare_D3 -0.81302 0.056987 -14.27 
usualactivities_D2 -0.16082 0.039628 -4.06 
usualactivities_D3 -0.41987 0.06288 -6.68 
pain_D2 -0.24883 0.04627 -5.38 
pain_D3 -0.81532 0.0652 -12.5 
anxiety_D2 -0.27736 0.042369 -6.55 
anxiety_D3 -0.75846 0.067625 -11.22 
ill 0.420932 0.093394 4.51 
St Dev of random parameter   
ill 1.05665 0.035822 29.5 
Error variance 
 0.363617 0.027707 13.12 
number of choices =12504; number of individuals =1563; 
LL = -6095.8563 
 
These results suggest respondents are attending to health, income and duration 
terms. Increased annual income (up to current income) increases utility, and all the 
EQ5D deviations from full health reduce utility. In all cases respondents are sensitive 
to the degree of health reduction (in all cases the Marginal Utility for an EQ-5D level 
3 attribute is significantly different from its level 2 equivalent). 
The marginal WTP to avoid a year in each of the 10 health states below full health is 
given by: 
)/exp(1 
nlnl
WTP          (6) 
 
In the Parent EQ-5D DCE study for long-term child ill health the structure of the DCE 
was the same as the short term, except the durations increased greatly, as did the 
cost. The child returned to current health after any illness: the parent was never 
asked to choose between lives of differing length for their child. Estimates from a 
mixed logit model estimated on these data are reported in Table M.4. 
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Table M.4: Parent EQ-5D DCE mixed logit results, long term illness 
 Coeff SE Z 
T x mobility_D2 -0.02142 0.015942 -1.34 
T x mobility_D3 -0.04355 0.022073 -1.97 
T x selfcare_D2 0.033997 0.015852 2.14 
T x selfcare_D3 0.000705 0.024817 0.03 
T x usualactivities_D2 0.002245 0.015353 0.15 
T x usualactivities_D3 0.007959 0.022451 0.35 
T x pain_D2 0.002724 0.015543 0.18 
T x pain_D3 -0.08445 0.02115 -3.99 
T x anxiety_D2 0.001874 0.016328 0.11 
T x anxiety_D3 -0.02804 0.025172 -1.11 
Cost -0.01202 0.0012146 -9.90 
Cost x IncomeMD 5.86E-08 1.17E-08 5.01 
Ill x IncomeMD -1.72E-05 4.25E-06 4.12 
T x Ill -0.078154 0.018492 4.27 
Ill 0.2654986 0.176412 1.50 
St Dev of random parameter   
Ill 3.072886 0.1561762 19.68 
Choices=4696; Individuals =587; LL = -2183.9668 
 
The pattern observed thus far in all the WTP studies (Vignette, EQ-5D; Adult, 
Parent) of significance of (nearly) all parameters breaks down in this case. 
The choice data indicate very little attention paid to the health attributes. The 
respondents do attend to the duration of the illness, the cost to avoid illness, and 
those with higher incomes are willing to pay more to avoid the illness. Although these 
results indicate that parents are willing to avoid long run illness for their children, they 
are of little use as the choices and hence the WTPS are not differentiated by the 
severity of the illness experienced by the child.  
 
Monetary Value of a QALY 
The model estimated for the responses to the EQ5D version of the questionnaire 
(Appendix M) can be used to estimate the value of obtaining an additional year of full 
health i.e. the WTP to acquire a QALY. Conceptually this identifies the reduction in 
income that would exactly offset the increase in utility associated with the length of 
life being extended by one year at full health. 
 
As Bleichrodt and Quiggin (1999) note, this value will depend on: the relative 
substitutability of income and time in the utility function (as defined by the relative 
sizes of the coefficients on ln(T) and ln(Income’) ), the income of the respondent, and 
the number of years before the additional year of life is gained. 
 
Analysis of the choice data indicated that respondents were not discounting. Hence 
in the analysis that follows we ignore all discounting of time i.e. respondents are 
indifferent to when consumption or extra years occur. This simplifying assumption is 
justified by the data. 
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An assumption has to be made as to whether additional income is earned when the 
additional year of life is gained. We start by assuming that that does not occur, and 
hence that the respondent has a fixed wealth which does not change as a result of 
the additional year of health being gained. We relax this below. We also assume that 
the respondent is at full health for all years considered. 
 
Assume that an individual has an initial wealth of W, and an expected life span of T.  
Given the utility function  
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The optimal allocation of wealth over time is to equalise it, so that 
Incomet=W/T=Y 
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If an additional year of life is given, and wealth is unchanged, then the utility over the 
life time is now: 
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To identify the maximum WTP for the extra year of health one has to identify the 
reduction in wealth that would leave the 2 utilities equal: 
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Solving for δ (the WTP to acquire the extra year) gives: 
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Or if defined in terms of the initial annual income: 
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The WTP for a QALY depends on the rate of substitution between time and income.  
As α tends towards 1 the WTP tends towards zero. At the limit, where α=1 the 
individual maximises utility over total wealth, and is not concerned about when it 
occurs (there is no decreasing marginal utility of income) and hence is not prepared 
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to sacrifice any wealth to obtain an extra year of life. However, if α<1 i.e. there is 
decreasing marginal utility in consumption, spreading the same wealth over more 
years increases welfare, as, at the margin, the marginal utility of consumption is 
increased in all years. Thus, as α gets smaller, WTP for a QALY will increase. WTP 
also increases in T, the original life expectancy.   
 
If the original T is equal to 1, then the addition of an additional year represents a 
100% increase in the amount of time over which the original fixed wealth has to be 
allocated: income per year will be halved. Forcing consumption back by this amount 
will cause significant reductions in utility and substantial increases in the marginal 
utility of income. 
 
If the original T =10, and the initial allocation of wealth is increased commensurately, 
so initially the average income is the same, then an addition of 1 year of life 
represents only a 10% increase in life expectancy: if initial wealth is allocated over all 
11 years, then average income per year does not fall greatly. Thus marginal utility of 
income does not increase as much. Hence, in the case of T=10, there is greater 
scope to reduce wealth in the quest for equalizing utility before and after the addition 
of a year of life. 
 
To illustrate these effects, Table M.5 reports the values for a QALY for three different 
income levels, and for an initial T of 1 and 10. 
 
Table M.5: WTP for a QALY, by income level, and number of years of life 
remaining (£) 
 Gross Household Income 
 £10,000 £31,655 £100,000 
T=1 6,100 
(3,400-8,90) 
19,456 
(10,700-28,200) 
61,500 
(33,900-89,100) 
T=10 12,300 
(3,600-20,900) 
38,900 
(11,600-66,200) 
122,900 
(36,500-209,200) 
 
As expected, the WTP increases in proportion to income. If one takes the median 
income of £31,655 then the WTP for a QALY would be £19,456 for a year gained 
immediately.  
 
These results assume that there is no rate of time preference. As the additional year 
of life occurs at the end of the period, then discounting with a positive discount rate 
will reduce the WTP. 
 
These results are based on the assumption above that the additional year of life 
does not affect wealth, i.e. that consumption in that year has to be met by 
reallocating consumption from other years. An alternative assumption is that the 
earning capacity of the individual was the same in that additional year. This changes 
the fundamental object being valued: it is now an additional year of life, plus an 
addition to wealth of Y. 
 
Again assuming no discounting over time, the implications for WTP is simple to 
derive: 
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WTP for a QALY increases simply by the amount of annual income. The logic of this 
is straightforward. When considering what reduction in wealth is required to make a 
person indifferent to gaining an additional year of life, with income, one knows that 
one can reduce wealth by the amount of that additional income as an initial estimate 
(that would leave them in their initial wealth position, with an additional year of life 
but with no income, so their utility cannot be reduced). That then leaves the 
individual at the point of the previous analysis (an additional year of life without 
income) and one can then proceed with the previous analysis to identify the 
additional reduction in wealth that can occur. 
 
Thus, WTP for a QALY for an individual at median income, under these 
assumptions, would be £31,655 + £19,456 = £51,111 per year. Similarly, all other 
estimates simply need to be updated by the value of annual income.  
 
M.2 Adult Sample – demographics and health 
A sample of 2211 adults was collected within the EQ5D sample. Some were 
removed because their speed of completion was so great that the data quality was 
considered unreliable. The active Adult EQ5D sample was then 2097. 
Demographics 
The sample was 52-48 split between females and males.  
 
Table M.6: Gender 
male Freq. Percent Cum. 
male 1,015 48.4 48.4 
female 1,081 51.55 99.95 
other 1 0.05 100 
Total 2097 100  
 
The distribution of occupations and class are shown in Table M.7. 
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Table M.7: Occupation  
We would like to know about the Chief Income Earner in your household 
This is the person with the largest income. 
If this person is 
 retired with an occupational pension then answer about their most recent 
occupation. 
 not in a paid job but has been out of work for less than 6 months, then answer 
about their most recent job. 
The Chief Income Earner is (or was): 
 
   
 Freq. Percent Cum. 
Semi or unskilled manual work 231 11.02 11.02 
Skilled manual worker 398 18.98 30 
Supervisory or clerical/ junior managerial/ professional/ 
administrative 510 24.32 54.32 
Intermediate managerial/ professional/ administrative 526 25.08 79.4 
Higher managerial/ professional/ administrative 177 8.44 87.84 
Student 24 1.14 88.98 
Casual worker – not in permanent employment 22 1.05 90.03 
Housewife/ Homemaker 21 1 91.03 
Retired and living on state pension 74 3.53 94.56 
Unemployed or not working due to long-term sickness 100 4.77 99.33 
Full-time carer of other household member 14 0.67 100 
Total 2097 100  
 
The geographical split of the sample is shown in Table M.8. The division between 
UK nations is close to the aggregate national population proportions with 9.3% from 
Scotland (nationally 8.4%), 5.3% from Wales (nationally 4.8%) and 2.1% from 
Northern Ireland (nationally 2.9%). Ethnicity and Education are summarised in 
Tables M.9 and M.10. 
 
Table M.8: Region 
region Freq. Percent Cum. 
East Midlands 177 8.44 8.44 
East of England 206 9.82 18.26 
London 214 10.21 28.47 
North East 102 4.86 33.33 
North West 172 8.2 41.54 
South East 337 16.07 57.61 
South West 195 9.3 66.91 
West Midlands 195 9.3 76.2 
Yorkshire & Humber 149 7.11 83.31 
Northern Ireland 45 2.15 85.46 
Scotland 194 9.25 94.71 
Wales 110 5.25 99.95 
Total 2097 100 
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Table M.9: Ethnicity 
ethnicity Freq. Percent Cum. 
White British 1,818 86.7 86.7 
White Irish 31 1.48 88.17 
Other White 104 4.96 93.13 
Black or Black British - Caribbean 17 0.81 93.94 
Black or Black British – African 12 0.57 94.52 
Other Black 0 0 94.52 
Asian British – Indian 33 1.57 96.09 
Asian British - Bangladeshi 3 0.14 96.23 
Chinese 12 0.57 96.8 
Other Asian 24 1.14 97.95 
Mixed ethnicity - white & black Caribbean 14 0.67 98.62 
Mixed ethnicity - white & black African 2 0.1 98.71 
prefer not to say 27 1.29 100 
Total 2097 100 
  
Table M.10: Education 
Which of these best describes the highest educational qualification you have 
obtained so far? 
education Freq. Percent Cum. 
No formal qualifications 111 5.29 5.29 
GCSE Level education (e.g. GCSE, O-Levels or 
Standards) 442 21.08 26.37 
A-Level education (e.g. A, AS, S-Levels, Highers) 447 21.32 47.69 
Degree or Graduate education (e.g. BSc, BA) 574 27.37 75.06 
Post-graduate education (e.g. PhD, MSc, MA) 272 12.97 88.03 
Vocational education (e.g. NVQ, HNC, HND) 240 11.44 99.48 
Prefer not to say 11 0.52 100 
Total 2097 100  
 
Median household pre-tax income was in the range £25,000 - £34,999. The 2013/14 
Households below average income (HBAI) statistics report from the DWP gives a 
median household income (2 adults) as £23,556. 
 
The age distribution is shown in Table M.12. 
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Table M.11: Household Income  
Please tell us your Household income group  
This is the amount you earn before tax, and includes the people you live with (partner, 
family) – but do not include people you house/flat share with. 
income        Freq. Percent Cum. 
Below £6,500 87 4.15 4.15 
£6,500 - £11,499 165 7.87 12.02 
£11,500 - £17,499 186 8.87 20.89 
£17,500 - £24,999 314 14.97 35.86 
£25,000 - £34,999 397 18.93 54.79 
£35,000 - £44,999 311 14.83 69.62 
£45,000 - £54,999 206 9.82 79.45 
£55,000 - £74,999 207 9.87 89.32 
£75,000 - £99,999 132 6.29 95.61 
£100,000 - £124,999 42 2 97.62 
£125,000 - £149,999 20 0.95 98.57 
£150,000 - £199,999 16 0.76 99.33 
more than £200,000 14 0.67 100 
Total 2097 100  
 
 
Table M.12: Age Groups 
agecat Freq. Percent Cum. 
18-19 25 1.19 1.19 
20-29 272 12.97 14.16 
30-39 414 19.74 33.91 
40-49 418 19.93 53.84 
50-59 439 20.93 74.77 
60-69 352 16.79 91.56 
70-79 163 7.77 99.33 
80+ 14 0.67 100 
Total 2097 100  
Health 
The mean EQ5D utility score value (maximum value of 1) was 0.81 
 
eq5d utility score Obs Mean Std. Dev. Min Max 
      
eq5dutility 2,097 0.812 0.255 -0.594 1 
 
The distribution of EQ5D utility scores is shown in Figure M.1. A total of 47 people in 
the sample reported a health state less than 0 (worse than death). 
  
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                    Final Report  
 
eftec 179 March 2017 
Figure M.1: Histogram EQ5D utility scores – Adult sample 
 
 
The history of the sample and their family members with diarrhoea and/or vomiting in 
the past year are shown in Table M.13 which shows proportions – e.g. 51% of the 
sample have had mild diarrhoea and/or vomiting lasting less than a day in the last 
year, 2% report having been hospitalised by diarrhoea and/or vomiting in the past 
year. 
 
Table M.13: History of diarrhoea and/or vomiting in past year 
In the past year please tell us if you or family members have had illnesses like this? 
 You Other adults 
in the family 
Children in 
the family 
None 
of them 
Mild diarrhoea and/or vomiting  <1 
day 0.512 0.282 0.114 0.375 
Mild diarrhoea and/or vomiting  , 1-3 
days, time off work/school, no Dr 
contact 0.214 0.153 0.095 0.663 
Mild diarrhoea and/or vomiting  , 1-3 
days, time off work/school, Dr contact 0.069 0.050 0.036 0.870 
Severe diarrhoea and/or vomiting, 
time off work/school,  > 1 Dr contact 0.052 0.033 0.021 0.906 
Severe food poisoning, 1+ nights in 
hospital 0.022 0.016 0.010 0.954 
 
The long term impacts of FBD can include a number of conditions. These conditions 
featured explicitly in the valuation scenarios in the Vignette sample.  
To aid comparison between the two adult samples (vignette, EQ5D), we report in 
Table M.14 the experience of the Adult EQ5D sample of those conditions. 
This reveals that 16% of the sample reported having experienced IBS, 16% arthritis 
and 1.8% Meningitis. 
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Table M.14: History of long run FBD conditions  
Please indicate if either you, or someone in your close family, has any 
experience of the following illnesses. 
 
you 
member 
close family 
Guillain-Barre Syndrome  0.018 0.018 
Irritable Bowel Syndrome 0.156 0.181 
Arthritis 0.161 0.296 
Febrile Convulsions 0.008 0.024 
Mesenteric adenitis 0.009 0.014 
Septicaemia 0.021 0.050 
Complicated Jaundice 0.011 0.022 
Osteomyelitis 0.010 0.019 
Hemolytic uremic syndrome (HUS) 0.008 0.014 
Thrombotic thrombocytopenic purpura (TTP) 0.005 0.020 
Renal Failure/ Dialysis 0.011 0.042 
Meningitis 0.018 0.049 
 
M.3. Choices, Task Difficulty & Protests – Adult sample 
Possible protest behaviour were investigated for people who selected a pay, or a no 
pay, option in all of the DCE sets they faced. 
 
People with this pattern of choices in the short term sets were prompted as to why 
that was the case using the responses shown in Tables M.15 and M.16. 
 
Table M.15: Why never chose to pay – short term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad - I could live with 
it. 54 2.58 2.58 
2. I would get better anyway, so it is not worth paying 
for the treatment. 61 2.91 5.48 
3. I would like to avoid the illness but I could not 
afford to pay what was asked 54 2.58 8.06 
4. I shouldn’t have to pay because the government 
should provide health care. 36 1.72 9.78 
5. I have an ethical/religious objection to taking 
medicines. 1 0.05 9.82 
6. Other (please specify) 18 0.86 10.68 
               n/a 1,873 89.32 100 
Total 2097 100  
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Table M.16: Why always chose to pay – short term 
Please select the option that best explains why you always chose to pay to avoid the 
illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was 
realistic so I ignored it 27 1.29 1.29 
2. The cost was small compared to the pain and 
suffering 270 12.88 14.16 
3. The cost was small compared to what I would 
lose missing work 75 3.58 17.74 
4. Other (please specify) 29 1.38 19.12 
               n/a 1,696 80.88 100 
Total 2097 100  
 
People choosing options 4-6 in Table M.15, and options 1 or 4 in Table M.16 were 
excluded from the estimation sample. The rates of such ‘protests’ were very low 
considering this was a health-payment study in the UK. 
 
The LR sets did not feature “pay” and “no pay” options, they comprised sets with 
differing lifespans and annual incomes – so the debrief questions were different. 
 
Life A always involved ill health, and respondents who always chose this option in 
the eight sets were prompted as to why that was the case. 
Life B always involved current health, and respondents who always chose this option 
in the eight sets were prompted as to why that was the case. 
 
The responses are shown in Tables M.17 and M.18. 
 
Table M.17: Why always chose a poorer health option 
Please select the option that best explains why you always chose Life A - the option in 
which there was a period of (red) ill health. 
 Freq. Percent Cum. 
1. I considered income, time spent  in both good and ill 
health, and the severity of illness - and I always 
preferred Life A 27 1.41 1.41 
2. I always picked the option with the longest total life, 
regardless of the income or severity of illness. 20 1.04 2.45 
3. Other 2 0.1 2.56 
4. n/a 1,866 97.44 100 
Total 1915 100  
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Table M.18: Why never chose a poorer health option 
Please select the option that best explains why you never chose Life A - the option in which 
there was a period of (red) ill health. 
 Freq. Percent Cum. 
1. I considered income, time spent  in both good and ill 
health, and the severity of illness - and I always 
preferred Life B. 204 10.65 10.65 
2. I always avoided the option with (red) ill health, 
regardless of the income or overall length of life 188 9.82 20.47 
3. Other  26 1.36 21.83 
4. n/a 1,497 78.17 100 
Total 1915 100  
 
Respondents were debriefed on how hard it was to understand the sets, and how 
hard it was to make the choices within them. 
 
Table M.19: How hard was it to understand the choice questions involving 
illness and money? – short term 
 Freq. Percent Cum. 
very difficult 36 1.72 1.72 
difficult 232 11.06 12.78 
neutral 476 22.7 35.48 
easy 845 40.3 75.77 
very easy 508 24.23 100 
Total 2097 100 
  
Table M.20: How hard was it to make the choice questions involving illness 
and money? – short term 
 Freq. Percent Cum. 
very difficult 79 3.77 3.77 
difficult 465 22.17 25.94 
neutral 482 22.99 48.93 
easy 704 33.57 82.5 
very easy 367 17.5 100 
Total 2097 100 
  
The choice tasks were complex, which was why so much effort had been assigned 
to preparation of the materials and testing and refining them in focus groups, 
interviews and pilot surveys.   
 
Rates of 2% and 11% respectively describing the short term sets as very difficult and 
difficult to understand were regarded as validating those efforts. The proportion 
finding the short run EQ5D DCE (very) difficult was 12%, slightly higher than the 
10% reporting this for the equivalent Vignette sets. 
 
Making the choices was more often reported as more difficult than understanding the 
choices, but this concerns difficulty making the decision rather than necessarily 
being confused by the information comprising the options. 26% of the Adult EQ5D 
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sample found making the choices (very) difficult, compared to 18% in the equivalent 
Vignette sets. 
 
Table M.21: How hard was it to understand the choice questions involving 
illness and money? – long term 
 Freq. Percent Cum. 
very difficult 74 3.53 3.53 
difficult 252 12.02 15.55 
neutral 411 19.6 35.15 
easy 863 41.15 76.3 
very easy 497 23.7 100 
Total 2097 100  
 
Table M.22: How hard was it to make the choice questions involving illness 
and money? – long term 
 Freq. Percent Cum. 
very difficult 135 6.44 6.44 
difficult 456 21.75 28.18 
neutral 466 22.22 50.41 
easy 691 32.95 83.36 
very easy 349 16.64 100 
Total 2097 100 
  
The long term DCEs were different and we expected them to be more of a challenge. 
Only 3.5% reported understanding them was very difficult, with another 12% 
reporting them as difficult. The equivalent vignette values were 4% and 9%. 28% 
found making the choices between the two lifepaths DCE (very) difficult; this was 
less than the 35% reporting this to be the case for the vignette long term choice sets. 
 
M.4 Parents Sample – demographics and health  
A sample of 720 parents was collected within the EQ5D (a sample size of 653 was 
achieved for the Vignette sample).  
 
Some were removed because their speed of completion was so great that the data 
quality was considered unreliable. The active Parent EQ5D sample was then 668 
(592 in vignette sample). 
Demographics 
The sample was 50-50 split between females and males (Table M.23). The 
distribution of occupations and class are shown in Table M.24. 
 
Table M.23: Gender 
male Freq. Percent Cum. 
male 331 49.55 49.55 
female 337 50.45 100 
Total 668 100  
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Table M.24: Occupation  
We would like to know about the Chief Income Earner in your household 
This is the person with the largest income. 
If this person is 
 retired with an occupational pension then answer about their most recent occupation. 
 not in a paid job but has been out of work for less than 6 months, then answer about 
their most recent job. 
The Chief Income Earner is (or was):    
 Freq. Percent Cum. 
Semi or unskilled manual work 67 10.03 10.03 
Skilled manual worker 125 18.71 28.74 
Supervisory or clerical/ junior managerial/ professional/ 
administrative 177 26.5 55.24 
Intermediate managerial/ professional/ administrative 150 22.46 77.69 
Higher managerial/ professional/ administrative 84 12.57 90.27 
Student 8 1.2 91.47 
Casual worker – not in permanent employment 6 0.9 92.37 
Housewife/ Homemaker 14 2.1 94.46 
Retired and living on state pension 8 1.2 95.66 
Unemployed or not working due to long-term sickness 18 2.69 98.35 
Full-time carer of other household member 11 1.65 100 
Total 668 100  
 
The geographical split of the sample is shown in Table M.25. The division between 
UK nations is close to the aggregate national population proportions with 7.6% from 
Scotland (nationally 8.4%), 5.5% from Wales (nationally 4.8%) and 2% from 
Northern Ireland (nationally 2.9%). 
 
Table M.25: Region 
region Freq. Percent Cum. 
East Midlands 41 6.14 6.14 
East of England 59 8.83 14.97 
London 92 13.77 28.74 
North East 29 4.34 33.08 
North West 77 11.53 44.61 
South East 96 14.37 58.98 
South West 62 9.28 68.26 
West Midlands 53 7.93 76.2 
Yorkshire & Humber 58 8.68 84.88 
Northern Ireland 13 1.95 86.83 
Scotland 51 7.63 94.46 
Wales 37 5.54 100 
Total 668 100 
  
Ethnicity and Education are summarised in Tables M.26 and M.27. 
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Table M.26: Ethnicity 
ethnicity Freq. Percent Cum. 
White British 555 83.08 83.08 
White Irish 11 1.65 84.73 
Other White 30 4.49 89.22 
Black or Black British - Caribbean 4 0.6 89.82 
Black or Black British – African 10 1.5 91.32 
Other Black 1 0.15 91.47 
Asian British – Indian 18 2.69 94.16 
Asian British - Bangladeshi 5 0.75 94.91 
Chinese 6 0.9 95.81 
Other Asian 12 1.8 97.6 
Mixed ethnicity - white & black Caribbean 5 0.75 98.35 
Mixed ethnicity - white & black African 1 0.15 98.5 
prefer not to say 10 1.5 100 
Total 668 100 
  
Table M.27: Education 
Which of these best describes the highest educational qualification you have obtained 
so far? 
education Freq. Percent Cum. 
No formal qualifications 17 2.54 2.54 
GCSE Level education (e.g. GCSE, O-Levels or 
Standards) 158 23.65 26.2 
A-Level education (e.g. A, AS, S-Levels, Highers) 151 22.6 48.8 
Degree or Graduate education (e.g. BSc, BA) 193 28.89 77.69 
Post-graduate education (e.g. PhD, MSc, MA) 84 12.57 90.27 
Vocational education (e.g. NVQ, HNC, HND) 60 8.98 99.25 
Prefer not to say 5 0.75 100 
Total 668 100  
 
Median household pre-tax income was in the range £25,000 - £34,999. The 2013/14 
Households below average income (HBAI) statistics report from the DWP gives a 
median household income (2 adults) as £23,556. 
 
The age distribution is shown in Table M.29. 
 
 
 
  
Estimating QALY and WTP for Microbiological Foodborne Disease (Phase 2)                    Final Report  
 
eftec 186 March 2017 
Table M.28: Household Income  
Please tell us your Household income group  
This is the amount you earn before tax, and includes the people you live with (partner, 
family) – but do not include people you house/flat share with. 
income        Freq. Percent Cum. 
Below £6,500 12 1.8 1.8 
£6,500 - £11,499 33 4.94 6.74 
£11,500 - £17,499 51 7.63 14.37 
£17,500 - £24,999 99 14.82 29.19 
£25,000 - £34,999 113 16.92 46.11 
£35,000 - £44,999 100 14.97 61.08 
£45,000 - £54,999 73 10.93 72.01 
£55,000 - £74,999 76 11.38 83.38 
£75,000 - £99,999 57 8.53 91.92 
£100,000 - £124,999 26 3.89 95.81 
£125,000 - £149,999 10 1.5 97.31 
£150,000 - £199,999 9 1.35 98.65 
more than £200,000 9 1.35 100 
Total 668 100  
 
Table M.29: Age Groups (Parent) 
agecat Freq. Percent Cum. 
18-19 26 3.89 3.89 
20-29 70 10.48 14.37 
30-39 149 22.31 36.68 
40-49 206 30.84 67.51 
50-59 146 21.86 89.37 
60-69 53 7.93 97.31 
70-79 18 2.69 100 
Total 668 100  
 
Parents were asked to think about a specific child when making their choices within 
the survey. This was to help make the valuation choices as realistic as possible. The 
ages of the children chosen as their “Nominated Child” are shown in Table M.30. If 
their nominated child was less than 4 they were directed into the Vignette version of 
the survey as this age is too young for the EQ-5D-3L Y form for recording children’s 
health status. 
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Table M.30: Age Groups (Child) 
Nominated 
Child Age 
Freq. Percent Cum. 
4 48 7.19 7.19 
5 52 7.78 14.97 
6 38 5.69 20.66 
7 54 8.08 28.74 
8 40 5.99 34.73 
9 35 5.24 39.97 
10 55 8.23 48.2 
11 38 5.69 53.89 
12 56 8.38 62.28 
13 51 7.63 69.91 
14 42 6.29 76.2 
15 55 8.23 84.43 
16 40 5.99 90.42 
17 64 9.58 100 
Total 668 100  
Health 
The mean EQ5D utility score value (maximum value of 1) was 0.87 
 
eq5d utility score Obs Mean Std. Dev. Min Max 
      
eq5dutility 661 0.872 0.244 -0.371 1 
 
The distribution of EQ5D utility scores is shown in Figure M.2. A total of 18 people in 
the sample reported a health state less than 0 (worse than death). 
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Figure M.2: Histogram EQ5D utility scores – Parent sample 
 
 
The history of the sample and their family members with diarrhoea and/or vomiting in 
the past year are shown in Table M.31 which shows proportions – e.g. 49% of the 
sample have had mild diarrhoea and/or vomiting lasting less than a day in the last 
year, 3% report having been hospitalised by diarrhoea and/or vomiting in the past 
year. 
 
Table M.31: History of diarrhoea and/or vomiting in past year 
In the past year please tell us if you or family members have had illnesses like this? 
 You Other adults 
in the family 
Children in 
the family 
None 
of them 
Mild diarrhoea and/or vomiting  <1 day 0.493 0.334 0.382 0.292 
Mild diarrhoea and/or vomiting  , 1-3 days, 
time off work/school, no Dr contact 0.217 0.187 0.314 0.485 
Mild diarrhoea and/or vomiting  , 1-3 days, 
time off work/school, Dr contact 0.084 0.100 0.151 0.734 
Severe diarrhoea and/or vomiting, time off 
work/school,  > 1 Dr contact 0.058 0.061 0.046 0.859 
Severe food poisoning, 1+ nights in 
hospital 0.031 0.045 0.033 0.900 
 
The long term impacts of f FBD can include a number of conditions. These 
conditions featured explicitly in the valuation scenarios in the Vignette sample.  
To aid comparison between the two parental samples (vignette, EQ5D), we report in 
Table 9 the experience of the Parent EQ5D sample of those conditions. 
This reveals that 17% of the sample reported having experienced IBS, 13% arthritis 
and 1.5% Meningitis. 
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Table M.32: History of long run FBD conditions  
Please indicate if either you, or someone in your close family, has any 
experience of the following illnesses. 
 
you 
member 
close family 
Guillain-Barre Syndrome  0.031 0.028 
Irritable Bowel Syndrome 0.174 0.180 
Arthritis 0.127 0.256 
Febrile Convulsions 0.018 0.052 
Mesenteric adenitis 0.018 0.025 
Septicaemia 0.021 0.057 
Complicated Jaundice 0.012 0.031 
Osteomyelitis 0.006 0.037 
Hemolytic uremic syndrome (HUS) 0.007 0.022 
Thrombotic thrombocytopenic purpura (TTP) 0.010 0.019 
Renal Failure/ Dialysis 0.012 0.031 
Meningitis 0.015 0.063 
 
M.5. Choices, Task Difficulty & Protests – Parent sample 
Possible protest behaviour were investigated for people who selected a pay, or a no 
pay, option in all of the DCE sets they faced. 
 
People with this pattern of choices in the short term sets were prompted as to why 
that was the case using the responses shown in Tables M.33 and M.34. 
 
Table M.33: Why never chose to pay – short term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad. 4 0.6 0.6 
2. My child would get better anyway, so it is not 
worth paying for the treatment. 10 1.5 2.1 
3. I would like my child to avoid the illness but I could 
not afford to pay what was asked 15 2.25 4.34 
4. I shouldn’t have to pay because the government 
should provide health care. 11 1.65 5.99 
5. I have an ethical/religious objection to my child 
taking medicines 0 0 5.99 
6. Other (please specify) 5 0.75 6.74 
               n/a 623 93.26 100 
Total 668 100  
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Table M.34: Why always chose to pay – short term 
Please select the option that best explains why you always chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was realistic 
so I ignored it 11 1.65 1.65 
2. The cost was small compared to my child's pain and 
suffering 140 20.96 22.6 
3. The cost was small compared to the costs involved in 
caring for my ill child. 25 3.74 26.35 
4. Other (please specify) 6 0.9 27.25 
               n/a 486 72.75 100 
Total 668 100  
 
People choosing options 4-6 in Table M.33, and options 1 or 4 in Table M.34 were 
excluded from the estimation sample. The rates of such ‘protests’ were very low 
considering this was a health-payment study in the UK. 
 
People who selected a pay, or a no pay, option in all of the long term DCE sets were 
prompted as to why that was the case using the responses shown in Tables M.35 
and M.36. 
 
Table M.35: Why never chose to pay – long term 
Please select the option that best explains why you never chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. The illness wouldn't be too bad. 10 1.5 1.5 
2. My child would get better anyway, so it is not worth 
paying for the treatment. 10 1.5 2.99 
3. I would like my child to avoid the illness but I could not 
afford to pay what was asked 110 16.47 19.46 
4. I shouldn’t have to pay because the government 
should provide health care. 28 4.19 23.65 
5. I have an ethical/religious objection to my child taking 
medicines 1 0.15 23.8 
6. Other (please specify) 19 2.84 26.65 
               n/a 490 73.35 100 
Total 668 100  
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Table M.36: Why always chose to pay – long term 
Please select the option that best explains why you always chose to pay to avoid the illness. 
 Freq. Percent Cum. 
1. I did not think the request for payment was realistic so I 
ignored it 15 2.25 2.25 
2. The cost was small compared to my child's pain and 
suffering 92 13.77 16.02 
3. The cost was small compared to the costs involved in caring 
for my ill child. 14 2.1 18.11 
4. Other (please specify) 18 2.69 20.81 
                n/a 529 79.19 100 
Total 668 100  
 
People choosing options 4-6 in Table M.35, and options 1 or 4 in Table M.36 were 
excluded from the estimation sample. As with the short term sets the rates of such 
‘protests’ were very low. 
 
Respondents were debriefed on how hard to was to understand the sets, and how 
hard it was to make the choices within them 
 
Table M.37: How hard was it to understand the choice questions involving 
illness and money? – short term 
 Freq. Percent Cum. 
Very difficult 30 4.49 4.49 
Difficult 81 12.13 16.62 
Neutral 144 21.56 38.17 
Easy 225 33.68 71.86 
very easy 188 28.14 100 
Total 668 100 
  
Table M.38: How hard was it to make the choice questions involving illness 
and money? – short term 
 Freq. Percent Cum. 
Very difficult 55 8.23 8.23 
Difficult 143 21.41 29.64 
Neutral 154 23.05 52.69 
Easy 190 28.44 81.14 
very easy 126 18.86 100 
Total 668 100 
  
The choice tasks were complex, which was why so much effort had been assigned 
to preparation of the materials and testing and refining them in focus groups, 
interviews and pilot surveys.   
 
Rates of 5% and 12% respectively describing the short term sets as very difficult and 
difficult to understand were regarded as validating those efforts. But we note that the 
proportion finding the short run EQ5D DCE (very) difficult was 17% as compared to 
12% for the equivalent Vignette sets. 
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Making the choices was more often reported as more difficult than understanding the 
choices, but this concerns difficulty making the decision rather than necessarily 
being confused by the information comprising the options.  
 
Table M.39: How hard was it to understand the choice questions involving 
illness and money? – long term 
 Freq. Percent Cum. 
very difficult 55 8.23 8.23 
Difficult 83 12.43 20.66 
Neutral 142 21.26 41.92 
Easy 225 33.68 75.6 
very easy 163 24.4 100 
Total 668 100  
 
Table M.40: How hard was it to make the choice questions involving illness 
and money? – long term 
 Freq. Percent Cum. 
very difficult 147 22.01 22.01 
difficult 145 21.71 43.71 
neutral 135 20.21 63.92 
easy 134 20.06 83.98 
very easy 107 16.02 100 
Total 668 100 
  
The long term conditions included much more information and were more 
demanding. Rates of 8% and 12% respectively described the sets as very difficult 
and difficult to understand, these were only marginally higher than the equivalent 
figures for the vignettes sets. 
 
Making the choices was more often reported as more difficult than understanding the 
choices and more often so in the long term sets than the short term ones.  
We note that the proportion finding making choices in the long run EQ5D DCE (very) 
difficult was 44% compared to 46% for the equivalent Vignette sets. 
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APPENDIX N: AGGREGATION OF WTP TO AVOID 
FOODBORNE ILLNESS – CAMPYLOBACTER 
SPP. 
 
The study reports estimates of average WTP to avoid foodborne illness experienced 
by adults or children, for both short and long term conditions from the stated 
preference study. 
 
Those estimates are at the level of the individual. This appendix sets out the process 
of aggregation from the individual WTP to the aggregate, national, value. This is 
described here in detail for Campylobacter spp. The process is the same for the 
other pathogens studied in the project. 
 
The Markov Transition Models (MTMs) developed within the project provide the 
foundation for the monetary aggregation. They provide estimates of the burden of 
disease in terms of QALY losses.  
  
The starting point of the MTM is the healthy state, whereby upon suffering from the 
FBD, the patient can move between states or stay in their initial state (with a step 
period of one week).  
  
In the case of Campylobacter spp. (see Figures N.1 - N.3) a patient can for example 
stay within their health state, or go from a healthy state to either uncomplicated 
diarrhoea or death. From uncomplicated diarrhoea, a patient could continue to have 
uncomplicated diarrhoea for more than one week, return to a healthy state or to 
develop a range of complications or sequelae. With the exception of death, it would 
be anticipated that a patient would eventually return to a healthy state, although with 
sequelae, the length of time before that occurs could be substantial. The likelihood of 
moving between states is captured by the transition probabilities associated with 
each arrow connecting the states in Figures N.1-N.3. 
 
Figures N.1 – N.3 illustrate the structure of the model. Figure N.2 shows the four 
types of complications possible with Campylobacter spp. such as hospitalising 
diarrhoea or septicaemia. As illustrated it is possible for a patient to remain with this 
complication for more than one week, eventually return to a healthy state, develop 
sequelae (Figure N.3) or die. At the end of 12 months, the model assumes that there 
are no further new cases of Campylobacter spp., but the impacts after that year of 
cases that developed within it are incorporated, using a 1 year time step, for a further 
100 years, with patients returning to a health state, or dying, with probability of the 
latter being based on a combination of the “all causes” death rate and any increases 
due to sequelae.  
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The MTMs determine the burden associated with the illness by comparing the 
aggregate QALY achieved if there was no illness to what is achieved when there is 
illness. The latter is identified using the utility burden associated with each state, and 
the number of person weeks/years that the population is modelled to spend in those 
states (including premature deaths). Given the long time horizon involved (since 
people may live with sequelae for many years after initially becoming ill), the QALY 
impacts are discounted at a value of 3.5% per annum. 
 
Generating aggregate WTP estimates of burden requires replacement of the QALY 
disutility of the states with the estimated WTP to avoid those states. There are two 
complications to that process. 
 
The first is that for many of the sequelae the WTP studies identified ‘fixed effects’ for 
illnesses with stated durations. For example, the vignette used to convey 
septicaemia in the valuation study included both short term impacts (being in an ICU) 
and also the duration until one recovered. Respondents were not sensitive to the 
longer duration, meaning we have only a WTP for a “fixed effect” of the illness itself.  
Essentially in the WTP estimates respondents are valuing a ‘case’ of septicaemia, 
not the duration of any recuperation from it to. Such duration-invariant WTPs are 
accommodated within the WTP aggregation by multiplying the estimate of the fixed 
effect by the number of cases simulated by the model nationally.   
 
For some conditions there is both a fixed and marginal effect: respondents reveal 
that their WTP is influenced by the duration, but there is also an additional fixed 
effect associated with each case. In that case we include both a WTP value 
associated with the number of cases, and a value associated with the duration of 
those cases.  
 
The second issue is that the vignette-based WTP estimates do not include a direct 
measure of the disutility associated with death. To address this gap we use the value 
of a QALY derived in the study: £19,456 as a conservative estimate of the value of 
years of life lost due to death arising from FBI. In terms of benchmarking, we note 
that a recent review the literature on WTP estimates for a QALY suggest a median 
value of €24,226, which is equivalent to £23,174 per QALY in 2015 prices (Ryen 
and Svensson, 2015).    
 
We use the Campylobacter spp. MTM as an exemplar of how the WTP aggregation 
process works. As explained above the health states and the numbers moving 
through each year are defined. Monetisation requires assignment of a WTP value to 
each episode spent in each state. 
 
From the Campylobacter spp. MTM model, disutility values are required for 9 
elements. Table N.1 reports the disutility scores derived from the literature that are 
used in the QALY estimates. For the initial year, where the condition is reported in 1 
week steps, the MTM takes the annual value of the disutility associated with a 
condition, and divides it by 52 to identify the loss associated with a week in the 
condition. The transition probabilities within the MTM are calibrated to account for 
conditions (such as uncomplicated diarrhoea) where the median duration may be 
less than 1 week. 
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Table N.1: Disutility scores from the Campylobacter spp. MTM, derived from 
the literature 
 Disutility 
Healthy 0 
Uncomplicated Diarrhoea 0.0912 
Hospitalizing Diarrhoea  0.167 
Febrile Convulsions 0.307 
Mesenteric Adenitis 0.552 
Septicaemia 0.606 
GBS 0.496 
IBS 0.181 
RA 0.388 
Dead 0.856 
 
Table N.2 reports WTP values estimated by this study: both the marginal value for a 
year in each state, and any fixed effects. These estimates are weighted averages of 
the adult and child estimates, as the cases in the population reflect both of these 
sources. It also reports the implied values that would be derived if one used £19,456 
per QALY for the disutility decrements reported in Table N.1.  
 
Table N.2: Values used in estimating aggregate WTP to avoid disease – 
Campylobacter spp.   
 
Conditions relevant to 
Campylobacter spp. only. 
Estimated as weighted average of 
Adult and Parent values. 
Stated preference  
estimates 
QALY 
estimates 
Fixed effect 
£’000 per year 
Marginal effect 
£’000 per case 
Marginal effect 
Uncomplicated Diarrhoea 
/vomiting 
0.060 2.006 
1.77 
Hospitalizing Diarrhoea /vomiting 0.084 3.313 3.25 
Febrile Convulsions 7.978 0 5.97 
Mesenteric Adenitis 1.747 0 10.74 
Septicaemia 35.98 0 11.79 
GBS 6.83 7.581 9.65 
IBS 14.05 0 3.52 
RA 6.51 1.584 7.55 
Dead -- 19.5 16.65 
 
 
The values in Table N.3 are multiplied by the number of person episodes spent in 
each state. Table N.3 reports these values for the WTP approach, and the 
contribution due to each condition. Deaths from all sources are aggregated. 
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Table N.3:  Estimates of monetary burden from pain and suffering arising from 
an annual caseload of Campylobacter spp. 
 
 WTP (£’000) 
Total 424,244 (308,244 - 540,264) 
Uncomplicated Diarrhoea 34,939 (30,900 - 38,900) 
Hospitalizing Diarrhoea 472 (427 - 518) 
Febrile Convulsions 339 (138 - 540) 
Mesenteric Adenitis 426 (218 - 635) 
Septicaemia 22,515 (15,700 – 29,300) 
GBS 6,855 (4,800 - 8,900) 
IBS 302,071 (187,160 - 417,00) 
RA 41,972 (29,800 – 54,100) 
Dead 14,654 (7,900 - 21,400) 
 
A caveat to note when considering the values in Table N.3 is that the value of deaths 
from each condition is aggregated into the ‘deaths’ total. A death caused by 
Septicaemia is captured in the Death category and not assigned to Septicaemia.  
 
 
 
 
 
 
 
 
 
 
 
 
  
